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Abstract
We evaluated the activity of the trinuclear platinum complex BBR 3464 in two 
human ovarian carcinoma cell lines (OAW42, A2780) and in their cisplatin- 
resistant counterparts (OAW42Mer, À2780cp8). An increased cytotoxic 
potency of BBR 3464 compared to cisplatin was generally observed, an a 
collateral sensitivity or a very modest cross-resistance to BBR 3464 was found 
in OAW42Mer and À2780cp8 cell lines, respectively. Loss of mismatch repair 
proteins (hMLHl, hPMS2) or overexpression of nucleotide excision repair 
proteins (ERCC1) was not detrimental for the cellular sensitivity to the 
trinuclear platinum complex. BBR 3464 intracellular accumulation and DNA- 
bound platinum were consistently higher than those observed with cisplatin. 
After exposure to BBR 3464 and cisplatin of purified DNA or intact cells, a 
similar sequence preference of DNA damage was observed. Conversely, 
interesting differences in the kinetics of formation and removal of DNA lesions 
at the single-gene (N-ras) level were observed between the two drugs.
The interference exerted by BBR 3464 with cell cycle progression and its 
ability to induce apoptosis were evaluated in OAW42 and OAW42Mer cell 
lines. Flow cytometric experiments indicated that in the two cell lines BBR 
3464 was able to induce a persistent G2M block whereas cisplatin caused an 
initial accumulation of cells in the S phase followed by an increase in the G2M 
cell fraction. Exposure to IC50 drug concentrations induced apoptosis in both 
cell lines. However, the percentage of cells with an apoptotic nuclear 
morphology was slightly higher after cisplatin than BBR 3464 treatment in 
OAW42 cells, whereas the opposite pattern was observed in OAW42Mer cells.
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Abstract
Degradation of the nuclear lamin B was detected in OAW42 cells after 
exposure to each drug whereas in OAW42Mer cells the cleavage was only 
appreciable after BBR 3464 exposure. In OAW42 cells the mitochondrial 
membrane potential (Av|/mt) was not affected by the two drugs, whereas in the 
OAW42Mer cell line a marked Av|/mt reduction was observed only after 
exposure to BBR 3464.
Overall, the results would suggest that the collateral sensitivity to BBR 3464 
observed in the OAW42Mer cell line might be attributable to the ability of this 
drug to modify DNA differently from that of cisplatin and, as a consequence, 
to induce different cellular responses to DNA damage such as the triggering of 
specific apoptotic pathways.
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(1) Introduction
1.1 Anticancer Drugs
Several therapeutic possibilities are available for the treatment of cancer: 
surgery, radiotherapy and chemotherapy. As regards pharmacological 
approaches in cancer therapy, increased knowledge of tumor biology obtained 
in the last 15 years with the identification of oncogenes, tumor suppressor 
genes, cell cycle, cell death and DNA repair genes, has opened important 
targets for the discovery/design and synthesis of novel anticancer drugs with 
improved antitumor activity.
At present, about 30 drugs are used in chemotherapy. These compounds are 
classified into different groups on the basis of their mechanism of action.
Antimetabolites, which are structural analogues of enzymatic cofactors or 
nucleosides, include inhibitors of folate synthesis, uracil analogues, cytidine 
analogues and purine analogues. These molecules are able to inhibit the 
synthesis of DNA precursors and/or can be themselves incorporated into 
nucleic acids, thus altering DNA replication and repair processes.
Another important class of anticancer drugs is represented by the poisons of 
the DNA topoisomerase I and II enzymes. By covalently binding the binary 
complex DNA-topoisomerase I, camptothecins are able to produce a 'cleavable' 
ternary complex of DNA-topoisomerase I-drug in which topoisomerase I 
activity is blocked. The presence of such cleavable complexes on genomic 
DNA seems to interfere with the DNA replication machinery thus altering 
normal DNA synthesis. Other drugs, such as DNA-topoisomerase II poisons
23
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doxorubicin, daunorubicin, mitoxantrone and etoposide are able to stabilise the 
binary complex DNA-topoisomerase II forming a ternary drug-DNA 
topoisomerase II complex, thus leaving on the cellular DNA highly toxic 
double-strand breaks.
Molecules which exert their cytotoxic activity acting on the mitotic spindle 
assembly or disassembly are classified as antimitotic drugs. Compounds such 
as vinblastine, vincristine and vinorelbine are able to prevent mitotic spindle 
formation by inhibiting microtubule polymerisation, whereas taxanes act by 
inhibiting microtubule depolymerisation thus stabilising the mitotic spindle.
Alkylating agents represent a class of anticancer drugs actively used in the 
clinical approach to cancer therapy. These compounds are known for their 
ability to become strong electrophilic intermediates able to covalently interact 
with nucleophilic centres (phosphate, aminic, sulphydrilic, hydroxylic, 
carboxylic and hymidazolic groups) located on proteins and nucleic acids. It 
has been demonstrated that the most important target of such drugs is the 
genomic DNA. Within it, the most frequently alkylated sites are N7 and O6 of 
guanine, N7 and N3 of adenine and N3 of cytosine. Several studies performed in 
the last few years, have provided evidence that these drugs exert their cytotoxic 
activity by altering the physiological DNA metabolism, in terms of replication, 
transcription and repair processes, thus producing molecular signals that can 
trigger apoptosis.
For many years it has been thought that alkylating agents targeted DNA in a 
random fashion whereas recent investigations have shown that the DNA-
24
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alkylation produced by these compounds is made with a certain degree of 
sequence specificity. Major groove alkylators, such as nitrogen mustards (for 
example, melphalan) and alkylsulfonates (for example, busulfan), covalently 
bind N7 only of guanines located in a run of guanines (5'-GGG-3') thus 
producing interstrand cross-links. Minor groove alkylating agents, such as 
benzoyl mustard tallimustine and CC-1065, covalently bind to N3 of adenines 
with the highest sequence specificity ever seen for alkylators: in fact, these 
agents are able to alkylate only the N3 of adenines located in the 5,-TTTTGA-3' 
and S'-PuNTTA-S' or 5'-AAAA-3' respectively (Hurley et al., 1984; Broggini et 
al., 1991, 1995; Colella et al., 1996).
Cisplatin and its derivatives could be, to a certain degree, also considered as 
major groove alkylators, although their molecular structures are different from 
those of classical alkylating agents described above. Platinum-based anticancer 
agents are able to covalently bind N7 of guanine with a certain degree of 
sequence selectivity thus producing various types of DNA adducts.
1.2 Cisplatin: properties and mechanism of action
Platinum coordination complexes have been known for many years. 
Cisplatin [cis-diammne-dichloroplatinum (II)], a bifunctional DNA damaging 
agent commonly used in cancer chemotherapy alone or in combination with 
other anticancer agent, was synthesised first in 1845 as Peyrone's chloride and
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its planar structure was deduced in 1893. Interest in the biological effects of 
cisplatin was stimulated in 1965 during studies on the effect of the electric 
current on E. coli. In these experiments cell division was inhibited not by 
electric current but also by the production of cis-diamminodichloroplatinum 
(II) from the platinum electrodes. Cisplatin was shown subsequently to have 
activity against a variety of experimental tumors, and today it is firmly 
established as a highly potent anticancer agents for the treatment of many 
malignancies, including testicular, ovarian, head and neck, bladder, germ cell, 
esophageal, and small cell lung cancers (Ozols and Young, 1991; Dancey and 
Le Chevalier, 1997; Loehrer. and Einhom, 1984).
. Cisplatin is a neutral square-planar coordination compound (Fig. 1). The two 
chloride ligands are stable at extracellular chloride concentration, but after 
diffusion into a cell, the lower chloride concentration therein facilitates 
exchange of the chloride ligands for water (Fig. 2). In fact, after intravenous 
administration cisplatin is relatively less reactive in the extracellular space, 
where the chloride concentration is about 100 mM, but, upon crossing the 
cellular membrane, it is activated in the intracellular space where the chloride 
concentration drops to about 3 mM. This exchange produces a potent 
bifunctional, positively-charged electrophilic aquated species, which represent 
the reactive form of the compound. The reactive product is able to react with 
any negatively charged-nucleophilic sites in the cell, including sulphydrilic, 
hydroxylic, carboxylic, hymidazolic, amminic and phosphate groups located on 
proteins and nucleic acids (Chu, 1994).
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Figure 1. Chemical structure of cisplatin.
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Figure 2. Hydration reaction of cisplatin. When cisplatin is dissolved in 
aqueous solution, chloride ions are displaced to allow the formation 
of aquated species, which are the reactive forms of the drug.
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(1) Introduction
The cytotoxic activity of cisplatin has been explained by a number of 
properties, including penetration of cellular membranes and accumulation in 
the cell and nucleus. Although this compound can interact with many structures 
in the cell, such as membranes, proteins, RNA and small thiol compounds 
(glutathione, cysteine, methionine), it has been extensively demonstrated that 
genomic DNA is the critical target for cisplatin cytotoxic activity. In this 
regard, it was observed that about 1% of the total amount of the drug which 
penetrates the cell combines with cellular DNA in the nucleus thus producing 
very cytotoxic platinum-DNA coordination complexes (Eastman, 1990; Chu, 
1994). Supporting this hypothesis there are some observations which indicate 
that cell lines unable to inactivate cisplatin by intracellular detoxification 
systems and/or to remove cisplatin-induced DNA damage are markedly more 
sensitive to this drug (Fram et al., 1990; Mistry et al., 1991; Kasahara et al., 
1991; Kelland et al., 1992c; Johnson et al., 1997)
As mentioned above, the cytotoxic activity of cisplatin is believed to be due 
to its ability to covalently bind nucleophilic reactive centres located on DNA 
and proteins. By a mechanism somewhat as demonstrated for alkylating agents, 
the formation of platinum-DNA complexes is achieved by a reaction formed by 
both an activation and a nucleophilic attack phase. By an SN1 kinetic reaction, 
the DNA-binding drug is activated by cellular metabolism processes in a 
reactive form which is able to attack nucleophilic groups via SN2 kinetics 
reaction. By means of several biochemical, biophysical and molecular biology 
approaches, it has been demonstrated that nucleophilic centres covalently
27
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bound by cisplatin are nitrogen atoms on position 7 of purinic bases (N7- 
Guanine and N7-Adenine) (Shin-Ichi Akiyama et al., 1999) (Fig. 3).
The lesions produced by cisplatin reacting with DNA are DNA-protein 
cross-links, interstrand DNA cross-links and intrastrand DNA cross-links, and 
all of these occur in the major groove of DNA. Quantitative studies show that 
DNA-protein cross-links account only for 1% of the cisplatin adducts formed in 
vitro whereas cross-links involving two nucleotides located on the same strand 
(intrastrand cross-links) or on the two opposite strands (interstrand cross-links) 
represent the most frequent cisplatin lesions (85-95%). Among these, the major 
lesion is a cross-link between two neighbouring guanines (1,2-intrastrand 
d(GpG)) which represents about 65% of the lesions both in experiments with 
purified DNA and in cells incubated with cisplatin. A further 25% of the 
lesions are cross-links between a neighbouring adenine and a guanine [1,2- 
intrastrand d(ApG)] and a neighbouring guanine and an adenine [1,2- 
intrastrand d(GpA)]. The remaining intrastrand cross-links are between two 
guanines separated by one or more bases [1,3-intrastrand g(GpNpG)]. Cisplatin 
also produces monofunctional lesions although sonie may occur as transient 
intermediates: in fact, cisplatin firstly forms monofunctional adducts with 
DNA, most of which are then converted into bifunctional adducts such as 
DNA-protein, DNA intrastrand and DNA interstrand cross-links (Crul et al., 
1997) (Fig. 4).
The therapeutic effects of cisplatin on human cancers may occur owing to 
several mechanisms. It has been demonstrated that by producing coordination
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Figure 3. Nucleophilic sites located on DNA bases preferentially attached by 
cisplatin. The highly-reactive electrophilic intermediates derived 
from cisplatin activation are able to covalently bind nucleophilic 
groups such as the N7 of guanines and adenines (DNA nucleotides).
•o
Figure 4. Cisplatin DNA adducts. (A) Cisplatin bound monofimctionally to 
guanine; (B) l,2-(GpG)-intrastrand cross-links; (C) l,3-(GpG)- 
intrastrand cross-links (N represents a base); (D) interstrand cross­
link; (E) cisplatin guanine-protein cross-link.
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complexes with DNA, cisplatin is able to inhibit DNA replication and chain 
elongation (Eastman, 1990). In fact, X-ray diffraction studies performed on a 
cross-linked dinucleotide [cis-Pt(NH3)2d(GpG)] indicated that the two guanines 
were completely destacked, and the deoxyribose sugar of the 5'- 
deoxyguanosine is in a C3'-endo pucker. Thus the intrastrand cross-link 
produces a severe local distortion in the DNA double helix, leading to 
unwinding and kinking (Bellon et al., 1991) which could be responsible for the 
alteration of the physiological metabolism processes of the DNA.
DNA damage caused by cisplatin seems to be the main cause of the 
antitumor activity of the drug, although the binding of cisplatin to DNA is not 
by itself sufficient to cause cell death. Cisplatin is much more toxic to dividing 
cells than resting cells, suggesting that some cell-cycle associated events, such 
as DNA replication and transcription, are required for its cytotoxic activity 
(Fraval and Roberts, 1979). Although its action is not dependent on a specific 
phase of the cell cycle, cisplatin can be up to 10 times more toxic to cells that 
are about to enter into S phase. Moreover, its toxic effect is a function of the 
amount of DNA damage remaining at the time cells enter S phase. These 
observations, together with the finding that DNA synthesis is inhibited in a 
variety of cells following platination, have led to speculation that inhibition of 
DNA replication may be the critical step in cisplatin toxicity, although some 
experimental results indicated that this hypothesis is not always true. Chinese 
hamster ovary cells (CHO), which are defective for a DNA repair pathway 
based on nucleotide excision repair (NER), and which are highly sensitive to
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cisplatin, were found to progress through S phase at a normal rate following 
exposure to the drug; these cells then arrested in G2 phase and subsequently 
died. DNA repair-competent cells could survive incubation with higher 
concentrations of cisplatin that inhibited DNA replication and slowed passage 
through the S phase. These cells also arrested in G2 following exposure to the 
drug. The fate of these repair-competent cells was dependent on the 
concentrations of cisplatin. At low concentration of the drug, the G2 arrest was 
transient and the cells eventually recovered, whereas at more toxic 
concentrations of the drug, the cells died. These data suggested that inhibition 
of DNA synthesis is not the critical step in cisplatin-induced cytotoxicity, and 
that essential events occur during G2 phase which determine the fate of the 
cells.
It should be emphasised that although G2 arrest appears to be a prerequisite 
for cell death (except at very high drug concentrations), not all such arrested 
cells died. At minimally toxic concentrations of cisplatin, cells may eventually 
bypass the block and return to normal cycling. Hence, there are two possible 
fates for a G2-arrested cell: survival or death. It has been demonstrated that G2 
arrest in radiation-damaged yeast is controlled by a gene of the NER system 
called RAD 9 (Weinert and Hartwell, 1988). Cells deficient in the Rad 9 gene 
product fail to arrest in G2 following DNA damage; instead they continue to 
cycle and then die (Weinert and Hartwell, 1988). An analogous system exists in 
mammalian cells, and this system may be relevant to the repair of DNA lesions 
induced by cytotoxic drugs such as cisplatin. A similar behaviour was observed
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in cells lacking DNA mismatch repair (MMR) activity: in fact, conversely the 
situation observed in MMR-proficient cell lines, no Gz-arrest but just a 0% 
delay was seen in MMR-deficient lines after exposure to alkylating agents and 
cisplatin (Hawn et al., 1995; Carethers et al., 1996).
Several investigators reasoned that the movement of the replication fork in 
cisplatin-treated cells would be inhibited selectively at sites of DNA damage, 
perhaps producing single strand gaps at the corresponding position in the 
daughter strand. It has been postulated that G; arrest could be a period during 
which such breaks would be repaired, a process often referred to as post- 
replicational repair (Eastman, 1990). Analysis of the DNA isolated from CHO 
cells after exposure to cisplatin indicated that it only contained double strand 
breaks (but not single strand breaks) and that these breaks occurred at a regular 
frequency within the chromatin (Sorenson, 1990), showing a typical pattern of 
the endonucleolytic digestion of chromatin DNA in the intemucleosome spacer 
regions. These breaks became evident after the cells had progressed to, and 
arrested in, Gz and their appearance correlated with toxicity. The breaks were 
not seen to be a consequence of cell death, since they occurred one day before 
NAD and ATP pools were depleted and two days before loss of membrane 
integrity. The overall levels of total RNA, mRNA, and protein synthesis did not 
decrease before the DNA breaks appeared, indicating that lethally injured cells 
continue to undergo apparently normal metabolic activity for several days. Both 
DNA digestion and cytotoxicity could be prevented by incubation of the cells 
with the protein synthesis inhibitor cycloheximide. These features are
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characteristic of programmed cell death (also called apoptosis) and the data 
altogether indicated that DNA lesions caused by cisplatin can trigger apoptosis 
via G2 arrest of the cell cycle progression (Anthoney et al., 1996; Sorenson and 
Eastman, 1988; Sorenson, 1990).
It has been postulated that DNA damage-dependent apoptosis is not the only 
way by which cisplatin can cause its antitumoral activity. As mentioned above, 
after exposure to this drug Ga-arrested cells can die by apoptosis or survive by 
removing platinum-induced lesions present on DNA. Cisplatin-DNA adducts 
may be qualitatively and quantitatively similar in some cell lines but the ability 
of the cell to repair this damage appears dependent on the amount of repair 
enzymes as well as the availability of deoxynucleotides such as thymidine 
which can be supplied by folate metabolism and the dTMP synthase cycle. It 
has been demonstrated that cisplatin can influence both methionine and folate 
metabolism (Scanlon et al., 1983; Scanlon et al., 1986; Scanlon et al., 1988; Lu 
et al., 1988; Kashani-Sabet et al., 1988) and that there is a correlation between 
cisplatin's toxicity and exogenous folate requirements for optimal human 
cancer cell growth. In fact, when higher cisplatin concentrations are necessary 
for cytotoxicity, lower exogenous concentrations of folinic acid are required for 
optimal cell growth. Thus, a cell line relying more on its endogenous folate 
metabolism rather than the exogenous component is less sensitive to the 
cytotoxic effect of cisplatin.
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1.3 Tumor cell resistance to cisplatin
The therapeutic efficacy of cisplatin is limited due to important side effects 
such as nephrotoxicity, nausea, vomiting, myelosuppression and ototoxicity 
(Prestayco et al., 1979). However the main clinical obstacle to the success of 
clinical treatment with cisplatin is intrinsic or acquired cellular resistance to 
this compound. In fact, some common tumors are intrinsically resistant to 
platinum and the frequent development of resistance in responsive tumors can 
be responsible for the failure of the cisplatin curative therapy. Relatively little 
is known about intrinsic resistance, but mechanisms of acquired resistance have 
been studied extensively (Chu, 1994; Andrews and Howell, 1990, Timmer- 
Bosscha et al., 1992; Zambie and Lippard, 1995) particularly in human tumour 
cells lines which had developed in vitro cisplatin resistance. In most cases the 
levels of resistance are less than 50-fold although there are reports of up to 
1000-fold resistance. Nevertheless, even a small increase in resistance of a 
tumour to cisplatin can be clinically important, since a large dose escalation 
leads to severe general toxicity.
The potential mechanisms responsible for this acquired cisplatin resistance 
suggested so far can be classified into two categories: those that lead to a 
reduction in the formation of cytotoxic DNA lesions and those that minimise 
their impact (Johnson et al., 1994). The first category includes decreased drug 
accumulation, increased drug efflux and enhanced intracellular drug 
inactivation by thiol-containing molecules such as metallothionein proteins and
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non-protein glutathione (GSH) (Andrews and Howell, 1990; Timmer-Bosscha 
et al., 1992; Zambie and Lippard, 1995; Johnson et al., 1994). The second 
category includes enhanced DNA repair and/or increased tolerance to DNA 
damage (Andrews and Howell, 1990; Timmer-Bosscha et al., 1992; Johnson et 
al., 1994) and alterations of genes involved in the cell cycle control such as p53 
(Zunino et al., 1997).
1.3.1 Intracellular drug accumulation
Reduced drug accumulation was observed frequently in cisplatin resistant 
cell lines obtained from tumours of different origin (human squamous 
carcinoma, human teratoma, murine leukemia and Chinese hamster ovarian 
carcinoma) (Hamilton et al., 1989, Andrews, 1994; Teicher et al., 1987; Hill et 
al., 1990). Conversely, investigations performed on other cell systems (human 
lung and rat ovarian carcinoma cells) provided evidence that differences in 
drug uptake between resistant and sensitive cells were not present (Meijer et 
al., 1990a; Sekiya et al., 1989). A reduced intracellular accumulation could 
result either from reduced uptake or active efflux, or both. Decreased cisplatin 
accumulation was due in part to defective influx of the drug in 2008 human 
ovarian carcinoma cells (Mann et al., 1990), but the real mechanisms of 
cisplatin transport into cells are not yet understood. Cisplatin generally is 
believed to enter the cells through passive diffusion, since the rate limiting 
factor for platinum uptake is the concentration of the platinum compound and
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the uptake of cisplatin is not saturatable (Hromas, 1987b). Moreover, the 
accumulation of cisplatin is not significantly inhibited by excess amounts of 
analogues of cisplatin, such as transplatin and carboplatin (Gately and Howell, 
1993).
There is some evidence suggesting that cisplatin uptake is mediated by 
membrane proteins. It has been shown that benzaldehyde compounds inhibit 
the uptake of cisplatin, presumably by forming Schiff bases with membrane 
proteins (Domish et al., 1989). Moreover, the NA-K ATPase inhibitor ouabain 
also inhibits cisplatin uptake by 50% (Andrews et al., 1991). However, it has 
been demonstrated that this pump itself does not directly transport cisplatin and 
that cisplatin accumulation is K-dependent (Andrews et al., 1991). These 
findings suggest that cisplatin accumulation is dependent on cell membrane 
potential. A model of cisplatin accumulation that accommodates most of the 
existing observations was formulated (Gately and Howell, 1993). In this model, 
about 50% of the initial rate of uptake is due to passive diffusion and the 
remaining 50% is due to facilitated diffusion through an, as yet, unidentified 
gated channel.
Cisplatin resistant cell lines are also frequently resistant to methotrexate and 
several metal salts, such as sodium arsenite, sodium arsenate, antimony 
potassium tartarate and cadmium chloride. It has been observed that cross- 
resistance to these agents by cisplatin resistant cells derived from human 
hepatoma and cervical adenocarcinoma resulted from multiple changes in the
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plasma membrane proteins that bind them (Shen et al., 1998). There may be a 
high-affinity uptake system for arsenite, arsenate and cisplatin.
Enhanced active efflux of cisplatin was observed in the cisplatin resistant 
human epidermoid carcinoma KCP-4 and in some other cisplatin resistant cells 
(Mann, et al., 1990; Fujii. et al., 1994a; Fujii. et al., 1994b). Experiments 
performed using somatic cell hybrids to test whether cisplatin resistance is a 
dominant or a recessive trait indicated that the resistance phenotype was 
incompletely dominant in the intraspecific hybrid between cisplatin resistant 
KCP-4 cells and cisplatin sensitive HeLa D980R-1 cells (HATs, ouAr). KCP-4 
cells showed a 70% decrease in cisplatin accumulation compared with the 
parental, cisplatin sensitive KB-3-1 cells, and the somatic cell hybrid showed a 
slightly higher cisplatin accumulation compared with KCP-4 cells when 
corrected for cell volume. These data indicate that defective accumulation is a 
co-dominant trait, and the data are consistent with the hypothesis that an active 
efflux pump for cisplatin is expressed in KCP-4 cells (Fujii et al., 1994a).
Cisplatin is not a substrate for P-glycoprotein GP-170 that is frequently 
overexpressed in multidrug-resistant cells and functions as a drug efflux pump 
(Gottesmann and Pastan, 1988).
The existence of an ATP-dependent glutathione S-conjugate export pump, 
named the GS-X pump, was hypothesised. This pump might efflux cisplatin 
conjugated with glutathione (GS-platinum complex) from L1210 murine 
leukemia cells (Ishikawa, 1992; Ishikawa et al., 1993) and as a consequence, 
plays a protective role by decreasing the intracellular concentration of the
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complex. The presence of an active efflux system for cisplatin was detected in 
KCP-4 cells (Fujii et al., 1994a). These cells have an ATP-dependent 
transporter for leukotriene C4 (LTC4), a substrate for the GS-X pump (Fujii et 
al., 1994b). The LTC4 transporter was inhibited by the GS-platinum complex. 
Significant ATP-dependent uptake of GS-platinum complex was observed in 
membrane vesicles from KCP-4, but not in those from parental KB-3-1 cells or 
multidrug resistant C-A500 cells, which overexpress multidrug resistance 
protein (MRP) (Ueda et al., 1999). These findings suggest that the GS-X pump 
is involved in reducing the accumulation of cisplatin in KCP-4 cells (Chen et 
al., 1998).
It has been proposed that the overexpression of multidrug resistance- 
associated protein (MRP) and the increased level of GSH in cisplatin-resistant 
human leukemia HL-60 cells are responsible for cisplatin resistance (Ishikawa 
et al,, 1996) However an MRP-transfected cell line that expressed high levels 
of MRP showed no cross-resistance to cisplatin (Cole et al., 1994). When the 
GSH levels in C-A120 cells that overexpressed MRP were increased to nearly 
the same levels as in KCP-4 cells by transfection with y-glutamyl cysteine 
synthase (y-GCS) cDNA, the resistance to, and the accumulation of, cisplatin in 
C-A120 cells were characteristics not significantly changed with respect to 
untransfected C-A120 cells (Chen, et al., 1998). These results indicate that 
MRP is not involved in cisplatin resistance.
Studies performed on cell lines résistant to both cisplatin and doxorubicin 
evidenced a positive association between canalicular multispecific organic
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anion transporter cMOAT (also known as Multidrug Resistance-associated 
protein 2 MRP2) overexpression and cisplatin resistance.
Studies performed transfecting cMOAT antisense cDNA in human hepatic 
cancer cells HepG2 (that express cMOAT) (Koike et al., 1997) indicated that 
cMOAT is involved in the transport of cisplatin and vincristine and in 
resistance to both agents. However, neither MRP nor cMOAT were detected in 
KCP-4 cells (Chen, 1998) and the characteristics of the LTC4 transporter 
expressed in KCP-4 vesicles were similar but not identical to that of MRP 
(Chuman et al., 1996). These findings suggest that an efflux pump for cisplatin, 
different from MRP and cMOAT, is involved in cisplatin resistance in KCP-4 
cells.
1.3.2 Cellular detoxification systems: glutathione and metallothioneins
It has been extensively demonstrated that detoxifying systems are important 
determinants of resistance to chemotherapeutic drugs based on their ability to 
neutralise cytotoxic activity of electrophilic agents such as cisplatin or quinone- 
containing agents like adriamycin.
Glutathione (GSH) is the most important non-protein thiol in living systems. 
It is known to function directly or indirectly in many important biological 
phenomena, including synthesis of proteins and DNA, transport (amino acids, 
ions and/or sugars), enzyme activity, metabolism and protection of cells (Arrick
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and Nathan, 1984; Kosower. and Kosower, 1978; Meister and Anderson, 
1983).
The biosynthesis of GSH proceeds via two successive ATP requiring steps, 
one catalysed by y-glutamylcysteine synthase (y-GCS) and the other catalysed 
by glutathione synthase (GS) respectively, thus producing a y- 
glutamylcysteinylglycine thiol tripeptide. It is important to note that such a 
biosynthetic pathway is also regulated by GSH itself through feedback 
inhibition. Under normal physiological conditions, the majority of GSH in 
mammalian cells exists in the reduced form (0.5 to 10 mM). Oxidation of GSH 
yields glutathione disulfide (GSSG). NADPH-dependent reduction of GSSG by 
the enzyme glutathione reductase (GR), as well as efflux of GSSG, effectively 
maintains the cellular concentration of GSSG at very low levels (5 to 50 pM). 
Furthermore, cellular GSH also participates in mixed disulfides with both 
protein and non-protein sulphydryls and in thiol esters of GSH (Arrick and 
Nathan, 1984).
GSH plays a role in decreasing the toxicity of several drugs by facilitating 
their metabolism to less active compounds. It acts as a nucleophile towards a 
wide variety of electrophilic agents leading to so-called GSH conjugates. These 
conjugates are either excreted as such or are metabolised to mercaptiiric acids 
and excreted in either bile or urine. This irreversible loss of GSH requires 
synthesis of GSH to restore the cellular GSH level (Kosower and Kosower, 
1978).
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The interaction of electrophilic agents with GSH can proceed spontaneously 
or it can be catalysed by Glutathione-S-transferase (GST), a family of cellular 
isoenzymes. These isoenzymes have generally been identified by both 
characteristic isoelectric points and substrate specificities. So far, three 
cytosolic GST families have been identified on the basis of their isoelectric 
points in man. These have been termed a  (basic), p (neutral) and n (acid, 
anionic). As these isoenzymes are known to have markedly different substrate 
specificities, both the total GST activity and the isoenzyme composition may 
be important determinants of a tumour cells ability to detoxify specific 
antineoplastic compounds (Douglas, 1987; Kosower and Kosower, 1978; 
Mannervik and Danielson., 1988; Meister and Anderson, 1983). Thus, the 
effectiveness of this conjugation pathway depends upon the cellular GSH 
concentration, the presence of GST of appropriate specificity and/or the 
capacity of the cell to rapidly resynthcsise GSH.
Along with direct interaction with drugs, xenobiotics and other chemical 
substances, GSH also plays a role in the detoxification of drug-induced free 
radical species. Free radicals may be formed physiologically, such as in 
metabolic processes in mitochondria, in microsomes and peroxisomes and 
could interfere with different cellular processes. Pathologically reactive oxygen 
intermediates may be generated by radiation, by elevated temperatures or by 
intracellular metabolism of chemical substances including antineoplastic agents 
like adriamycin, daunomycin, bleomycin, mitomycin C, which are activated to
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semiquinone radicals by NADPH-dependent flavin reductase (Meijer et al., 
1990a).
GSH is also essential for the synthesis of the DNA precursors 
deoxyribonucleoside triphophates (dNTPs). In fact, the synthesis of dNTPs 
from ribonucleotide diphophates is catalysed by ribonucleotide reductase 
through a system involving glutaredoxin, NADPH and GR. This may give GSH 
a function in the repair of DNA damage. The depletion of GSH may inhibit 
repair through the reduction of the dNTP pool size, although the requirement 
for repair synthesis would be small when compared to that needed for 
replicative DNA synthesis (Castellot et al., 1979; Holmgren, 1979; Luthman et 
al.,1979).
In addition to GSH, metallothioneins (MTs), may act as another nucleophile 
towards electrophilic agents. This family of 6-7 KDa proteins appears to serve 
a number of different biological purposes, such as zinc homeostasis and 
detoxification of heavy metals. In the case of exposure to electrophilic agents, 
the increased supply of MTs could provide the ‘neutralising* nucleophilic 
equivalent since MTs, which contain 30% of cysteine residues (20 of 61 amino 
acids), are rich in nucleophilic thiol groups. Although the majority of these 
thiols are bound to zinc, it appears that they are still capable of reacting with 
cisplatin and thus may serve as intracellular "sinks" that inactivate incoming 
cisplatin. It is known that MT gene transcription is strongly induced by heavy 
metal ions, glucordcoids, interferon and stress, whereas the ability of cisplatin 
to induce MT expression is still unclear (Chu, 1994).
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It has been demonstrated that cisplatin is able to bind MTs with a molar ratio 
of 10 platinum atoms for 1 MT molecule (much higher than that of GSH) and, 
when cisplatin binds to MT, it loses its amine ligands and displaces heavy 
metal ions as described by the following reaction:
(Zn2VMT+10(NH3)2Pt2 -> (Ptl4) 1o-MT+20(NH3)+7(Zii2+)
In the last few years it has been extensively demonstrated that cellular 
resistance to cisplatin is multifactorial and that one of the possible determinants 
of such a resistance can be an inactivation of the drug by cellular thiols such as 
GHS and MTs which are able to prevent the reaction between the cisplatin and 
cellular nucleic acids. Results from several studies performed have provided a 
correlation between cisplatin resistance and increased levels of GSH in several 
murine and human tumour cell lines (Ilromas et al., 1987a; Richon et al., 1987; 
Mansouri et al., 1989; Beherens et al., 1987; Fram et al., 1990; Fujiwara et al., 
1990; Hospers et al., 1988; Meijer et al., 1990b; Hamilton et al., 1985; 
Andrews et al., 1988; Andrews et al., 1989).
A direct correlation was observed between the degree of cisplatin resistance 
and GSH levels in a panel of human small cell lung carcinoma cell lines 
(hSCLC) (Hospers et al., 1990b). Moreover a close correlation between GSH 
and native cisplatin resistance has also been reported in human ovarian 
carcinoma cells (Mistry et al., 1990).
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Cellular GSH can be depleted by administration of various compounds able 
to interact with GSH by forming conjugates and promoted by the action of 
glutathione S-transferases (GST). The most frequently used method to decrease 
GSH is via inhibition of glutathione synthesis by buthionine sulfoximine (BSO) 
(Griffith and Meister, 1979) which selectively interacts with y-GCS, one of the 
two GSH synthesis enzymes. Long-term GSH depletion with BSO in murine 
mammary carcinoma P-66 cells, however, resulted also in an inhibition of 
protein and DNA synthesis and a reduction of cells in the S-phase (Dethlefsen 
et al., 1986). This cellular toxicity may well be cell-type dependent as in most 
studies dealing with GSH depletion by BSO no signs of toxicities are 
mentioned. Selectivity may be achieved in situations in which the tumour cells 
and the normal cells have different quantitative requirements for GSH.
The effect of BSO on the GSH content of a number of normal tissues and 
three experimental tumours was studied in female CH/HeJ mice (Lee et al.,
1987). Considerable diversity in response to treatment with BSO was 
demonstrated. GSH depletion can be achieved in tumours with BSO doses 
lower than those required for normal tissues, with the exception of the lung. 
This supports the idea that the therapeutic index of some chemotherapeutic 
drugs can be improved by BSO.
It has been shown that when BSO is used to reduce GSH levels, the cytotoxic 
effect induced by cisplatin in tumour cell lines varies in a 22-fold cisplatin- 
resistant hSCLC cell line, with a 2,5-fold increase in GSH content compared to 
the parent cell line, exposure to BSO reduced cellular GSH content to a non-
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detectable level and increased the cisplatin cytotoxic activity (Meijer et al., 
1990b). Other studies, however, found no effect of BSO treatment on cisplatin- 
induced cytotoxicity (Richon et al., 1987; Teicher et al., 1987). A probable 
explanation for this is that a reduction of GSH content below a critical level, 
and perhaps more importantly, at certain subcellular compartments such as the 
nucleus, is required to obtain a marked sensitisation to this drug by BSO. 
Measuring the total GSH can, therefore, be misleading since the concentration 
of GSH in a particular compartment of the cell may be far more important than 
the average cellular concentration. Another reason for the observed 
discrepancies in the results may be the fact that the steady state of GSH is 
generally used to express the capacity of this defence system, without 
considering GSH biosynthetic capacity of individual cell lines.
The activity of the GSH-related enzyme GST may also be a factor in 
determining drug response. Overexpression of one or more GST isoenzymes 
has been found in a number of different tumour cell lines selected in vitro for 
resistance to alkylating agents (Bakka et al., 1981; Robson et al., 1987; Wang 
and Tew, 1985). GST was found to be elevated in a cisplatin resistant human 
squamous carcinoma cell line. The isoelectric point of the GST isoenzyme was 
4.8 in both the resistant and the parental sensitive cell line, which suggests the 
induction in the resistant cells of the predominant isoenzyme present in the 
parental cell line (Teicher et al., 1987). In a cisplatin-resistant human 
melanoma cell line, a 5.4-fold increase in GST activity was associated with a
4.5-fold elevation of the GST-tc isoenzyme protein consequent to a 15.2-fold
44
(1) Introduction
increase in mRNA levels (Wang et al., 1989). Also in a Chinese hamster ovary 
cell line, cisplatin resistance was associated with an increase in GST activity 
and GST-tt mRNA. No apparent gene amplification of the GST-ti gene was 
observed in resistant cells (Saburi et al., 1989). Also in this study, no increased 
GST activity was found in a cisplatin-resistant human prostate cancer cell line. 
Again, overexpression of GST-ti in two GST-7T-transfected cell lines did not 
influence cellular sensitivity to alkylators such as chlorambucil, melphalan and 
cisplatin (Nakagawa et al., 1990).
Inhibitors of GST activity, such as ethacrynic acid (EA), have successfully 
been used in a Walker-256 rat breast carcinoma cell line with acquired 
resistance to nitrogen mustards and in two human colon carcinoma cell lines, 
HT29 and BE (Tew et al., 1988). EA mediated inhibition of GST also increased 
melphalan-induced cytotoxicity in RPMI8322 melanoma cells (Ringborg et al., 
1990). S-nitroso-compûunds, such as S-nitroso-L-glutathione, inhibited the 
GST of rat liver by competing with GSH for its binding site at the reactive 
centre of the GST enzyme (Akman et al., 1988).
The role of GSH at the nuclear level is still unclear. Previous studies 
indicated that GSH reacts in vitro with monofunctional adducts of platinated 
DNA (Eastman, 1987). Such a reaction would prevent, and thereby decrease, 
the formation of more toxic bifunctional cisplatin-adducts and thus reduce the 
cytotoxicity of cisplatin. Data supporting this evidence emerged from a variety 
of studies. Experiments performed on a cisplatin-resistant mouse leukemia 
L1210 cell line indicated that such a resistance might be due in part to
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enhanced quenching of morioadducts (Micetich et al., 1983) thus suggesting a 
critical role for GSH in preventing platinum monoadduct rearrangements. In a 
cisplatin-resistant hSCLC cell line characterised by a decrease in total DNA 
platination, a decrease in intra- and interstrand cross-links formation or an 
enhanced DNA repair capacity and no change in cellular platinum content were 
observed as compared to the parental cell line (Hospers et al. 1988, 1990a,b; 
Meijer et al., 1990a). GSH-depletion with BSO resulted in an increase in the 
amount of platinum bound to DNA as well as in the formation of Pt-GG 
adducts (Meijer et al., 1990a). These data would appear to suggest that high 
levels of GSH are responsible for the reduction of reactive platinum resulting in 
lower net platination and, consequently, in lower levels of intrastrand and 
interstrand cross-links (Hospers et al., 1990b; Meijer et al., 1990a).
The involvement of MTs in acquired resistance to cisplatin is rather 
controversial. MTs can be induced by heavy metals such as cadmium and zinc. 
Cadmium resistance induced in vitro in a human epithelial and a mouse 
fibroblast cell line, resulted in high levels of MTs and cross-resistance to 
cisplatin, In cytosols from cells resistant to this drug, 70% of the platinum 
appeared in the MTs fraction, whereas less than 5% was recovered in the 
corresponding fraction from non-resistant cells (Bakka et al., 1981). Induction 
of MTs by chronic culture in cadmium chloride and zinc chloride also led to 
cross-resistance with cisplatin in human ovarian carcinoma cells (Andrews et 
al., 1987). A 17% of the total cellular platinum in cadmium resistant cells was 
associated with the MTs fraction, against only 4% in the parent cells. It was
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also demonstrated that cellular resistance to cisplatin is associated with an 
increase in MTs and their mRNA level in a panel of human cell lines, and that 
reversal of the cisplatin resistant phenotype is accompanied by a decrease in 
MTs content. Another study reported that the introduction of an eukaryotic 
expression vector encoding MT Ha (a human MT isoform) into mouse C217 
cells conferred the cisplatin resistance phenotype to the cells (Kelley et al.,
1988). Conversely, in a Chinese hamster ovarian cancer cell line resistant to 
cisplatin, no increase in MTs mRNA or MTs gene amplification was observed 
(Saburi et al., 1989). Moreover, results from other studies demonstrated that 
overexpression of MT mRNA could not be related to cisplatin-resistance in a 
panel of human ovarian cancer cell lines resistant to cisplatin as well as in a 
series of human ovarian cancer cells directly obtained from untreated patients 
and patients . whose tumors were refractory to cisplatin-containing 
chemotherapy (Schilder et al.,1990). Although MT overexpression may be 
associated to cisplatin resistance induction, its causal role remains to be 
established.
1.3.3 Cellular DNA repair pathways and cellular resistance/tolerance to 
cisplatin-induced DNA damage
It has been widely accepted that genomic DNA is the primary target for 
cisplatin and its derivatives. Approximately 1% of the cellular platinum binds 
to DNA inducing covalent lesions such as monofunctional adducts and
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bifunctional (interstrand, intrastrand and DNA-protein cross-links) adducts. 
Results from several studies illustrated the importance of induction and 
removal of the DNA lesions produced by cisplatin in determining cell 
sensitivity to this drug. It has been demonstrated that in human microcitoma 
cell lines resistant to cisplatin a very low level of cisplatin-DNA adducts (in 
particular interstrand cross-links) was present (Hospers et al., 1990b). 
Moreover, an increased extent of DNA-lesion repair was observed in a 
cisplatin-resistant human teratoma cell line with respect to the parental 
counterpart (Hill et al., 1990). Again, studies performed on human and rat 
ovarian cancer cell lines, revealed a greater induction of the unscheduled DNA 
synthesis in cisplatin-resistant cells than in sensitive cells.
The fact that a different cytotoxic activity of alkylating agents and platinum- 
based drugs was found in cell lines characterised by alterations in some of the 
most important DNA repair pathways suggested a strong correlation between 
DNA repair system functional status and cellular sensitivity to DNA damaging 
anticancer drugs.
Damaged DNA repair is a molecular process essential to the maintenance of 
life, evolved at an early time for the restoration of the original status of the 
genome (Hanawalt, 1995). Repair mechanisms contribute to the genetic 
stability maintenance and the physiological relevance of such pathways is 
evidenced by the fact that these systems operate in all organisms from bacteria 
to mammals and are surprisingly similar. Nevertheless, most DNA repair 
processes are error prone. The lack of a 100% efficiency in repair mechanisms
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has contributed to the genetic diversity on earth and to the generation of 
variants in populations within species (Boulikas, 1992).
The repair of damaged DNA is an important molecular defence system 
against endogenous and exogenous events which, targeting genomic DNA, 
could be potentially mutagenic and lethal.
Endogenous DNA lesions can arise from:
• normal DNA metabolism processes such as replication and 
recombination which can produce both the formation of single-base 
mismatches or small insertions/deletions introduced by DNA polymerase 
and large insertions/deletions respectively;
• chemical reactions such as DNA hydrolysis, hydrolytic deamination 
of cytosine, 5-methylcytosine, adenine and guanine to uracil, thymine, 
hypoxanthine and xanthine respectively, depurination via hydrolytic 
breakage of the glycosyl bond linking DNA bases and sugar-phosphate 
backbone, hydroxyl (OH*) and superoxide (O^*)-induced oxidation to 
produce oxidised DNA bases such as 8-oxoguanine/hydroxoguanine and
5,6-dihydroxy-dihydrothymine and, finally, méthylation in which S- 
adenosylmethionine acts as methyl groups donor thus producing N7- and 
0 6-methylguanine and N3-methyladenine.
DNA damages can arise also from the action of exogenous factors including:
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• ultraviolet light which is able to directly modify some DNA bases 
thus producing cyclobutane pyrimidine dimers (T o T  and C oT ), 6-4 
photoproducts between two adjacent pyrimidines (T oC ), cytosine hydrate 
and thymine glycol;
• ionizing radiations which are able to interact both with the sugar- 
phosphate backbone and with single DNA bases thus producing single and 
double strand breaks;
• chemicals such as methylating agents, benzene, benzopyrene and 
anticancer drugs most of which produce carcinogen DNA damages (Karran 
and Bignami, 1994).
Such DNA lesions are all virtually repaired by the different DNA repair 
systems although the efficiency of each repair process depends on the 
chemistry of the lesion, the intrinsic cellular capacity for repair and the 
structure and dynamics of the chromatin (active transcription and replication) 
(Bohr, 1991). These considerations are also valid for lesions produced by 
anticancer drugs which are able to induce several different DNA lesions such 
as modified nucleotides, DNA cross-links and DNA single- or double-strand 
breaks.
DNA lesions induced by these drugs can be repaired in the following ways 
(Salles et al., 1995; van Vuuren, 1995; Wood, 1996).
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Direct repair of the damaged base. This mechanism is used to repair minor 
damage, such as simple alkylation of bases caused by atmospheric methyl 
halides and the products of nitrate metabolism. The most important enzymes 
involved in this pathway are MGMT (0 6-methylguanine-DNA 
methyltransfrases; Wood, 1996) which are small proteins, highly conserved 
during evolution, that act by mobilising the methyl group on the O6 position of 
guanine and sequestering it on a designed acceptor cysteine within the MGMT 
molecule itself. Transfer of the methyl group to the protein inactivates the 
MGMT. Thus the reaction is stoichiometric with each MGMT molecule able to 
act once. An important corollary of this is that the cell’s capacity to repair O6- 
methylguanine lesions is correlated strongly to the number of preexisting 
MGMT molecules.
Another important enzyme able to directly repair the damaged nucleotide is 
the photolyase enzyme which is involved in removal of cyclobutane pyrimidine 
dimers (photoproducts) (van Vuuren, 1995).
Multienzvmatic DNA repair pathways. While direct repair is performed by 
only one enzyme, three different multienzyme systems are involved in the 
removal of damaged regions of DNA: Base Excision Repair (BER), Nucleotide 
Excision Repair (NER), Post-replication daughter strand repair, Mismatch 
Repair (MMR) and Recombinational repair.
BER is a “very short patch repair” able to remove simple types of lesion that 
result in relatively minor structural alterations of individual DNA bases
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(produced by different chemical or physical agents: oxidative agents, X-rays or 
alkylating agents), such as N3- and N7-methyladenine, thymine glycols and G-T 
mispairs which are removed from DNA as free bases. This repair process is 
initiated by enzymes called DNA glycosylases that cleave the bond between the 
damaged base and the sugar-phosphate backbone leaving an 
apurinic/apyrimidinic site which is subsequently recognised and removed by an 
AP-endonuclease and a DNA-deoxyribose phophodiesterase. The gap in the 
DNA sequence is then filled by DNA polymerase p and a DNA ligase. (Sancar, 
1995; Sobol et al., 1996).
The NER is a “short patch repair” system which recognises a wide variety of 
structurally unrelated DNA lesions, such as UV photoproducts and bulky 
adducts, including those produced on DNA by cisplatin. The NER process 
involves several steps: after recognition of the lesion, the damaged DNA strand 
is incised at both sides of the adduct. Next, the damaged base(s)-containing 
region is removed, the gap is filled by DNA reparative synthesis and finally the 
remaining nick is ligated (Sancar, 1996; Mu et al., 1996). NER may be coupled 
to transcription and acts in an ATE-dependent fashion.
If replication is blocked by a lesion, post-replication daughter strand repair 
can re-initiate downstream if the lesion is in the leading-transcribed strand. 
Replication can also restart 3’ of the damage if the lesion is in the lagging 
strand. The single-stranded gaps, that are left in the newly synthesised DNA 
strand in this process, are repaired by recombinational strand exchange, using
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the daughter strand as a template, allowing complete replication of the DNA 
(Kaufinann, 1989b).
MMR is also a post-replicational type of repair. This “long patch repair” 
pathway involves several steps: after damage recognition, the newly 
synthesised strand is cleaved, followed by degradation of the DNA region 
containing the mismatch. Finally, the gap is filled and ligated by DNA 
polymerase and ligase respectively (Kunkel, 1995).
The recombinational repair pathways, Non Homologous End Joining (NHEJ) 
and Homologous Recombination Repair (HRR), are known to be involved in 
the processing of very cytotoxic DNA lesions such as double-strand breaks 
(Takata et al., 2000) and DNA interstrand cross-links (Cole, 1973; Cole et al., 
1976; Jachymczyk et al., 1981). Repair of DNA double-strand breaks by HRR 
requires the presence of homologous duplex DNA elsewhere in the genome, 
i.e., either a homologous chromosome or a sister chromatid. It commences by 
partial degradation of the double-strand break, leaving single-stranded ends, 
followed by protein binding to the free ends. Subsequently, strand exchange 
with duplex DNA is initiated (van Vuuren, 1995). NHEJ simply acts to process 
and ligate broken ends without a requirement for extensive homology (Takata 
et al., 2000).
There is a substantial overlap in the substrate specificity of these systems and it 
is important to underline that these DNA repair pathways do not act 
independently but are closely correlated since they are able to recognise similar
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substrates, although with different affinity. For example, 0 6-methylguanine 
adducts could be directly recognised and repaired by MGMT but it could also 
be recognised as 0 6-meG-C or 0 6-meG-T mismatch by the MMR system. 
Cisplatin induced intrastrand cross-links can be recognised by both MMR and 
NER. The NER pathway, in particular, is thought to remove virtually any 
lesion (Wood, 1996; Sancar, 1995). Repair of cisplatin-DNA adducts is 
believed to occur mainly by this pathway (Kunkel, 1995). Interstrand cross­
links might also be repaired by the NER system. However, evidences emerged 
from several studies would suggest that the removal of such DNA lesions 
requires the participation of NER and recombinational repair proteins (Cole, 
1973; Cole et al., 1976; Jachymczyk et al., 1981; Zambie and Lippard, 1995; 
Sancar, 1995; Wood, 1996).
No involvement of the BER pathway in elimination of cisplatin-DNA lesions 
has been demonstrated. As regards MMR, very recent studies have 
demonstrated the ability of this system to recognise intrastrand cross-links 
(Yamada et al., 1997; Fink et al., 1998) and, in an attempt to repair these, 
MMR seems to be able to generate molecular signals triggering apoptosis.
Due to their great importance in determining cellular sensitivity to cisplatin 
and its derivatives NER, Recombinational Repair and MMR will be illustrated 
in detail.
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1.3.3.1 Nucleotide excision repair (NER)
The NER system is one of the most important DNA repair mechanisms, 
because of its wide substrate range (Wood, 1996; Sancar, 1995). In humans, the 
NER pathway has been studied by means of three inherited disorders 
(Xeroderma pigmentosum (XP), Cockayne syndrome (CS) and TTD, a 
photosensitive form of trichotiodystrophy) in which a defective NER 
mechanism is involved. Genes encoding for proteins involved in NER have 
been named as the subclasses of XP in which they arc lacking, whereas others 
have been designated ERCC genes (excision repair cross-complementing 
genes). Some independently identified XP proteins and ERCC gene products 
are identical (for example, ERCC2 is identical to XPD and ERCC3 is identical 
to XPB; O'Donovan and Wood, 1993). The NER reaction mechanism is 
represented in Figure 5. First, the damage is recognised by XPÂ-RPA 
(replication protein A, also referred to as ‘human single-stranded binding 
protein’ (HSSB) complex) (step 1). XPA contains a zinc finger and has a high 
affinity for damaged DNA. XPE is thought to play a role as a stimulatory or 
accessory factor for the binding of XPA-RPA to DNA. Next (step 2), the DNA 
is unwound by two subfactors of the general transcription factor TFIIH: XPB 
and XPD. These two factors exhibit helicase activities, each in opposite 
direction (XPB 3->5 and XPD 5->3). The XPC-HHR23B complex also binds 
to the damaged strand in this phase of the process and acts as a stabiliser for the 
unwound state of the DNA. Next (step 3 and 4), the dual incisions are made.
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Figure 5. Model for nucleotide excision repair (NER) in humans. Damage (★) 
is recognised by the XPA-RPA complex, stimulated by XPE (Step
1). Subsequently, two subfactors of TFIIH, XPB and XPD, unwind 
the DNA after which the XPC-HR23B complex is recruited (Step
2). Next, XPG makes the 3' incision (Step 3) and XPF-ERCC1 
makes the 5' incision (Step 4). The damaged part is released and the 
postincision complex is dissociated by RCF, leaving behind the 
gapped DNA protected by RPA, PCNA and other proteins (Step 5).
. . .  Finally, the gap is filled and ligated (Step 6).
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First, XPG incises 3* of the lesion and remains bound to the damaged site. It 
plays a structural role in maintaining a stable complex and in recruiting XPF- 
ERCC1, which incises 5’ of the lesion (Hoeijmakers and Bootsma, 1994). XPA 
also acts as an anchor to recruit XPF-ERCC1. The. damaged part is now 
released as a 27-29 nucleotide long fragment (step 5) then the post incision 
complex is dissociated by a protein called RCF (replication factor C). Both the 
gapped DNA and the excised oligomer are complexed with proteins. Two of 
these proteins are proliferating cell nuclear antigen (PCNA) and RPA; the 
others have not yet been identified. Complexation is a necessary step in order 
to protect the excision gap from non-specific nucleases until repair synthesis 
take place. Repair is performed by DNA polymerases ô or e. Finally, a ligase 
seals the remaining nicks (step 6).
It has been demonstrated that NER status can contribute to determine cellular 
sensitivity to different classes of DNA-damaging anticancer drugs such as 
cisplatin and minor groove-DNA alkylators Tallimustine and CC-1065 (Damia 
et al., 1996). Specifically, a role for enhanced DNA repair in cisplatin 
resistance has been observed frequently (Andrews and Howell, 1990; Calsou 
and Salles, 1993). In several resistant rodent cell lines, increased repair of 
cisplatin adducts was demonstrated (Eastman and Schulte, 1988; Sekya. et al., 
1989; Sheibani et al., 1989). In one of the sensitive cell lines, the L1210 mouse 
leukaemia cell line, a mutation in the XPG gene was found and increased repair 
rates of DNA damage in a resistant L1210 subline could be attributed to the 
reversal of this mutation (Vilpo et al., 1995). The existence of such mutations
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in other cell lines is not known. Increased repair of cisplatin-DNA adducts 
(measured by atomic absorption spectroscopy) has also been demonstrated in 
resistant human tumour cell lines (Ali-Osman et al., 1994; Bedford et al., 1988; 
Masuda et al., 1990; Parker et al., 1991). For example, the cisplatin resistant 
ovarian cancer cell line A2780cp70 was found to be about two-fold more 
efficient in repairing cisplatin adducts than the sensitive A2780 cells (Johnson 
et al., 1994; Masuda et al., 1990; Parker et al., 1991). A study on human 
bladder and testicular tumour cells showed that the less sensitive (RT112) was 
able to repair all platinum-DNA adducts whereas the five-fold more sensitive 
line (SUSA) was unable to remove the majority of DNA platination during the 
same period of post treatment (Bedford et al., 1988).
Increased repair of cisplatin-DNA lesions has also been demonstrated in 
patient derived cells. In one study, the rate of DNA repair in tumor cells from 
patients undergoing cisplatin treatment was quantified. A 2.8-fold increase in 
repair rate was found in tumour cells obtained from patients who underwent 
progression after cisplatin therapy, as compared to the level of repair in tumour 
cells obtained before treatment (Ali-Osman et al., 1994). Moreover, a study in 
tumour cells obtained from different individuals prior to treatment revealed that 
intrinsic DNA repair capacity varied as much as 10-fold (Jones et al., 1994). As 
a consequence, repair capacity in untreated tumours may be correlated to the 
clinical outcome of subsequent treatment, and information on this subject could 
be relevant for the clinical use of cisplatin.
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Repair efficiencies of different types of cisplatin adducts vary considerably.
In in vitro assays using mammalian cell-free extracts it has been demonstrated
that the most abundant l,2-d(GpG) intrastrand adduct is repaired poorly as
compared to the other cisplatin DNA adducts (Szymkowski et al., 1992). In this
system, the l,2-d(ApG) and l,3-d(GpG) intrastrand adducts were removed 30-
50% more efficiently than the l,2-d(GpG) intrastrand adduct (Szymkowski et
al., 1992; Huang et al., 1994). The repair rates for interstrand cross-links and
monofunctional adducts are difficult to measure. Since they are formed in very
low amounts, highly sensitive assays are required. High disappearance rates of
monofunctional adducts were reported in drug resistant cells but, since such
lesions are potential precursors for bifunctional adducts, it is probable that this
high rate of disappearance reflects adducts rearrangement rather than DNA
repair (Bedford et al., 1988). In fact, when monofunctional platinum adducts
(which were unable to rearrange to bifunctional adducts) were investigated in
an in vitro assay using human cell-free extracts, no repair for these adducts was
observed (Calsou et al., 1992). In an in vitro system using mammalian cell-free
extracts, no repair of interstrand cross-links was detected, which indicated that
»
repair of interstrand cross-links by the mammalian NER pathway is much less 
efficient than that of any of the intrastrand adducts (Szymkowski et al., 1992). 
In contrast, in other studies, performed with rat ovarian tumour cells and non­
small cell lung cancer cell lines, interstrand cross-links removal was observed. 
In both cases, resistant sublines did not show increased repair of the interstrand 
cross-links (Bungo et al., 1990; Zeller et al., 1991). However, several other
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groups reported an increased repair of interstrand cross-links in resistant 
tumour cell lines as compared to sensitive ones (Bedford et al., 1988; Hill et 
al., 1990; Calsou et al., 1992; Jones et al., 1991; Zhen et al., 1992; Johnson et 
al., 1994). The differences in rate of repair between the different cisplatin 
adducts may be due to specific distortions of the DNA helix induced by these 
adducts. It is believed that the repair proteins recognise the change in DNA 
conformation rather than the platinum compound itself (van Vuuren, 1995).
The NER mechanism involves several steps, each step requiring several 
proteins. It is not clear which step is rate limiting. In fact, both damage 
recognition and the incision step have been postulated to be rate-limiting in the 
NER process (Visse, 1994; Chu and Chang, 1990; Shivji et al., 1992). In order 
to determine the mechanisms responsible for the increase in NER activity in 
resistant tumour cells, the relative levels of proteins involved in NER have 
been measured (Tab. I).
The gene encoding for the general recognition factor XPA was found to be 
more actively transcribed in ovarian tumour cells from patients clinically 
resistant to platinum compounds, as compared to those obtained from patients 
clinically sensitive to these agents (Dabholkar et al., 1994). The levels of the 
other general recognition protein RPA have been investigated in vitro, in 
human ovarian cancer cell lines. Conversely, no overexpression of the other 
general recognition protein RPA, was observed in cisplatin-resistant sublines of 
human ovarian cancers as compared to parental cells (Bissett et al., 1993; 
Clugstone et al., 1992). Expression of the stimulatory factor XPE has also been
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Table I. Proteins involved in nucleotide excision repair (NER).
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studied in several human tumour cell lines. Studies performed with HeLa cell 
extracts showed that two nuclear factors that recognise UV-modified DNA 
were overexpressed in the cisplatin-resistant sublines (Chao et al., 1991a). One 
of these factors is believed to be XPE and the other has not been identified. 
These cisplatin-resistant HeLa cells showed cross-resistance to UV-induced 
damage supporting the hypothesis that XPE is involved in repair of cisplatin 
adducts as well as of UV damage. Another study from the same research group 
demonstrated that these UV-damage recognising factors were inducible by 
cisplatin (Chao et al., 1991b). Moreover, in human tumour cell lines of various 
origin a 2.7 to 4.3-fold expression of XPE was found in cisplatin-resistant cells 
with respect to their cisplatin-sensitive parental cells (Chu and Chang, 1990). It 
was also demonstrated that these cisplatin resistant cells had acquired an 
increased DNA repair activity. In the cisplatin-resistant cell lines described 
above, the levels of two of the three known DRPs (Damage Recognition 
Proteins) involved in NER were increased and, therefore, it is reasonable to 
believe that cisplatin can influence the expression of these proteins. High levels 
of these DRPs may lead to a more efficient repair of the cisplatin-DNA adducts 
and hence induction of cisplatin resistance. Also, it seems likely that cells that 
overexpress XPA and XPE proteins may acquire cross-resistance to DNA 
active drugs other than cisplatin, since these factors are capable of recognising 
multiple forms of damaged DNA (Chu and Chang, 1990).
ERCC1, which is involved in making the 5’ incision in the NER pathway, is 
considered the most important marker for NER activity in several studies
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(Reed, 1996a,b). In fact, increased levels of ERCC 1 were observed in tumour 
cells from patients with ovarian cancer resistant to cisplatin chemotherapy 
(Dabholkar et al., 1994; Dabholkar et al., 1992). In an in vitro study, 
pronounced differences in the basal levels of ERCC 1 were observed between 
sensitive and resistant ovarian cancer cells, with the resistant cell line showing 
a 30- to 50-fold higher level of ERCC 1 than the sensitive one.
In vitro studies carried out on NER deficient-Chinese hamster ovarian 
carcinoma cells lacking functional ERCC1,2, 3,4, 5 or 6 genes, confirmed that 
ERCC1 and ERCC4 genes play a fundamental role in the repair of cisplatin and 
melphalan-induced DNA lesions since cells lacking such proteins were 
hypersensitive to these drugs (Damia et al., 1996). These findings were 
supported by data emerging from experiments in which transfection of ERCC 1 
mutant cells with an expression vector carrying the wild type ERCC1 gene 
rendered them more resistant to both cisplatin and melphalan (Bramson and 
Panasci, 1993).
The importance of a functional ERCC1 protein was also demonstrated in a 
study performed on human ovarian cancer and T cells in which it was shown 
that ERCC I may exist in at least two forms: a full length form and an 
alternatively spliced form that lacks exon VIII (van Duin et al., 1986; 
Dabholkar et al., 1994) and codes for a functionally inactive ERCC1 protein. It 
seems probable that the portion of the protein codified by the exon VIE is 
responsible for making the 5* incision into cellular DNA. In cisplatin resistant 
cells, the molar ratio between the alternative spliced form and the full length
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form of ERCC1 was found to be lower than that of cisplatin-sensitive cells, 
thus indicating a possible correlation between the level of alternative splicing 
of ERCC 1 and cisplatin-DNA lesion repair activity of the NER.
These data altogether indicate that clinical resistance to cisplatin seems to be 
associated with an increased expression of ERCC1 protein and/or a higher 
‘alternative spliced form/full length form’ molar ratio of the ERCC1 mRNA in 
ovarian cancer patients (Dabholkar et al., 1994). Moreover, in a study 
performed on parental Chinese hamster ovarian cancer cells, it was found that 
overexpression of the ERCC1 resulted in a hypersensitivity to cisplatin and 
melphalan. It was suggested that the overexpression of ERCC 1 protein would 
prevent the dissociation from DNA of the incision complex, thus inhibiting 
repair, or alternatively lead to more incisions than other NER proteins could 
repair (Bramson and Panasci, 1993).
As regards the two hclicases, XPD (ERCC2) and XPB (ERCC3); results 
obtained from studies carried out on ovarian cancer and testicular tumour cells 
showed an upregulation of these in cisplatin-resistant cells as compared to 
sensitive cells (Dabholkar et al., 1992; Tavema et al., 1994).
Increasing evidence has become available regarding the presence of a 
considerable intragenomic heterogeneity of the DNA repair processes. Since 
the genes only constitute a small fraction of the overall genome (<1%), any 
changes in gene-specific repair would not be detected using traditional assays 
for the overall genome (Bohr, 1991). DNA repair appears to take place
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preferentially on the transcribed strand of expressed genes (Sancar A., 1995; 
Friedberg, 1996; Hanawalt, 1994; Bohr, 1991). Moreover, preferential repair is 
confined to genes which are transcribed by RNA polymerase II (Sancar, 1995). 
The current hypothesis for the reaction mechanisms of transcription-coupled 
repair has been described (Friedberg, 1996): Briefly, when RNA polymerase II 
encounters a lesion during transcription, it stalls. The stalled complex (Fig. 6) 
is recognised by transcription proteins (probably TFIIS), by proteins CSA and 
CSB (McLaughlin et al., 1993), and by the product of a gene named Mfd (i.e. 
transcription repair coupling factor TRCF). TRCF is believed to bind DNA 
specifically at a site where RNA polymerase II is stalled by interacting with 
DNA-RNA polymerase II complex (Friedberg, 1996). Subsequently, RNA 
polymerase II backs up or is removed, and the recognition protein-complex 
recruits XPA and TFIIH to the lesion site that is now accessible. The NER 
complex (XPG, XPF-ERCC1) then assembles at this site, and repair synthesis 
takes place, restoring a lesion-free duplex that can now serve as a template for 
transcription as well as in NER. Two types of TFIIH complex have been 
isolated from yeast and are referred to as the TFIIH holoenzyme and the 
nucleotide excision repairosome (Drapkin et al., 1994; Haidar et al., 1994). 
These complexes share some components but also have some different, unique 
features. The relationship between these two forms is still unclear. However, it 
is likely that a fraction of the NER system is specifically committed to, and 
active on, the transcribed strand of active sequences in the genome. (Sullivan, 
1995).
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Figure 6. Model for transcription-coupled DNA repair in mammalian cells.
Arrested RNA polymerase II undergoes a conformational change to 
• initiate transcript shortening and reannealing of DNA strands at the 
lesion site. The coupling factor (or factors recruits TFIIH and the 
additional elements required for incisions, excision and repair 
synthesis. After repair, transcription resumes, thereby completing 
the RNA transcript in progress and facilitating the passage of an 
advancing replication fork.
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Experimental research into repair of cisplatin adducts demonstrated that 
there is a higher repair rate in the actively transcribed genes than in the silent 
genes (May et al,, 1993) or in the non-coding regions of the DNA (Zhen et al., 
1992; Johnson et al., 1994). Moreover, higher repair rates of interstrand cross­
links on active genes were detected in resistant rather than in sensitive human 
ovarian cancer cell lines (Johnson et al., 1994). For cisplatin-induced 
intrastrand cross-links, the difference was much smaller (Zhen et al., 1992). 
Intrastrand cross-links are preferentially removed from actively transcribed 
regions with strand specificity.
Repair of cisplatin DNA adducts as measured by atomic absorption 
spectrometry occurs in a biphasic manner: a rapid phase for the first 6 hours 
after drug incubation followed by a slower period (Johnson et al., 1994; 
Eastman and Schulte, 1988; Parker et al., 1991; Calsou et al., 1992; Bungo et 
al., 1990; Jones et al., 1991; May et al., 1993). Separation between the two 
phases is more clear in resistant than in sensitive cells, although this may be 
due to the relatively low levels of repair observed in the sensitive cell lines. 
(Johnson et al., 1994; Eastman and Schulte, 1988). As regards interstrand 
cross-link removal, the biphasic repair mode is less obvious as compared to 
overall platinum removal (Calsou et al., 1992). A probable explanation is that 
the rate of formation for interstrand cross-links is slower than that of other 
platinum adducts, as the interstrand cross-links are formed in two steps 
(monofunctional binding and then rearrangement to the interstrand cross-links). 
Intrastrand adducts are also formed in two steps, but at a greater pace than the
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interstrand cross-links. When formation and removal are simultaneously in 
action, it is difficult to determine the relative contribution of each to the 
interstrand cross-links concentration at a given time point. When studying the 
repair kinetics for other DNA-damaging agents, such as UV, photoproducts and 
alkylating agents, a similar biphasic repair mode is obtained (May et al., 1993), 
implicating that initial fast DNA repair followed by slow DNA repair might be 
universal for NER and not specific for platinum adducts removal. The biphasic 
mode of repair probably indicates that NER is more active directly following 
induction of DNA damage. It is conceivable that the transcription-coupled 
repair process is faster than overall genomic repair.
1.3.3.2 Recombinational Repair
Recombinational repair systems are involved in the processing of DNA 
double-strand break lesions (Sweigert and Carrol, 1990), a particular class of 
DNA damages which can occur during DNA replication and which can be also 
generated after cell exposure to ionising radiation (Takata et al;, 2000). It has 
been extensively demonstrated that the failure to repair these lesions is 
responsible for cell-killing induced by ionising radiation since the persistence 
of double-strand breaks on genomic DNA induces the formation of 
chromosome aberration preventing successful cell division at the next mitosis 
(Price, 1993).
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Since double-strand breaks are so deleterious to the cells, it is not surprising 
that there are two repair pathways able to process these DNA lesions: Non 
Homologous End Joining (NHEJ) and Homologous Recombination Repair 
(HRR). The main difference between these two recombinational repair 
pathways is that HRR is able to process DNA double-strand breaks only in the 
presence of homologous duplex DNA in the genome (either a homologous 
chromosome or, more likely, a sister chromatid) whereas NHEJ is able to 
process these lesions without a requirement for extensive homology (Takata et 
al., 2000).
Results from several studies indicate that these two pathways are conserved 
from the bacteria to yeast (Shinoara et al., 1992; Aboussehkra et al., 1992;. 
Basile et al., 1992) and that similar mechanisms persist from yeast to humans 
(Boulton et al., 1996; Siede et al., 1996; Thompson and Schild, 1999). 
Specifically, it has been found that while HRR is the primary mechanism of 
double-strand breaks repair in yeast, vertebrate cells use both NHEJ and HRR 
pathways extensively (Liang et al., 1998, Johnson et al., 1999; Lin et al al., 
1999; Pierce et al., 1999).
Direct evidence for the repair of double-strand breaks induced by ionising 
radiation by the recombinational repair pathways was firstly obtained by 
microinjecting X-irradiated plasmid DNA into oocyte nuclei from Xenopus 
Laevis and was subsequently confirmed by experiments performed in vivo 
with the SCID mouse mutant which is characterised by a severe 
immunodeficiency due to a defect in V-(D)-J rejoining, a site-specific
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recombinational event responsible for the huge diversity of DNA sequences in 
T cell receptor and immunoglobulin genes. The mice themselves as well as cell 
lines derived from them have been shown to be hypersensitive to ionising 
radiation (Fulop and Phillips, 1990; Hendrickson et al., 1991) probably due to a 
failure to repair double-strand breaks (Biedermann et al., 1991). It has been 
postulated that the animals lack an activity involved in an early stage of 
recombination which is necessary for both repair and V-(D)-J rejoining 
pathways (Hendrickson et al., 1991).
As mentioned above, two models of recombinational repair of double-strand 
breaks have been proposed: the single-strand annealing model (NHEJ; Lin et 
al., 1984) and the double-strand break repair model (HRR; Szostak et al., 1983) 
(Fig. 7). The NHEJ occurs at direct repeats. The DNA termini at the double- 
strand break are digested by the 5l->3' exonuclease until complementary 
sequences are exposed, when annealing and ligation occur. This provides a 
rapid means of repairing this form of damage, but deletions are inevitable. In 
the alternative method, the HRR, after that DNA termini at the double-strand 
breaks are digested by the 5'->3' exonuclease, an homologous pairing occurs 
between the segment of DNA containing the damage and the duplicate 
sequence from the second copy of this stretch of nucleic acid. Strand exchange, 
and possibly, branch migration, follow, and gap-filling DNA repair replication 
precedes resolution ot the recombination intermediates. This model implies that 
the nucleic acid at the site of damage is conserved without loss of genetic 
information. Direct repeats, which are a prerequisite for the NHEJ system,, are
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Figure 7. A model for the repair of ionising radiation-induced double-strand 
breaks. The altered residues at the S'-termini are first excised by a 
3'-phosphodiesterase. Thereafter, the double-strand gap is extended 
on both strands by a Mg2+-dependent 5'->3' exonuclease. If direct 
repeats are present at the site of the DSB, then repair may occur by 
single-strand annealing of complementary sequences with deletion 
of the exonucleolytically-digested regions around the strand break. 
In stretches of DNA lacking direct repeats, including most of those 
which encode proteins, correction of the damage is carried out by 
the double-strand break repair pathway. Homologous sequences 
from the two chromosomal copies of the gene are paired, and strand 
transfer, DNA replication, DNA ligation and resolution of 
intermediates follow.
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more likely to occur between protein-coding sequences, and these two 
mechanisms might be complementary, allowing the possibility to perform rapid 
repair of less important sections of the genome, and a slower but more accurate 
repair of segments containing key coding sequences.
The recombinational repair of double-strand breaks was firstly extensively 
elucidated in Escherichia coli (West, 1992) and then in eukaryotic systems, 
such as RAD52 epistasis group of Saccharomyces cerevisiae and mammalian 
cells. The analysis of radiosensitive yeast mutants has revealed a number of 
genes involved in HRR, which comprise the RAD52 epistasis group (Baumann 
and West, 1998; Kanaar et al., 1998; Shinohara and Ogawa, 1995). Among 
these, the structure and function of Rad51 have been conserved to a remarkable 
degree among all eukaryotes. Rad51 is structurally and functionally related to 
the E. coli recombination protein RecA (the agent responsible for catalysing 
homologous pairing and strand exchange in the bacterial HRR) 
(Kowalczykowski, 1994). The functional forms of both RecA and Rad51 are 
multimeric helical nucleoprotein filaments that form on single-stranded DNA 
ends produced at double-strand breaks (Ogawa et al., 1993). These filaments 
are involved in the search for homologous sequence, DNA pairing and strand 
exchange. As mentioned above, recombination intermediates produced in this 
way are then processed further in reactions that involve DNA synthesis, branch 
migration, resolution of Holliday junctions and ligation. The conservation of 
the RAD52 epistasis group genes from yeast to vertebrate cells suggests that 
the basic mechanism of HRR is maintained during evolution. However, while
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S. cerevisiae RAD51 mutants are viable, RAD51 deficiency in vertebrate cells 
causes rapid chromosomal aberrations and cell death (Sonoda et al., 1998). One 
possible explanation for this lethality is that the larger size of the vertebrate 
genome requires more HRR activity for chromosome stability (Haber, 1999; 
Sonoda et al., 1998). RAD51 paralogs (genes related by duplication within a 
single genome) have been identified in many eukaryotes and constitute the 
Rad51-related gene family (Tacker, 1999; Thempson and Schild, 1999). Four 
proteins, Rad51, Rad55, Rad57 and Dmcl, constitute the complete set of RecA 
relatives in S. cerevisiae (Takata et al., 2000), whereas seven members of the 
Rad51 protein family have been identified, thus far, in mammals. In human 
cells, Rad51, Dmcl, XRCC2, XRCC3, RadSIB (also called Rad51Ll/hRec2), 
RadSIC (also called Rad51L2) and RadSIC (also called Rad51L3) are highly 
conserved (Takata et al., 2000). While human Dmcl is about 50% identical to 
human Rad51, the other human Rad51 paralogs are 20% to 30% identical to 
human Rad51. These paralogs are less than 30% identical to each other and to 
yeast Rad55 and Rad57 (Thacker, 1999). Overexpression of Rad51 in yeast 
partially suppresses the DNA repair defects of rad55 and rad57 mutant strains 
(Hays et al., 1995; Johnson and Symington, 1995), implying that Rad55 and 
Rad57 may functionally cooperate with Rad51. This idea is supported by 
physical interactions between Rad51 and Rad55 and between Rad55 and Rad57 
(Hays et al., 1995; Johnson and Symington, 1995; Sung, 1997). Similarly, 
physical interactions occur between human Rad51 and XRCC3, XRCC3 and 
RadSIC, and between RadSIB and RadSIC (Dosanjh et al., 1998). These
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findings suggest that Rad51 paralogs may function as Rad51 accessory factors, 
analogous to yeast Rad55 and Rad57.
It has been extensively demonstrated that germ line mutations in BRCA1 and 
BRCA2 genes result in a marked increase in the risk of early onset breast and 
ovarian cancers (Futreal et al., 1994; Friedman et al., 1994; Castilla et al., 
1994; Wooster et al., 1995; Tavtigian et al., 1996). These two genes appear to 
have multiple functions including roles in transcriptional regulation (Chapman 
and Verma, 1996; Monteiro et al., 1996; Milner et al., 1997; Irminger-Finger et 
al., 1999) and cell cycle checkpoints control (Larson et al., 1997; Hsu and 
White, 1998; Patel et al., 1998). BRCA1 and BRCA2 have transcription 
activation functions (Chapman and Verma, 1996; Monteiro et al., 1996; Milner 
et al., 1997); BRCA1 co-activates transcription with p53 (Ouchi et al., 1998; 
Zhang et al., 1998). Very recent findings suggested that products of the BRCA1 
and BRCA2 genes also participate in HRR by directly interacting with the 
recombinational repair protein Rad51 (Moynahan et al., 1999; Snouwaert et al., 
1999) thus confirming results from previous studies showing that BRCA1 and 
BRCA2 mutants are phenotypically similar to rad51 mutants (Scully et al., 
1997; Sharan et al., 1997; Abbott et al., 1998).
In addition to contributing to HRR of double-strand breaks on DNA, BRCA1 
has also been involved in other DNA repair pathways like transcription- 
coupled base-excision repair of oxidative DNA damage (Gowen et al., 1998; 
Abbott et al., 1999). Furthermore, a recent study reported biochemical 
interactions between BRCA1 and proteins required for DNA-end joining,
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nucleotide mismatch repair, DNA replication, and signal transduction in 
response to damage (Wang et al., 2000). This study also identified interactions 
between Brcal and other proteins thought to be involved in recombinational 
repair. Although these data altogether raise the possibility the BRCA1 
contributes to multiple cellular DNA damage responses, the specific 
mechanisms through which BRCA1 contributes to these processes remain to be 
determined.
Results from recent studies carried out in mouse ES cells indicated that 
BRCA1 is required for the formation of subnuclear RadSl complexes in 
response to cellular damage by ionising radiation and cisplatin, thus suggesting 
that cellular sensitivity to DNA lesions generated by chemical cross-linking 
agents is mediated by the HRR. Accordingly, cells lacking normal BRCA1 or 
Rad51 functions are more sensitive to ionising radiation (Gowen et al., 1998) 
and cross-linking agents (Husain et al., 1998; Bhattacharyya et al., 2000) 
compared with normal cells.
Bacterial and yeast studies demonstrated that repair of interstrand cross-links 
generated on DNA by damaging agents such as cisplatin, mitomycin C, 
chloronitrosoureas and nitrogen mustards requires both participation of NER 
and recombinational repair proteins (Cole, 1973; Cole et al., 1976; Jachmczyk 
et al., 1981). In fact, yeast mutants defective in NER or HRR DNA repair 
systems show increased sensitivity to cisplatin, indicating that these repair 
pathways are involved in removal of the DNA lesions caused by this agent 
(Hartwell et al., 1997). It has been postulated that NER proteins are responsible
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for lesion recognition and for single strand incision and/or double-strand breaks 
formation at the sites of damage whereas recombinational repair proteins are 
responsible for repairing the intermediates formed by NER proteins acting on 
interstrand cross-links. The intermediates acted on by recombinational repair 
proteins may include double-strand breaks formed by incision of both strands at 
the lesion, daughter strand gaps caused when replicative polymerases are 
blocked by lesions, or DNA ends formed when polymerases encounter single 
strand incisions. In the first case, recombinational repair can be employed to 
accurately 'heal' the double-strand break using a homologous duplex as a donor 
of sequence information; in the latter two cases, recombinational repair can be 
used to accurately restore a functional replication fork. Recombinational repair 
is also important for restoring replication forks when unrepaired intrastrand 
cross-links are encountered by DNA polymerases (Kadyk and Hartwell, 1992, 
1993). Results from several studies indicated that certain DNA intrastrand 
cross-links generated by cisplatin and other damaging agents such as 
mitomycin C, chloronitrosoureas and nitrogen mustards are refractory to be 
removed via NER and translesion synthesis pathways (Hughes et àl., 1992; 
Huang et al., 1994; Hoffmann et al., 1997). It has been hypothesised that this 
refractoriness likely results from the binding of high mobility group proteins to 
the adducts (Hughes et al., 1992; Huang et al., 1994; Hoffinann et al., 1997).
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1.3.3.3 Mismatch repair (MMR)
Maintenance of genomic stability requires the proper functioning of DNA 
replication, repair, and recombination processes. Among these, mismatch repair 
(MMR) plays a prominent role in the correction of biosynthetic mistakes made 
during replication from newly synthesised strands that escape DNA polymerase 
proofreading (Modrich, 1994). In humans the MMR can repair modified bases, 
mispaired bases (for example T opposite G) or the addition of extra nucleotides 
up to a number of four, resulting in unpaired bases (Modrich, 1994; Kunkel,
1995). Heteroduplexes containing more than four unpaired bases are not 
efficiently corrected by the MMR system (Kunkel, 1995).
MMR was originally described in bacteria that are able to repair mispair- 
containing bacteriophages (Wildenberg and Meselson, 1975). In the bacterial 
system, the most important components are MutS, MutL and MutH gene 
products, named after their corresponding bacterial mutator strains. The MutS 
protein initially recognises and binds to mismatched DNA (Su and Modrich, 
1986). After this, MutH and MutL form a complex with MutS to carry out 
excision repair; MutH has endonuclease activity, but the specific activity of 
MutL has not been identified. The important role played by the MMR proteins 
is emphasised by the fact that they are highly conserved from bacteria to yeast 
to mammals. Biochemical and genetic studies in human cells have defined five 
genes whose products play a key role in MMR including hMSH2 (Fishel et al., 
1993; Leach, et al., 1993), hMSH3 (Fujii and Shimada, 1989; Risinger et al.,
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1996) and hMSH6 (also called GTBP or p i60; Palombo et al., 1995; 
Drummond et al., 1995), which are homologues of the bacterial MutS protein, 
and hMLHl (Papadopoulos et al., 1994; Bronner et al., 1994) and hPMS2 
(Nicolaides et al., 1994), which are homologues of the bacterial MutL protein 
(Tab. H). A sixth human gene, hPMSl, has also been suggested to be important 
for MMR, although biochemical studies supporting its involvement in this 
repair process are not yet available (Kolodner, 1996). Both the bacterial and the 
eukaryotic systems direct the repair to the newly replicated DNA strand, require 
multiple components and can cut the strand to be repaired either upstream or 
downstream of the mismatch. How these recognition proteins discriminate 
between the newly synthesised strand and the mother strand in humans is still 
unclear. In bacteria, the newly synthesised strand is recognised by the lower 
level of méthylation (Modrich, 1994). This hypomethylation probably also 
plays a role in the process of recognition in humans. hMSH2, either by itself 
(Fishel et al., 1994) or when dimerised with hMSH6 (Palombo et al., 1995) or 
hMSH3 (Acharya et al., 1996) binds small DNA mismatches (Fig. 8). The 
human MutL homologues, hMLHl and hPMS2, form an heterodimer (called 
hMutLa; Li and Modrich, 1995) and join the complex after the initial binding 
by either hMSH2-hMSH6 (hMutScc heterodimer) or hMSH2-hMSH3 (hMutSp 
heterodimer). Analysis of the mismatched nucleotide-binding specificity of the 
hMutSa and p protein complexes showed that they have overlapping but not 
identical binding specificity (Acharya et al., 1996). The human MMR pathway 
(Fig. 8) starts by the protein hMSH2 or MutSa (a complex composed of
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Table II. Human homologues of bacterial MutS and MutL mismatch repair 
. (MMR) proteins.
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Figure 8. Model for mismatch repair (MMR) in humans. Damage (★) is 
recognised by hMSH2 and hMSH6 or hMSH3 (Step 1). 
Subsequently, hMLHl, hPMSl and hPMS2 are recruited (Step 2). 
Then, the DNA is unwound by a helicase (Step 3), and a DNA 
polymerase repairr the damage with the aid of RPA.
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hMSH2 and a protein named GTBP or pl60) that recognises the mispaired 
bases (step 1). Which of the two proteins is active depends on the number of 
mispaired bases. Other recognition proteins, such as hMSH3, might function in 
this step of the MMR pathway. Following recognition, hPMSl, hPMS2 and 
hMLHl interact with the DNA-MutSa binary complex (step 2). The exact role 
of these proteins is not known, but mutations in the encoding genes are 
associated with hereditary non-polyposis colorectal cancer (HNPCC), a disease 
characterised by a defective MMR system (Modrich, 1994; Chung and Rustgi,
1995). From this point on, many enzymes involved have not been characterised 
yet, but subsequent steps would include unwinding of the DNA by a helicase 
(step 3) and excision of the mismatched base containing DNA region by a bi­
directional exonuclease. An as yet unidentified DNA polymerase fills the gap, 
possibly with the aid of RPA. Finally, the DNA is sealed by a ligase (Kunkel 
1995; Chung, and Rustgi, 1995). The process is probably more complicated, as 
recently several other components required for MMR have been identified 
(Kolodner, 1996).
Loss of MMR causes destabilisation of the genome and results in high 
mutation rates, particularly in microsatellite sequences in both the non-coding 
(Aaltonen et al., 1993; Thibodeau et al., 1993) and coding portion of the 
genome. Such sequences are found in coding regions of HPRT (Bhattacharyya 
et al., 1994), APRT (Hess et al., 1994), APC (Huang J et al., 1996), type n  
TGF-p receptor (Markowitz et al., 1995), CHK-1 (Codegoni et al., 1999; 
Bertoni et al., 1999), E2F-4 (Souza et al., 1997), ICE (Souza et al., 1996)
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hMSH3 (Yamamoto et al., 1998), hMSH6 (Yamamoto et al., 1998) and Bax 
(Rampino et al., 1997) genes, and mutation rates are increased at these loci in 
MMR-deficient cells. The majority of hereditary non polyposis colon cancers 
are due to defects in either MLH1 or MSH2 (Papadopoulos et al., 1994; 
Bronner et al., 1994; Hemminki et al., 1994; Liu B et al., 1996). Defects in 
PMS1 or PMS2 are less frequent (Nicolaides et al., 1994; Hemminki et al., 
1994; Liu B et al., 1996). Although the MMR system seems to be normal in the 
heterozygote cells containing a single functional gene copy, during 
carcinogenesis, the remaining wild-type allele is somatically mutated, resulting 
in the complete loss of MMR function in the tumour (Leach et al., 1993). In 
addition to hereditary nonpolyposis colon cancer, loss of MMR occurs 
frequently in many types of sporadic cancers as well, including endometrial, 
small and non-small cell lung, pancreatic, gastric, ovarian, cervix, and breast 
cancer (Risinger et al., 1993; Merlo et al., 1994; Shridhar et al., 1994; Han et 
al., 1993; Wooster R. et al., 1994). Mice that are deficient in MLH1, MSH2 or 
PMS2 have microsatellite instability in many tissues and a predisposition to 
form tumours, particularly lymphoma (Baker et al., 1996; de Wind et al., 1995; 
Reitmar et al., 1995; Baker et al., 1995).
Recently, MMR has been implicated in cellular processes other than 
stabilising the genome after replication. These processes include: (a) the 
recognition of lesions other than conventional mispairs, such as cisplatin 
adducts, and (b) the participation in a cell-cycle checkpoint control system
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which may trigger apoptosis (Hawn et al., 1995). These two alternative 
functions appear to be interconnected.
Several studies have documented that loss of MMR is an important 
mechanism of resistance to a variety of clinically important drugs, due to the 
fact that the MMR system can recognise and bind to various types of adducts in 
DNA as well as to mismatches. Rather than being a major effector of the 
removal of such adducts, the main role of the MMR seems to be as a detector 
of specific types of DNA damage in a way which is represented in Figure 9.
There exist a number of cell lines with known inactivating mutations in the 
MMR genes. The human colorectal adenocarcinoma cell line HCT-116, which 
is hMLHl deficient due to a hemizygous mutation in hMLHl resulting in a 
truncated non-functional protein, exhibits microsatellite instability and does not 
correct mismatches in cell-free extracts (Parsons et al., 1993; Boyer et al.,
1995). Transfer of chromosome 3, on which the hMLHl gene is located, into 
HCT-116 cells corrects the MMR defect, reverses the mutator phenotype and 
sensitises the cells to the methylating agent iV-methyl-N-nitro-Af-nitroguanidine 
(MNNG), thus indicating that restoration of functional MMR abolishes 
méthylation tolerance (Koi et al., 1994). Similarly, the human endometrial 
adenocarcinoma cell line HEC59, which is hMSH2 deficient due to different 
mutations in each of the two hMSH2 alleles (Boyer et al., 1995), is resistant to 
MNNG when compared to a subline into which chromosome 2, containing a 
wild-type copy of hMSH2 gene, has been transferred (Umar et al., 1997). 
Furthermore, the human endometrial adenocarcinoma cell line HEC-l-A,
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Figure 9. Basic sequence of events that seem to be the basis for cytotoxicity of 
cisplatin. (A) Formation of the 1,2 d(GpG) intrastrand cross-link 
adduct; (B) misincorporatioh of a base (T) opposite the adduct at the 
next round of replication; (C) recognition of the adduct/mispair by 
the mismatch repair (MMR) system; (D) attempted futile repair; (E) 
generation of a signal that triggers apoptosis.
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which cames mutations in hPMS2, exhibits microsatellite instability and 
resistance to MNNG when compared to the MMR-proficient KLE cells 
(Risinger et al., 1995).
Methylating agents such as /V-methyl-7V-nitrosourea (MNU), MNNG, 
procarbazine and temozolomide form a variety of adducts in DNA, among 
which 0 6-methylguanine is the most toxic. Although the MMR system does not 
seem to be able to recognise the alkylated guanine directly (Moggs et al., 
1997), it does recognise the 0 6-methylguanine-thymine mispair that occurs 
after erroneous incorporation of a thymine rather than a cytosine opposite the 
0 6-methylguanine during the next cycle of DNA replication (Griffin et al., 
1994). One hypothesis (Fig. 10) is that having recognised the mismatch, the 
MMR system incises the thymine-containing strand, excises the thymine and 
surrounding bases, creating a gap, and then fills in the gap via repair synthesis. 
However, because a thymine is again incorporated opposite the persisting O6- 
methylguanine, the site is once again recognised by the MMR system, and a 
new round of attempted repair is triggered. This futile cycling is envisioned as 
increasing the risk of a double-strand break at the time of the next S phase that 
could then trigger apoptosis (Karran and Bignami, 1994). This model predicts 
that loss of MMR confers tolerance to methylating agents such as MNU and 
MNNG by virtue of the fact that the cell does not attempt repair and subsequent 
futile cycling. This hypothesis is supported by the evidence that selection of 
cells for resistance to MNU and MNNG frequently results in loss of MMR (Kat 
et al., 1993) and loss of guanine-thymine mismatch binding activity (Griffin et
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Figure 10. Model for mismatch repair (MMR) and apoptosis activation 
connection. After the formation of the 0 6-methylguanine adduct, an 
0 6-methylguanine-thymine mispair occurs after erroneous 
incorporation of a thymine rather than a cytosine opposite the O6- 
methylguanine during the next cycle of DNA replication. The 
MMR pathway recognises the mismatch and MMR System incises 
the thymine-containing strand, excises the thymine and surrounding 
bases, creating a gap, and then fills in the gap via repair synthesis. 
However, because a thymine is again incorporated opposite the 
persisting 0 6-methylguanine, the site is once again recognised by 
the MMR system, and a new round of attempted repair is triggered 
thus generating a futile cycling which could be able to increase the 
risk of a double-strand break at the time of the next S phase and, as 
consequence, to trigger apoptosis. Loss of MMR would be 
accompanied with loss of the futile cycling-mediated apoptosis and 
hence by increased cellular resistance.
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al., 1994; Branch P. et al., 1993). Loss of MMR seems to be important as a 
mechanism of resistance to two drugs currently used in the clinic, both of 
which produce a large number of 0 6-methylguanine adducts, namely 
temozolomide and procarbazine (Liu L et al., 1996; D’Atri et al., 1997; 
Friedman et al., 1997). There is an interesting interplay between MMR and 
MGMT, which is able to directly remove the methyl group from the O6 
position of guanine and which represents the major route for removal of these 
DNA-adducts. However, these alkylated guanines are only toxic to the cells if 
they are detected by the MMR system. For cells with normal MMR, high levels 
of MGMT prevent the drug-induced cytotoxic effect by removing the O6- 
alkylguanine DNA adducts, and inactivation of this enzyme by a potent 
inhibitor (0 6-benzylguanine or fotemustine) sensitises cells to killing by 
temozolomide (Pegg et al., 1993). In MMR-deficient cell lines, inactivation of 
MGMT fails to sensitise cells to temozolomide, suggesting that even large 
numbers of DNA adducts are not cytotoxic in the absence of the MMR 
detector, although they may be very mutagenic. Thus, MMR mutations seem to 
override the MGMT mechanism of resistance (Liu L et al., 1996); if the cell 
cannot detect the presence of the adducts on DNA, then it matters less how 
many such adducts are present.
Several recent studies provide evidence that the MMR functional status is an 
important factor in determining cellular sensitivity to a variety of anticancer 
drugs other than MNU, MNNG and temozolomide. MMR deficiency due to the 
lack of hMSH2 or hMLHl or hPMS2 expression was found to be associated
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with resistance to the procarbazine (Friedman et al., 1997), DNA-minor groove 
monofunctional alkylating agents tallimustine, CC-1065 and carzelesin (Çolella 
et al., 1999), 6-thioguanine (Aebi. et al., 1997; Hawn et a l, 1995) and some of 
the platinum-based drugs. Even though cisplatin and its derivatives could not 
be considered classical alkylators, their capacity to covalently bind the DNA at 
N7-purine nucleophilic sites has been extensively demonstrated.
It is known that DNA is the primary intracellular target of cisplatin and 
eukaryotic cells respond to the presence of cisplatin adducts in DNA by 
activating signal transduction pathways that result in cell cycle arrest and 
apoptosis (Eastman, 1990). The first indication that MMR might be a 
determinant of sensitivity to cisplatin was the observation that introduction of 
MutS or MutL mutations into E. coli (already hypersensitive to cisplatin due to 
the presence of a DNA adenine Methyltransferase (dam) mutation) caused them 
to become resistant (Fram et al., 1985). Subsequently it was demonstrated that 
in two unrelated cell systems, loss of either hMLHl (HCT-116 cells) or 
hMSH2 (HEC59 cells) function resulted in low level cisplatin (Anthoney et al., 
1996; Aebi et al., 1996; Drummond et al., 1996) and carboplatin resistance 
(Fink et al., 1996), and that some human tumour cell lines selected for 
resistance to cisplatin (2008/A, for example; Naredi et al., 1995) exhibit a 
marked microsatellite instability and are defective in strand-specific MMR 
(Drummond et al., 1996). The fact that loss of MMR results in resistance to 
both cisplatin and carboplatin was not unexpected because although carboplatin 
contains a 1,1 -cyclobutanedicarboxylato-leaving group and undergoes aquation
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more slowly, the structures of aquated forms of cisplatin and carboplatin are the 
same as are the types of adducts.
Pure hMSH2 has been reported to bind to platinated DNA in electromobility 
shift assays (Mello et al., 1996). Human MutSa, a heterodimer of hMSH2 and 
hMSH6, has also been shown to bind DNA containing adducts produced by 
cisplatin (Duckett et al., 1996) and has greatest affinity for lesions in which a 
thymine has been misincorporated opposite the 3' guanine (Yamada et al.,
1997). It is interesting to note that adducts formed by other two cisplatin 
derivatives, oxaliplatin and transplatin, are not recognised by the MMR system 
(Fink et al., 1996; Duckett et al., 1996). These two drugs do not differ in their 
cytotoxicity to MMR-deficient and -proficient tumour cell lines (Fink et al.,
1996), suggesting that the components of the MMR system responsible for the 
difference in sensitivity are quite specific in their ability to discriminate types 
of closely related DNA adducts.
It is not yet clear how the platinum adducts are recognised by the MMR 
proteins. It has been demonstrated biochemically that hMSH2 can bind 1,2 
d(GpG) intrastrand cross-link adducts (which are the predominant DNA 
damages produced by platinum-based compounds), but it is also possible that 
the MMR system recognises monoadducts, monoadducts modified by the 
reaction with glutathione, or interstrand cross-link adducts as well. As 
hypothesised for monofunctional methylating agents and DNA-minor groove 
alkylators, also in this case it is possible that cisplatin adducts locally distort the 
DNA in a manner that mimics the presence of either a single-base mismatch or
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an insertion/deletion mispair. The current paradigm is that, as for the 
methylating agents, the MMR system serves as a detector for cisplatin-damaged 
DNA: during the replication of DNA platinated guanine could not be able to 
form an hydrogen bond with its physiological partner thymine thus producing a 
mispair recognised by MMR proteins. Then, the MMR system removes 
unmodified thymine leaving platinated guanine which, after the reparative 
synthesis, is again unable to correctly bind cytosine. The site will again be 
recognised by MMR proteins and a new round of attempted repair will be 
performed starting a futile cycle which could trigger apoptosis (Fig. 10). In this 
context, resistance due to the loss of MMR system activity is thought to result 
from failure of the cell to recognise the cisplatin adducts and activate futile 
cycling and other signalling pathways that trigger apoptosis (Fink et al., 1998). 
An alternative hypothesis (Crul et al., 1997) for the involvement of the MMR 
proteins in cisplatin DNA adduct repair was postulated: by binding cisplatin- 
DNA adducts, hMSH2 may shield these adducts from repair (mainly performed 
by NER), thus allowing these adducts to persist. Loss of MMR would be 
accompanied with loss of the shielding by hMSH2 and hence by enhanced 
repair of such adducts, leading to increased resistance (Fig. 11). Both 
hypotheses for the involvement of the MMR proteins in the repair of cisplatin 
lesions are plausible. Since they do not necessarily exclude each other, the 
actual situation in vivo could be a combination of the two.
Data supporting the hypothesis of MMR system as a detector able to initiate 
activation of signalling pathways are emerging. It has recently been reported
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Figure 11. An alternative model for the involvement of the mismatch repair 
(MMR) proteins in cisplatin DNA adduct repair. (A) By binding 
cisplatin-DNA adducts, hMSH2 may shield these adducts from 
repair (mainly performed by NER), thus allowing these adducts to 
persist. (B) Loss of MMR would be accompanied with loss of the 
shielding by hMSH2 and hence by enhanced repair of such adducts, 
leading to increased cellular resistance.
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that cisplatin activates c-jun NHz-terminal kinase 1 by a p21-activated kinase 
protein 65 and a mitogen-activated protein kinase ^-independent mechanism 
more efficiently in MMR-proficient cells than in MMR-deficient cells. 
Moreover, cisplatin seems to be able to activate c-Abl kinase only in the MMR- 
proficient cells, since this response is completely absent in MMR-deficient 
cells (Nehmé et al., 1997). These findings reveal that activation of c-jun NH2- 
terminal kinase 1 and c-Abl by cisplatin is in part dependent on the MMR 
functional status, and suggests that these kinases are part of the signal 
transduction pathway activated when MMR proteins recognise DNA adducts 
produced by alkylating and platinum-based agents.
Data obtained after exposure of MMR-proficient cells to both MNNG and 6- 
thioguanine, indicate the MMR system as being able to promote G2 cell cycle 
arrest and cell death (Carethers et al., 1996; Hawn M.T. et al., 1995). In fact, 
exposure of MMR-deficient cells to these drugs did not induce a G2 block but 
rather just a Gi delay. The arrest at the G2 cell cycle checkpoint may allow the 
cell to attempt repair of DNA mismatches and prevent the replication of 
mutated DNA. The signals generated by the detection of DNA lesions by the 
MMR system are unknown, although there is some evidence that they work via 
regulation of the p34cdc2-cyclin B1 complex (King et al., 1994). Very recently it 
has been reported that hMLHl-deficient tumour cell lines also fails to engage 
G2 cell cycle arrest after cisplatin damage (Brown et al., 1997). These data 
altogether indicate the possibility that the MMR system is linked to the G2 
checkpoint thus suggesting that the MMR system is involved not only in the
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repair of true mismatches but also in processes that limit the replication of cells 
when DNA damage is detected. In addition, it has been reported that MMR can 
cooperate with p53. In fact, studies performed in human coloncarcinoma HCT- 
116 cell line evidenced that lack of hMLHl enhances the role of p53 in 
protecting the cells from cisplatin-induced DNA damage (Vikhanskaya et al., 
1999).
Overall such evidence indicated that loss of MMR can result in drug 
resistance both directly, by impairing the ability of the cells to detect DNA 
damage, and indirectly, by increasing the mutation rate at loci that mediate 
resistance to other classes of drugs. Although, by the direct route, loss of the 
MMR pathway results only in a relatively small degree of resistance to 
platinum-containing drugs, several lines of evidence suggest that this resistance 
is nevertheless of substantial biological and clinical significance. Specifically: 
(a) this low-level resistance to cisplatin has been reported to be sufficient to 
produce progressive enrichment for MMR-deficient tumour cells during 
treatment in vitro (Fink et al., 1997); (b) MSH2+/+ embryonic stem cells (de 
Wind et al., 1995) grown as xenografts have been shown to be responsive to 
cisplatin treatment whereas isogenic MSH2'/' tumours were not, suggesting that 
the degree of cisplatin resistance conferred by loss of MMR is sufficient to 
produce a large difference in clinical responsiveness in vivo (Fink et al., 1997);
(c) loss of MMR has been reported in tumour cell lines selected for resistance 
to both cisplatin (Aebi et al., 1996) and doxorubicin (Drummond et al., 1996);
(d) the frequency of positive immunoblot analysis for hMLHl protein in
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ovarian carcinomas obtained after chemotherapy with a cisplatin or 
carboplatin-containing regimen was shown to be substantially lower than the 
frequency observed in tumours sampled before treatment (Brown et al., 1997). 
Although the samples were not paired, this loss of hMLHl expression is 
consistent with the concept that treatment with platinum drugs can enrich for 
MMR-deficient cells.
The issue of when loss of MMR occurs during oncogenesis remains 
controversial even for hereditary nonpolyposis colon cancer, which represents 
the best-defined clinical situation (Tomlinson et al., 1996). However, once such 
cells are present in the tumor, their genomic instability may result in the 
accumulation of additional mutations that contribute to of tumour progression. 
Enrichment of these cells as a result of chemotherapy would be expected to 
accelerate this process. Indeed, microsatellite instability, a hallmark of the 
genomic instability due to loss of MMR (Loeb, 1994), has been reported to be 
present in up to 94% of the patients with therapy-related leukemia or 
myelodysplastic syndromes, consistent with drug-induced enrichment for 
genetically unstable cells (Ben-Yehuda et al., 1996).
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1.3.3.4 Connection between MMR and Transcription-coupled NER
Since alterations in NER and MMR pathways determine opposite effects on 
the cellular response to cisplatin, it is plausible that the balance between the 
activities of these two systems can be an important factor in determining the 
sensitivity profile of tumour cells to DNA-damaging anticancer drugs.
Recently, it was found that in E. coli carrying mutations in MMR genes, 
rapid repair of the transcribed strand of active genes after UV damage was 
selectively abolished (Mellon and Champe, 1996). This implicates an 
association between MMR and NER, i.e components of DNA MMR system 
probably function in transcription coupled repair (TCR) as well. It was also 
shown that this connection exists in eukaryotes, since several MMR-deficient 
human tumour cell lines, characterised by mutations in the hMSH2, hPMS2 
and hMLHl genes, demonstrated the same deficiency in TCR as the E. coli 
mutants (Mellon et al., 1996). In addition, TCR was restored in a mutant 
human cell line whose MMR-deficiency had been corrected by chromosome 
transfer (Mellon et al., 1996). The following working model was proposed to 
explain these findings (Mellon and Champe, 1996): RNA polymerase II stalls 
at a lesion in the template strand, thereby altering the conformation of the 
DNA. Some features of this altered DNA of the surrounding region might 
resemble a mismatched heteroduplex to which the MMR proteins could bind. 
TRCF would then displace the stalled RNA polymerase II. The lesion is
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stabilised at a distance by the MMR proteins and is available for recognition by 
the NER proteins.
The implications of a connection between MMR and TCR-NER for cisplatin 
therapy are not clear. The MutSa complex binds cisplatin 1,2-intrastrand cross­
links, but it does not recognise the 1,3-intrastrand adducts (Duckett et al.,
1996). However, as mentioned above, it is still not clear which of the cisplatin 
DNA adducts is the most toxic lesion.
1.3.3.5 Structure-specific damage-recognition proteins (DRPs).
The first step in DNA repair is the recognition of the damage. A wide variety 
of proteins are involved in this process. These proteins probably do not 
recognise specific adducts, but merely bind to sites where damage has caused 
more or less specific conformational changes in DNA (Bruhn et al., 1992; 
Donahue et al., 1990). Main goals in recent research were to identify and 
characterise DRPs, and to investigate a possible correlation between their 
relative levels of expression in tumour cells and the sensitivity of these cells to 
chemotherapy. For cisplatin, the DRPs of the NER system are of importance, 
but also other proteins that bind to platinated DNA have been identified (Tab. 
HI). Many of these DRPs contain a 'high-mobility group' (HMG) domain. The 
HMG domain (also referred to as HMG-box) (Grosschedl et al., 1994) is. a 
DNA-binding motif such as zinc finger, helix-tum-helix or leucine zipper 
(McA’Nulty and Lippard, 1996a). The HMG domain is found in a large
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number of proteins (McA’Nulty and Lippard, 1996a). HMG-domain-containing 
proteins have been divided into two subfamilies based upon their ability to bind 
DNA in a sequence-specific versus structure specific manner (Grosschedl et al„ 
1994). The HMG-domain-containing proteins that recognise cisplatin adducts 
all belong to the second category. Most of the HMG-domain proteins tested to 
date bind DNA modified with cisplatin but not with transplatin (Zambie and 
Lippard, 1995). In addition, the binding of HMG-domain proteins is specific 
for the 1,2-intrastrand adducts (Zambie and Lippard, 1995). The l ,2-intrastrand 
adducts unwind the DNA duplex by 13° and cause a 34° kink in the direction 
of the major groove (Anin and Leng, 1990). Other adducts, not recognised by 
HMG-domain proteins, cause different degrees of bending and unwinding 
(Visse, 1994; Anin and Leng, 1990). Thus, it seems likely that the HMG- 
domain proteins recognising the l,2-d(GpG) and l,2-d(ApG) cisplatin-DNA 
intrastrand adducts are specific for their typical distortion of the DNA helix. It 
is highly unlikely that human cells encode a binding protein specific for 
cisplatin-damaged DNA. Thus, the HMG-domain proteins must have another, 
as yet unidentified, intrinsic function in the cell. It is speculated that they are 
involved in transcription (McA’Nulty and Lippard, 1996a). This could occur by 
direct activation of transcription of the regions accessible to transcription or by 
assisting factors involved in transcription to bind DNA and activate RNA 
polymerase II (McA’Nulty and Lippard, 1996a). For the interactions between 
HMG-domain proteins and cisplatin-damaged DNA, as well as for the effects 
of HMG-domain proteins binding to cisplatin adducts on the biological activity
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of cisplatin, several hypotheses have been postulated (Fig. 12). Initially it was 
thought that when HMG-domain proteins bind to the cisplatin DNA adducts, 
they serve as recognition elements for repair, thus recruiting other proteins in 
the NER cascade to the site of damage (Fig. 12a). However, this hypothesis 
was proven not to be valid (Brown et al., 1993; McA’Nulty and Lippard, 
1996b). The second model proposes that HMG-domain proteins bind tightly to 
cisplatin-DNA adducts and prevent access of the repair complex to the site of 
the damage shielding the cisplatin adducts from the NER proteins (Fig. 12b). 
The third possibility is that the cisplatin lesions titrate the HMG-domain 
proteins away from their natural binding sites, thereby decreasing the ability to 
perform their natural function in the cell (Fig. 12c).
In yeast, a protein that binds platinated DNA was identified and named Ixrl 
(Brown et al., 1993; McA’Nulty and Lippard, 1996b). The protein contains two 
HMG domains and is able to bind l ,2-intrastrand cross-links specifically. 
Moreover, Ixrl did not bind unmodified DNA or DNA modified with 
transplatin (Brown et al., 1993). Disruption of the DCR1 gene resulted in 
increased resistance to cisplatin (Brown et al., 1993; McA’Nulty and Lippard, 
1996b) thus indicating that in mutant cells lacking Ixrl, the shield is absent, 
thereby allowing repair to occur. Notably, it was found that disruption of the 
IXR1 gene did not alter the sensitivity of yeast to other DNA-damaging agents 
such as UV irradiation, but that the effect was specific for cisplatin (Brown et 
al., 1993).
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Figure 12. Possible mechanism for the interactions between cisplatin-DNA 
adducts and HMG-domain proteins. (A) HMG-domain proteins act 
as damage recognition elements and enhance repair; (B) HMG- 
domain proteins shield the cisplatin-DNA adducts from the repair 
proteins; (C) the cisplatin-DNA adducts titrate the HMG-domain 
proteins away from their natural binding sites, thereby decreasing 
the ability to perform their natural function in the cell.
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Multiple studies identified two HMG-domain proteins in human cells, which 
were designated HMG1 and HMG2 (Szymkowski et al., 1992; Huang et al., 
1994; Bissett et al., 1993; Clugston et al., 1992; McLaughlin et al., 1993; 
Billings et al., 1994; Hughes et al.; Marples et al., 1994; Pii and Lippard, 1992; 
Toney et al., 1989). The difference between HMG1 and HMG2 is in the size; 
HMG2 (26.5 KDa) is somewhat smaller than HMG1 (28 KDa) (Hughes et al.,
1992). These two proteins are able to bind l,2-d(GpG) and l,2-d(ApG) 
intrastrand cross-links but do not bind l,3-d(GpG) intrastrand adducts (Pil and 
Lippard, 1992). As mentioned above, the fact that these latter cisplatin DNA 
lesions are repaired more efficiently than 1,2-intrastrand adducts (Huang et al., 
1994) is a further support to the theory that HMG-domain proteins shield the 
cisplatin adducts from the NER machinery. In unmodified DNA, higher affinity 
for single-stranded DNA over double-stranded DNA for HMG-domain proteins 
has been described (Isackson et al., 1979); this is consistent with a role for 
these proteins in transcription initiation since single-stranded DNA is required 
for transcription. However, in platinated DNA, similar levels of HMG1 and 2 
binding to double-stranded and single-stranded DNA was observed (Hughes et 
al., 1992). Levels of HMG 1 and 2 proteins were shown to increase in a dose 
dependent manner in parental HeLa cells after exposure to different levels of 
cisplatin (Hughes et al., 1992). No changes in the expression of these two 
proteins have been found in resistant cells (as compared to the sensitive 
counterpart) derived from ovarian, testicular and bladder tumours (Bissett et 
al., 1993; Chao et al., 1991a; McLaughlin et al., 1993).
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To investigate the possibility that cellular sensitivity to platinum compounds 
is related to binding activity of thé HMG1 and 2 proteins to DNA adducts, 
rather than to absolute levels of these proteins, these binding activities were 
studied in ovarian tumour cells derived from twelve different patients (Bissett 
et al., 1993). No correlation between binding activity and drug sensitivity was 
observed. However, another study reported increased levels of HMG-binding 
activity as a function of sensitivity of the investigated cells to cisplatin 
treatment (Billings et al., 1994); intrinsic differences in the cell lines used in 
the two studies may explain the observed discrepancy.
Another DNA damage-recognition protein has been identified in HeLa cells 
(Toney et al., 1989), and human testicular and bladder tumor cells (McLaughlin 
K. et al., 1993). After the isolation of its encoding human cDNA (Bruhn S.L. et 
al., 1992), the protein was named SSRP1 (structure-specific recognition protein 
1). The SSRP1 protein contains one HMG domain. As with the other DRPs, the 
protein binds only 1,2-intrastrand cisplatin DNA adducts and not 1,3- 
intrastrand lesions. Moreover, the protein does not recognise adducts formed by 
transplatin or DNA damage caused by UV exposition. Higher levels of such a 
protein were found in cisplatin resistant testicular tumour cells with respect to 
their sensitive counterpart (McLaughlin et al., 1993). Conversely, in studies 
carried out on other tumor cell lines, no differences were observed 
(McLaughlin et al., 1993; Bruhn et al., 1992; Donahue et al., 1990). Moreover, 
the protein was not inducible after cisplatin exposure (Bruhn et al., 1992). As 
yet, the natural function of SSRP1 is still unclear.
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Several other HMG-domain-containing proteins have been described (sex 
determining region Y SRY, human upstream binding factor hUBF, 
mithocondrial transcription factor H MTFII). However, involvement of such 
proteins in the recognition of cisplatin DNA damage and cisplatin toxicity still 
remains to be determined.
1.4 Cell cycle progression and apoptosis
The life cycle of an eukaryotic cell consists of four phases: mitosis (M) and 
DNA synthesis (S), and the two periods in between gapl (Gi) and gap2 (Ga). 
When DNA is damaged, progression of the cell cycle to replication (S phase) 
could lead to mutations in the daughter DNA. To counteract this mutation 
threat, cells employ mechanisms to arrest the cell cycle temporarily when DNA 
is damaged, probably to allow repair to occur. Cell cycle arrest is governed by a 
series of control systems called 'checkpoints' (Enoch and Norbury, 1995). 
Activation of these checkpoints provides the cells with additional time to 
complete DNA repair (Fig. 13). However, if the damage appears to be 
irreparable, the cell can undergo apoptosis (Bedford, et al., 1988). In these 
processes, the p53 protein plays a key role. After DNA damage, the p53 protein 
is thought to bind DNA and to activate or regulate multiple genes involved in 
the control of cell cycle progression, in DNA repair pathways and in apoptosis. 
It has been suggested that replication as well as cell cycle arrest are necessary 
for induction of apoptosis (Anthoney et al., 1996; Sorenson and Eastman,
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Figure 13. Mammalian DNA damage checkpoints. DNA damage induces the 
arrest of the cell cycle progression in Gj and/or G2 phases. Delayed 
progression through S phase has also been noted fo r  some DNA 
damaging agents. Cell cycle arrest is mediated by a series of control 
systems commonly termed checkpoints (composed by cyclin and 
cyclin-dependent kinases) able to prevent the formation and/or 
activation of the complexes which can be thought of as the engine 
of the cell cycle.
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1988). However, at extremely high levels of DNA damage , apoptosis has been 
described without prior cell-cycle arrest or replication (Sorenson and Eastman, 
1988; Boulikas, 1996).
Replicative bypass is defined as the ability of the replicative complex of a 
cell to synthesise DNA past the site of DNA damage. Bypassing of cisplatin- 
DNA adducts during the S-phase of the cell cycle would allow a cell to 
progress into G2 in which it could arrest and repair the damaged sites before 
proceeding into mitosis (Brown, 1995). Enhanced replicative bypass has been 
observed in four different cisplatin resistant human ovarian cancer lines as well 
as in rodent cell lines as compared to cisplatin-sensitive cell lines (Gibbons et 
al., 1991; Mamenta et al., 1994). Research into the mechanism of replicative 
bypass demonstrated that only DNA polymerase P is able to bypass the 
cisplatin DNA l,2-d(GpG) intrastrand adduct. Moreover, DNA polymerase p 
was able to elongate the arrested replication products of DNA polymerases a, Ô 
and e (Hoffmann et al., 1995). The main difference between DNA polymerase 
p and other polymerases is believed to be the ability of the former to frequently 
dissociate and re-associate with the DNA strand, and to catalyse extension from 
the position upstream of the cisplatin DNA adduct, probably by reinitiating 
replication at the site opposite to the adduct (Hoffmann et al., 1995). Induction 
of DNA polymerase p has been observed in CHO cells after exposure to 
various DNA-damaging agents but not after treatment with cisplatin (Fomace 
et al., 1989). In addition, a 3 to 5-fold increased levels of DNA polymerase p 
mRNA were found in the cisplatin resistant human ovarian cancer cell line
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A2780cp8 with respect to its cisplatin sensitive counterpart A2780 (Scanlon et 
al., 1989a,b; Scanlon and Kashani-Sabet, 1989; Valentinis et al., 1993).
In recent years several studies were performed on different model systems 
including yeast, frog, mouse and human cells to better understand the 
mechanisms governing DNA damage-induced cell cycle arrest. In mammalian 
cells, cells cycle progression is halted in Gi and/or G] phases following DNA 
damage and, for certain DNA damaging agents, a prominent S phase delay has 
also been reported (Brown, 1995). As mentioned above, delay at these points in 
the cell cycle appears to be governed, in large part, by a series of checkpoints 
(Hartwell, 1992; Murray, 1992; Hartwell and Kastan 1994). Activation of these 
DNA damage checkpoints has been proposed to extend the period of time for 
DNA repair to occur before entry into S phase or mitosis. This in turn would 
suppress the replication of damaged DNA templates and the likelihood of their 
correct segregation into daughter cells. Cell cycle arrest can thus contribute to 
the fidelity with which genetic information is passed from one generation to the 
next, and the loss of these control systems can often have dramatic 
consequences on genome stability and cell survival following genotoxic stress 
(Livingstone et al., 1992; Yin et al., 1992; Hartwell., 1992; Hartwell and 
Kastan, 1994).
Cells exposed to cisplatin have been described to arrest in Gi as well as G] 
phases (Sorenson et al., 1990; Evans and Dive, 1993; Fan et al., 1994). Gi 
arrest is regulated by the product of the p53 gene (Fan et al., 1994). p53 could
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also be involved in the regulation of G2 cell cycle block although wild-type p53 
function does not seem to be required for G2 arrest following DNA damage 
(Kastan et al., 1991; Kuerbitz et al., 1992; O’Connor et al., 1993a). After 
cisplatin treatment, arrest in G2 appears to be more obvious than of Gi (Evans 
and Dive, 1993). Multiple studies have investigated, mostly using flow 
cytometric analysis, the cell cycle arrest caused by cisplatin and the underlying 
mechanisms. The duration of the G2 block was proportional to the 
concentration of cisplatin to which the cells were exposed (Ormerod et al., 
1994). In addition, a slower migration through S-phase was observed (Ormerod 
et al., 1994). These studies demonstrated that in order to reach G2 , where arrest 
for repair is possible, replication of the DNA-damaged template is a 
prerequisite (Ormerod et al., 1994), thus stressing the importance of replicative 
bypass.
In yeast and humans, cisplatin was found to induce a G2 arrest, and this arrest 
was mediated by the product of a gene named weel. The pathway leading to 
cell cycle arrest was kinase dependent and it was demonstrated that cells more 
resistant to cisplatin showed more pronounced arrest in G2 , whereas cells 
hypersensitive to this agent failed to show such an arrest (Thiebaut et al.,
1994). Hence, the ability of the cell to arrest the cell cycle in G2 might be a 
major determinant of resistance to cisplatin.
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1.4.1 p53
The tumour suppressor gene p53 encodes a nuclear phosphoprotein that is 
formed by 393 amino acids and can be divided into at least 3 domains: an 
amino-terminal acidic transactivating domain, a central evolutionarily 
conserved DNA binding domain and a complex carboxy-terminal domain that 
houses potential nuclear localisation sequences, a homotetramerisation domain 
and a putative DNA damage recognition domain, p53 is the most commonly 
mutated gene found in human tumours. The majority of mutations are missense 
mutations that are clustered into the central DNA binding domain (Friend 
1994; Greenblatt et al., 1994). Since the p53 protein can function as a 
sequence-specific DNA-binding protein that regulates gene expression, either 
positively or negatively (Volgelstein and Kinzler, 1992), these mutations block 
p53 DNA binding and transactivating activity and have frequently been termed 
“loss-of-function” mutations (Zambetti and Levine, 1993). p53 mutations are 
commonly associated with cellular accumulation of the p53 protein and 
evidence exists of a possible “gain-of-function” for certain p53 mutations 
(Zambetti and Levine, 1993). p53 also has the capacity to repress transcription 
of genes containing TATA elements (Mack et al., 1993). When DNA is 
damaged, the levels of p53 are increased, probably by stabilisation of the 
protein rather than by increased gene expression (Fritsche et al., 1993). High 
levels of p53 induce a Gi arrest by transcriptional activation of genes involved 
in the Gi cell cycle checkpoint. Loss of p53 may thus contribute to the genomic
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instability common in tumour cells, both by allowing tumour cells to replicate 
damaged DNA and by promoting the survival of cells with genomic alterations 
accumulating with time (Miyashita and Reed, 1995). Many different DNA- 
damaging agents, such as ionising radiation, UV radiation and 
chemotherapeutic drugs, including cisplatin, can induce p53 (Zhan et al., 1993). 
In turn, p53 transactivates a number of different genes (Fig. 14) including 
GADD 45, encoding a protein involved in DNA repair (Hollander et al., 1993); 
p21WAF1/CIP1, encoding a cyclin-dependent kinase inhibitor involved in Gi and 
G2 cell cycle arrest (Butz et al., 1995); MDM2, encoding an inhibitor of p53 
transcriptional activation and a promoter of p53 deregulation (Fajac et al., 
1996; Kondo et al., 1995); and BAX (Miyashita and Reed, 1995; Eliopoulos et 
al., 1995), encoding a promoter of apoptosis. Moreover, p53 has also been 
involved in the negative regulation of some proteins, such as the apoptosis 
inhibitor bcl-2 (Haidar et al. 1994).
It has been shown that DNA strand breaks are necessary and sufficient for 
DNA damaging agents to activate p53 (Nelson and Kastan,1994). This might 
explain why DNA base damaging agents like nitrogen mustard and cisplatin 
induce p53 relatively slowly compared to gamma-irradiation or the 
topoisomerase II inhibitor, etoposide (Fan et al., 1994). Previous studies 
performed showed that p53 dependent Gi arrest could be induced by nuclear 
injection of linearised plasmid DNA. This was the case whether the DNA was 
cut by enzymes that produced blunt ends, 5'- or 3'overhangs. p53 dependent Gi 
arrest was also observed after injection of circular DNA plasmid containing a
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Figure 14. Scheme for the different scenarios that follow DNA damage- 
induced p53 activation. Upon DNA damage, p53 becomes active 
and can trigger several cellular events via two distinct and parallel 
pathways: transcription-independent and -dependent pathways. Via 
transcription-independent pathway, p53 may lead to DNA-repair or 
apoptosis. The transcription-dependent process is more elaborated 
and involves activation, probably in a simultaneous fashion, of 
several target genes (MDM2, p21WAF1/CIP1, Bax, GADD 45 etc) that 
may lead to different outcomes such as degradation of p53, 
apoptosis, cell cycle arrest and DNA repair.
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large gap (2.9 kb gap) or single-stranded circular DNA whereas with 
supercoiled, nicked or small gap (25bp gap)-containing circular DNA plasmid 
it was not. Again, the length of the linear DNA was also important for p53 
activation since a 49 bp oligonucleotide was effective at inducing Gi block but 
a 27 bp fragment or single-stranded oligonucleotides up to 49 nucleotides in 
length did not induce Gi arrest (Nelson and Kastan 1994; Huang LC et al.,
1996)!
Recent studies have suggested that p53 might itself act as the direct DNA 
damage sensor (Jayaraman and Prives, 1995; Lee et al., 1995). p53 seems to 
have the ability to recognise and stably associate, in vitro, with short single- 
stranded DNA regions (<40 nucleotides) and insertion/deletion mismatch 
lesions. However, the fact that short single-stranded oligonucleotides (17-49 
bases) did not induce Gi arrest when microinjected into the nucleus of a wild- 
type p53 line (Huang LC et al., 1996) suggests that other components, such as 
ATM gene product (Savitsky et al., 1995; Kastan et al., 1992), might have to 
assemble with p53 on to the damaged DNA template to activate Gi arrest.
1.4.2 p53 and Gi delay
Arrest of cell cycle progression in Gi phase following DNA damage requires 
the function of the p53 tumour suppressor protein (Kastan et al., 1991; 
Kuerbitz et al., 1992). While cells with an intact p53 pathway exhibit y-ray 
induced Gi arrest, cells with p53 gene mutations, which occur commonly in
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human cancer (Hollstein, 1991; Levine et al., 1991), or cells expressing viral 
oncogenes, whose products bind to and inactivate p53 function, lack Gi arrest 
response to DNA damage (Kastan et al., 1991, Kuerbitz et al., 1992; Kessis et 
al., 1993; O’Connor et al.,1993b; Zambetti and Levine, 1993). As mentioned 
above, the mechanism by which p53 induces cell cycle arrest can best be 
understood from the transcriptional activation function of the p53 tumour 
suppressor (Pietenpol, 1994).
Among the several genes involved in p53-mediated Gi delay, one gene 
product in particular has been focused upon as the means by which p53 induces 
such an arrest of the cell cycle: p21WAF1/CIPI. This protein is a potent inhibitor 
of the activity of the cyclin dependent kinases (CDKs) encoded by the 
WAF1/CIP1 gene, the promoter of which contains p53 binding elements. The 
discovery that p21 was a potent inhibitor of the CDKs provided a potential 
mechanism by which p53 could inhibit the cell cycle engine in Gi phase. After 
DNA damage, induction of p53 leads to transactivation of the p21WAFI/CIP1 gene 
thus inducing an intracellular accumulation of this protein. By binding to 
cyclin/CDK complexes cyclin D/CDK4 and cyclin A/CDK2, p21 inhibits their 
kinase activity thus inducing growth arrest at Gi phase (El-Deiry et al., 1993) 
(Fig. 14). In support of this proposition, it was found that cyclin E/ÇDK2 
complexes were inactivated in a p53-dependent manner following DNA 
damage and that binding of p21 to this kinase correlated with its inactivation 
(El-Deiry et al., 1994; Dulic et al., 1994). p21 also binds to PCNA, 
proliferating cell nuclear antigen involved in DNA replication. This finding
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suggests that p21 might coordinately regulate CDK and PCNA activity (Fig. 
14). Several studies have been performed to understand the functional 
significance of such p21-PCNA binding. Data obtained thus far indicates that 
the primary purpose of such an interaction may not be to inhibit DNA 
replication per se but it is possible that p21 regulates some aspect of PCNA 
function in NER. Although in certain studies performed in vitro the role of p21 
in determining NER activity was not clear (Flores-Rozas et al., 1994; Waga et 
al., 1994, Lin et al., 1994), recent investigations in human cells lacking p21 
gene have revealed that such cells have reduced DNA repair activity and are 
more sensitive to agents that induce DNA damage repaired through the NER 
pathway (MacDonald et al., 1996), thus indicating that p21 could possess a 
dual role in both the Gi checkpoint and DNA repair.
Besides p21, additional components are required in the p53-mediated Gi 
arrest. The GADD45 gene product, the expression of which is induced by p53, 
has been shown to block re-entry of cells into the S phase suggesting that this 
protein might contribute to Gi checkpoint regulation probably by stimulating 
the DNA resynthesis step of the NER pathway (Smith et al., 1996).
Gi delay following DNA damage allows an extended period of time for 
DNA repair to occur before entry into the S phase. However, once DNA repair 
has been completed the cell, if required, must recover from this stasis and re­
enter the cycle. To do so the cell must coordinate several events including 
inactivation of p53 and p21, and regeneration of active cyclin/CDK complexes. 
The transcriptional inactivation of p53 could take place through MDM2, a p53-
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induced gène product that binds to the amino-terminal transactivating domain 
of p53 and blocks p53 transcriptional activity (Wu et al., 1993; Chen et al.,
1994). Once p53 has been inactivated, the longevity of Gi delay is then limited 
by the stability of the newly synthesised p53-regulated gene products that 
induce Gi block.
1.4.3 The G2 delay
Several recent studies demonstrated that cells exposed to a variety of DNA 
damaging agents such as y-irradiation, alkylating agents and cisplatin showed a 
marked accumulation in the G2-M phase of the cell cycle. However, several 
lines of evidence suggest that the mechanisms by which the same agent induces 
a G2 block can differ depending on the origin and the genetic and biochemical 
characteristics of the cellular model (O'Connor and Kohn, 1992; Hartwell and 
Kastan, 1994; Weinert and Harwell, 1988; O'Connor and Fan, 1996).
A current view of the G2 checkpoint controlling the G2 to M transition in 
drug-treated cells suggests a system of mutually interacting kinases and 
phosphatases (O'Connor and Fan, 1996; Kohn et al., 1994; Hoffman et al., 
1993) which act at the level of cyclin Bl/cdc2 complexes to maintain DNA 
damaged cells in G2 phase.
In some of the earliest biochemical studies on the mammalian G2 checkpoint 
it has been observed that DNA damage-induced G2 arrest was associated with 
suppression of p34cdc2 kinase activity. It was proposed that DNA damage
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suppressed the removal of inhibitory phosphorylations from the threonine-14 
and tyrosine-15 positions of cdc2, probably through suppression of the cdc2- 
activating phosphatase cdc25 and/or by up-regulation of the cdc2-inhibitory 
kinases Weel or Mikl.
Cdc2 and cdc25 have been suggested to interact in an autocatalytic-feedback 
loop to bring about rapid activation of the cdc2 kinase (Hoffinann et al., 1993). 
In this positive-feedback loop, cdc25 binds to a small fraction of the excess 
pool of cdc2/cyclin B1 complexes. As a result of cdc2 dephosphorylation the 
now active cdc2 would focus its initial kinase activity towards cdc25 itself. 
Hyperphosphorylation of cdc25 has been correlated with up-regulation of 
cdc25 activity (Hoffinann et al., 1993; O'Connor et al., 1994) which could in 
turn allow this relatively low abundance cdc25 protein the extra activity it 
might need to rapidly dephosphorylate the remaining hyperphophosrylated- 
cdc2/cyclin B1 complexes in G2 cells (O'Connor et al., 1994). Given the ability 
of cdc2 to phosphorylate cdc25 one might expect that if cdc25 had productive 
access to cdc2 it would become hyperphosphorylated in G2 arrested cells. Such 
a state could be achieved even if cdc2 was only transiently activated and then 
immediately down-regulated by Weel/Mikl kinases. Since cdc25 does not 
become hyperphosphorylated in G2 arrested cells, cdc2-cdc25 interaction either 
does not occur or there must be an up-regulation of a cdc25-inhibitory 
phosphatase that rapidly converts cdc25 back into its hypophosphorylated state. 
Consistent with the possibility that the G2 checkpoint prevents cdc25-cdc2 
interactions it was found that the interaction between cdc2 and cdc25 did not
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occur in DNA damaged G2 arrested cells (O'Connor et al., 1994).
An additional mechanism contributing to G2 block is the downregulation of 
cyclin Bl. Investigations performed on the HeLa cell line showed that cyclin 
B1 mRNA and protein levels accumulate from very low levels at the Gi/S 
phase border to peak levels in G2/M and most of this accumulation occurs as 
cells enter G2/M phase (Pines and Hunter, 1989). It has been demonstrated that 
y-irradiation of S phase synchronised HeLa cells suppresses cyclin Bl mRNA 
and protein accumulation probably by suppression of mRNA stability and 
promoter activity (Muschel et al.,1991; Muschel et al.,1993; Maity A. et al.,
1995). Reduced levels of cyclin Bl would limit the level of cyclin Bl/cdc2 
complexes in G2 arrested cells perhaps below the threshold level required for 
the mitotic entry. However, the evidence that forced expression of cyclin Bl in 
HeLa cells did not eliminate G2 delay, indicates the possibility that an 
additional regulatory mechanisms could contribute to G2 checkpoint control in 
this cell line probably by imposing cdc2-inhibitory phosphorylations in the 
DNA damaged cells (Lock and Keeling, 1993; Metting and Little, 1995)
These data altogether indicate that the G2-M checkpoint control could be 
regulated by two independent mechanisms that might cooperate at the level of 
cyclin Bl/cdc2 complexes (ede2 inhibitory phosphorylation and suppression of 
cyclin Bl levels) although recent studies suggested a possible involvement of 
p53 in the G2-M checkpoint control. The importance of p53 in controlling the 
G2 checkpoint was evidenced by studies in which it was found that the 
cytotoxic activity of DNA damaging agents can be enhanced by agents that
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disrupt G% checkpoint control preferentially in cells defective for p53 (Lau and 
Pardee, 1982; Fan et al., 1995; Powel et al., 1995; Russell, et al., 1995). Using 
inducible systems for wild-type p53 overexpression it was found that p53 can 
induce G2 delay (Stewart et al., 1995; Agarwal et al., 1995). Thus, although 
wild-type p53 is not required for G2 arrest following DNA damage, it might 
contribute an extra layer of protection to G2 checkpoint control (Kastan et al., 
1991; Kuerbitz et al., 1992; O'Connor et al., 1993b). In accord with this 
possibility, a number of workers have found that chemical inhibitors of G2 
checkpoint function are less effective at overriding G2 block in cells with intact 
p53 function (Fan et al., 1995; Powel et al., 1995; Russell, et al., 1995).
These data, taken together, indicated a possible role for wild-type p53 in G2 
checkpoint but the mechanistic basis is presently unknown. It is likely that the 
p53-induced G2 delay could be mediated by p21WAFI/CIP1 which is able to 
inhibit cyclin bl/cdc2 kinase activity, albeit poorly (Harper et al., 1993, 1995). 
In addition to this possibility, p53, which also possesses transcriptional 
repression activity, when overexpressed, could down regulate components 
required for the G2/M transition, such as cyclin Bl.
The length of G2 delay following DNA damage has been correlated with cell 
survival (Weinert and Hartwell, 1988; Hartwell and Weinert, 1989, McKenna 
et al., 1991). In these situations, cells that failed to arrest or cells that only 
briefly delayed progression were found to be more sensitive to DNA damage. 
Such findings complied with the paradigm that G2 delay ensures for completion 
of DNA repair before cell division and that cells that enter in mitosis
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prematurely are more likely to suffer the deleterious consequences of DNA 
damage (Hartwell and Kastan, 1994). However, several studies have indicated 
that prolonged G2 arrest does not always translate into a survival advantage.
As mentioned above, G2 cell cycle arrest and cell death seem to be promoted 
by the MMR system (Carethers et al., 1996; Hawn et al., 1995). It is likely that 
the arrest at the G2 cell cycle checkpoint may permit the cell to attempt repair 
of DNA mismatches and prevent the replication of mutated DNA. To support 
this hypothesis, it has been demonstrated that hMLHl-deficient tumour cell 
lines were not able to engage G2 delay after cisplatin damage (Brown et al.,
1997), thus indicating a possible tight link between G2 checkpoint control and 
the molecular pathways responsible for DNA damage detection and repair.
1.4.4 Apoptosis
After exposure to DNA damaging agents, cell death can occur by necrosis or 
apoptosis, which are morphologically and biochemically distinct processes. 
Whereas necrosis results from a loss of osmoregulation and is characterised by 
cell swelling and random DNA degradation by lysosomal enzymes at late 
stages, apoptosis is a programmed form of cell death, characterised by surface 
blebbing, cytoplasmic contraction, nuclear condensation, packing of cellular 
components within membranes prior to their budding from the cell as apoptotic 
bodies and chromatin cleavage by endogenous nucleases at an early stage 
(Eastman, 1990; Fajac et al., 1996; Wyllie, 1993). The chromatin is cleaved
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into oligonucleosomal-length fragments, which can be visualised by gel 
electrophoresis, since these fragments produce a very characteristic 'ladder' on 
the gel (Fajac et al., 1996).
Although some cell types respond to wild-type p53 induction, consequent to 
DNA damage activation, by arresting in Gi phase other cell types respond by 
undergoing apoptosis (Michalovitz et al., 1990; Martinez et al., 1991; Yonish- 
Rouach. et al., 1991; Lowe et al., 1993a,b; Clarke et al., 1993, Fan S. et al., 
1994; 1995). The mechanistic basis for these cell type differences remains to be 
determined, however, some insights come from studies in cells overexpressing 
c-myc or E2F-1 (Wagner et al., 1994; Wu and Levine 1994; Qin et al., 1994). 
These transcription factors, along with the transcription factor b-myb (Lin et 
al., 1994), can drive cells into S phase in spite of active p53. Although 
apoptosis in S phase commonly results from this by-pass, S phase entry may 
not be essential, since p53 can induce apoptosis in c-myc deregulated cells 
arrested in Gi by isoleucine withdrawal (Wagner et al., 1994).
Whether "priming" a cell for S phase, by activating genes required for S 
phase progression, is a sufficient signal for apoptosis remains to be 
investigated. Cancer cell types that do not normally undergo apoptosis 
following wild-type p5 3 -overexpression may harbour deregulated E2F- or c- 
myc, or alternatively may combat apoptosis by alternative mechanism such as 
overexpression of bcl-2 (Walton et al., 1993) or suppression of bax induction 
(Zhan et al., 1994). Interestingly, p53-mediated apoptosis can be suppressed by 
growth factors which in turn produce a more stable Gi arrest (Canman et al..
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1995). These results suggest that growth factor signals impinge upon the 
decision making process which determines Gi arrest and/or apoptosis. the 
outcome of which is to sway judgement towards Gi arrest and survival.
The bax gene, which encodes a product that counters bcl-2's ability to protect 
cells against apoptosis (Oltvai et al., 1993) is transcriptionally activated by 
wild-type p53 (Selvakumaran et al., 1994; Miyashita. et al., 1994; Miyashita 
and Reed, 1995). Interestingly, bax is only up-regulated in those wild-type p53 
cell lines that commit to apoptosis following p53 activation (Zhan et al., 1994). 
Moreover, bcl-2 mRNA levels decline following p53 activation (Selvakumaran 
et al., 1994; Zhan et al., 1994). These findings suggest that p53-dependent 
apoptosis might arise as the balance between bax and bcl-2 alters. Enriching 
this model are recent results that indicate that bcl-Xt mRNA levels are also 
induced by wild-type p53 in cells that commit to p53-dependent apoptosis 
(Zhan et al., 1996). Like bcl-2, bcl-Xt protects against apoptosis (Boise et al.,
1993). These results suggest that bax-induced apoptosis can be modulated 
independently of bcl-2 and that bcl-Xt might raise the threshold for bax- 
induced apoptosis. Despite these findings it is unclear how the apoptotic 
machinery becomes activated by bax. Also, studies into requirement of p53- 
dependent transactivation for apoptosis have yielded conflicting results with 
some studies suggesting that the transactivating activity of wild-type p53 may 
not be required for apoptosis in all cell types (Gaelics et al., 1994).
p53 disruption not only abrogates Gi arrest following DNA damage but it 
can also suppress apoptosis in susceptible cell types. Key experiments
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performed on murine embryonic fibroblasts transformed with adenovirus El A 
revealed that such cells were sensitised to apoptosis induced by ionising 
radiation and some chemotherapeutic agents and importantly, wild-type p53 
function was required for this sensitisation (Lowe et al., 1993a). Experiments 
performed on different cell lines demonstrated that those with a functionally 
intact p53 pathway were, on average, more sensitive to ionising radiation, 
etoposide, nitrogen mustard and cisplatin than cell lines with mutant p5 3 
(O'Connnor et al., 1993; Fan et al., 1994). The decreased sensitivity of the 
mutant p53 cell lines correlated with an evasion of p53-mediated apoptosis, 
illustrating that the mutant p53 lines had a survival advantage. Results obtained 
in different cellular models have tended to promote the single impression that 
p53 confers decreased sensitivity to DNA damaging agents. However, the 
cellular context and the type of DNA damaging agent now appear to be 
important in determining the outcome of p53 activation. In fact, in contrast to 
what is described above, most workers have failed to observe any impact of 
p53 disruption on the cellular sensitivity to DNA damaging agents in 
experiments performed on murine embryonic fibroblasts, colon carcinoma 
cells, breast cancer cells, and head and neck cancer cell lines (Bràchman et 
al.,1993; Slichenmyer et al., 1993; Fan. et al., 1995; Powell et al., 1995). 
Moreover, a recent study carried out on human ovarian cancer cells suggested 
that the loss of functional p53 can increase cisplatin cytotoxicity in these cells, 
with loss of Gi/S checkpoint control and decreased cisplatin-DNA adduct 
repair (Pestell et al., 2000).
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From the clinical point of view, of particular interest is the ability of 
cisplatin-induced DNA damage to trigger apoptosis. After exposure to 
cisplatin, DNA damage is believed to be a major trigger for apoptosis (Fan et 
al., 1995) and thus the rate of repair of cisplatin DNA adducts in cells treated 
with this drug may be related to the rate of apoptosis. Cisplatin has 
demonstrated induction of apoptosis in multiple tissue types (Havrilesky et al., 
1995; Otto et al., 1996), In murine mammary and ovarian cells, it was 
demonstrated that the rate of apoptosis increased with increasing doses of 
cisplatin treatment (Marples et al., 1994). Furthermore, a study on mouse 
leukemia LI210 cells demonstrated a dual response of these cells to exposure 
to cisplatin; at high doses, the cells rapidly underwent apoptosis, whereas at 
lower doses the cells were blocked in G2 . After blocking in G2 , the cells could 
either regain their proliferating ability and re-enter the cell-cycle or could die 
from failure to overcome the G2 arrest (Sorenson et al., 1990; Otto et al., 1996). 
When resistant cells from a human ovarian carcinoma cell line were compared 
to their sensitive, parental counterparts, it was found that the resistant cell lines 
needed higher doses of cisplatin to induce apoptosis (Fajac et al., 1996). 
Another study on ovarian cancer cells demonstrated that resistant cells 
overexpressed the protein product of the bcl-2 gene (Eliopoulos et al., 1995), 
which is a negative regulator of apoptosis. However, in another study, no 
correlation between cisplatin sensitivity and the ability to engage in apoptosis 
was observed (Ormerod et al., 1996). There are major differences in the 
intrinsic propensity of various cells to undergo apoptosis (Borner et al., 1995;
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Fan et al.* 1995), and cycling cells are far more vulnerable to cisplatin induced 
apoptosis than non cycling cells (Evans and Dive, 1993; Ormerod et al., 1996). 
Finally, mutations in genes involved in apoptosis, such as p53, can also play a 
role in the ability of cells to undergo apoptosis (Anthoney et al., 1996). Various 
attempts have been made in the last few years to correlate p53 status to 
chemosensitivity in clinical tumors. Specifically, as regards the susceptibility of 
ovarian cancers to cisplatin, two studies, based on a combined 
immunohistochemical and molecular analysis, suggested that tumors with p53 
aberrations are significantly less sensitive to cisplatin-based chemotherapy than 
those with functional p53 (Buttitta et al., 1997; Righetti et al., 1996). In one of 
these studies (Righetti et al., 1996) the correlation between p53 alteration and 
response to chemotherapy was however only found for one specific type of 
mutation (missense) and p53 accumulation by immunohistochemistry was 
observed only in cases with this type of mutation. Nevertheless, in another 
series no relation between p53 alterations analysed using 
immunohistochemistry and PCR followed by DNA-sequencing, and response 
to cisplatin-based. chemotherapy was observed (Di Leo et al., 1995). Similar 
results were found in another immunohistochemical study in stage HI and IV 
patients (Jacquemier et al., 1994). In addition, no correlation between 
chemosensitivity and p53 accumulation was found in another group of patients 
analysed by immunohistochemistry combined with molecular analysis (Smith- 
Sorensen et al., 1998)
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1.5 Circumventing cellular resistance to cisplatin
For many human tumours the clinical efficacy of the chemotherapeutic 
agents such as cisplatin, is still limited by different factors. These limitations 
have resulted in a great deal of effort having been expended to identify and/or 
develop new active anticancer molecules with higher antitumour activity and 
lower side effects.
In recent years the molecular mechanisms by which cisplatin exerts its 
cytotoxic activity and those probably responsible for cellular resistance to 
cisplatin have been identified. The proposed mechanisms may contribute to 
development of a variable degree of cellular resistance but none of them 
completely explains the resistance of several tumours or the pattern of cross- 
resistance among different damaging agents.
These findings have stimulated intensive effort in the development of new 
platinum-based compounds with improved pharmacological properties. In this 
context, the most important strategy used is the modification of platinum-based 
preexisting molecules in order to develop non cross-resistant analogues of 
cisplatin. For example, cytotoxic activity of platinum-based drugs could be 
enhanced through the synthesis of derivatives that form DNA adducts with 
higher affinity for High Mobility Group (HMG)-proteins thus shielding these 
lesions from NER repair proteins more efficiently than the cisplatin DNA 
lesions. (McANulty and Lippard, 1996a; Anin. and Leng, 1990).
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Investigations performed on the trans isomer of cisplatin (transplatin) 
evidenced that this molecule did not have any antitumoural activity because it 
is sterically unable to form the very toxic 1,2-GpG and 1,2-ApG intrastrand 
cross-links. The lack of activity of transplatin might be associated with the 
formation of high levels of monofunctional adducts mostly detoxified by 
glutathione through a rapid reaction whereas a minority probably rearranges to 
form bifunctional 1,3 and 1,4 GpG intrastrand cross-links or DNA interstrand 
cross-links likely removed by DNA repair systems.
A large number of mononuclear platinum compounds have been developed 
as potential candidates for clinical use (Fig. 15). Among these compounds, 
carboplatin [cis-diammine, 1,1-cyclobutane dicarboxylato platinum (II)] was 
the first additional platinum complex which received worldwide registration 
and acceptance. With carboplatin the major toxicity found for cisplatin have 
been substantially reduced (Calvert et al., 1985; Yarbo, 1992) although 
randomised studies showed that the two drugs appear broadly comparable in 
terms of response rates (Mangioni et al., 1989; Horwich et al., 1992). 
Furthermore, several studies documented a certain degree of cross-resistance 
between the two compounds probably due to the fact that the cellular and 
molecular mechanisms by which these drugs induce their cytotoxic activity are 
similar. Thus, while carboplatin unequivocally offers to patients a more 
acceptable level of morbidity compared to cisplatin, the clinically significant 
problems of intrinsic and acquired cisplatin resistance persist. These data thus 
indicated that carboplatin greatly alleviated the high level of patient morbidity
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Figure 15. Chemical structures of some of mononuclear platinum-based agents 
used in clinical trials.
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but it was also evident that the greatest problem remained the circumvention of 
the cellular resistance. This goal was accomplished by defining strategies based 
on refinements of preclinical tumour models for agent evaluation and 
rationally-driven synthetic chemistry through integration of recently accrued 
knowledge of tumour resistance mechanisms to both cisplatin and carboplatin.
For many years, preclinical antitumour evaluation of potential platinum- 
based anticancer drugs involved screening for activity against rapidly growing 
transplantable murine tumor cell lines, such as L1210 and P388 leukemias 
(Vendetti, 1983) and their variants possessing acquired resistance to cisplatin. 
Although this approach led to the discovery of platinum complexes 1,2- 
diamminocyclohexane (DACH), 1,2-diamminocycloheptane and tetraplatin, an 
important caveat concerning the adoption of these preclinal models was 
evident. In fact, DACH complex and tetraplatin were found to be very active 
against L1210 cells but inactive against cisplatin-resistant variant of the murine 
ADJ/PC6 model (Goddard et al., 1991).
To get round the problem described above, a different screening strategy was 
adopted. A panel of human ovarian cancer cell lines, containing examples of 
both intrinsic and acquired resistance to cisplatin and, where possible, well 
characterised for mechanisms underlying resistance/sensitivity to this drug, was 
selected.
By means of this innovative approach, several cisplatin-derived compounds 
chemically synthesised were evaluated for their antitumoural activity, general 
toxicity and cross-resistance with respect to cisplatin. Among these, the most
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important and promising drugs are JM216 (bis acetate ammine 
dichlorocyclohexylamine platinum IV) and oxaliplatin (oxalate-1,2- 
diamminocyclohexane platinum H).
JM216 is an orally administered platinum compound which has been 
evaluated in phase II clinical trials against small-cell lung cancer, non-small- 
cell lung cancer, prostate and ovarian cancer and is currently undergoing phase 
III clinical evaluation (McKeage et al., 1995). It was selected as the lead 
compound of a series of ammine/amine Pt (TV) dicarboxylates, designed to 
show improved lipophilicity and gastrointestinal stability in an effort to 
overcome the limited gastrointestinal absorption observed with cisplatin and 
carboplatin (Giandomenico et al., 1991).
In preclinical studies, JM216 exhibited activity comparable to that of 
cisplatin against a panel of in vitro human ovarian carcinoma cells lines 
(Kelland et al., 1993a), lung cancer (Twentyman et al., 1992) and human 
cervical squamous cells (Mellish et al., 1993) and showed lack of cross­
resistance to cisplatin in a panel of six pairs of human tumour cell lines, both 
parental sensitive and with acquired resistance to the latter drug. However, a 
very recent study (O'Neil et al., 1999) confirmed that JM216 exhibits a 
comparable level of cytotoxicity to that of cisplatin in human ovarian cancer 
cells sensitive (CHI) or with acquired (CHlcisR9) and intrinsic (SKOV-3) 
resistance to cisplatin, thus indicating a certain degree of cross-resistance 
between cisplatin and JM216 in these cell lines. Other studies found that this 
drug, similarly to other platinum-based drugs, is able to exert its cytotoxic
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activity through induction of p53-dependent apoptosis and that cellular 
resistance could be attributable to an increased tolerance to platinum-DNA 
adducts, to an enhanced gene-specific repair and to elevated GSH levels.
Oxaliplatin is a member of the family of DACH platinum complexes and is a 
third generation platinum antitumour drug (Chaney, 1995). At present it has 
entered in clinical European phase II trials and data obtained thus far indicate 
an encouraging activity and manageable toxicity in a variety of tumours usually 
resistant to cisplatin (Cvitkovic, 1998).
As mentioned above, the advantages of oxaliplatin over cisplatin include less 
severe clinical toxicity and retained activity against cisplatin-refractory tumours 
(Kelland, 1993b; Kelland and McKeage, 1994). Preclinical studies performed 
on both in vitro and in vivo experimental models confirmed that this derivative 
exhibits different spectra of activity and toxicity from cisplatin, often with a 
lack of cross-resistance between the two agents (Tashiro et al., 1989; Pendyala. 
and Creaven, 1993; Chaney, 1995).
Comparative analysis of the sensitivity pattern assayed in a panel of 60 
tumour cell lines suggested that oxaliplatin differs mechanistically from 
cisplatin and other platinum drugs (Rixe et al., 1996). In fact, it is likely that 
the trans-R,R configuration of the DACH moiety confers superior cytotoxic 
activity and drug binding to cellular DNA (Inagaki and Sewaki, 1995). 
Experimental results indicated that oxaliplatin exerts its cytotoxic effect 
through mechanisms of action and/or of resistance probably different from 
those of cisplatin (Woynarowski et al., 1998). In fact, investigations performed
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on the human ovarian cancer cell line A2780 evidenced that lesions produced 
by oxaliplatin on cellular DNA are fewer than those of cisplatin. Furthermore, 
after exposure of cells to the two drugs, general platination levels found in 
oxaliplatin-treated cells are lower than those found in cisplatin-treated cells, 
thus indicating that to achieve comparable cytotoxicity fewer oxaliplatin DNA 
adducts are necessary.
It has also been hypothesised that this higher oxaliplatin cytotoxic activity 
could reflect a more difficult repair of DNA lesions with respect to those of 
cisplatin although, in different experimental models and using different 
experimental approaches, some workers evidenced a similar DNA-lesion 
removal, capacity between the two drugs (Woynarowski et al., 2000). Very 
recent data (Woynarowski et al., 2000), tentatively explain the greater lethality 
of oxaliplatin in comparison to cisplatin by a reduced replicative bypass (thus, 
by an elevated inhibition of DNA chain elongation) and by a different 
processing of oxaliplatin-DNA lesions which could also elicit different 
downstream responses. For instance, cisplatin had been found maximally active 
in cells Where the MMR DNA repair pathway was intact (Aebi et al., 1996; 
Fink et àl., 1996) whereas oxaliplatin adducts are poorly recognised by MMR 
proteins (Fink et al., 1996) and the drug retains a high cytotoxic activity in 
MMR-deficient cells.
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1.6 The novel multinuclear platinum complex BBR 3464
Recently, an alternative option in the design of platinum-based analogues has 
led to the development of multinuclear platinum compounds. Dinuclear and 
trinuclear platinum complexes represent a new class of anticancer agents 
distinct for DNA binding and antitumour activity from their mononuclear 
counterparts. Moreover, chemical studies have shown that dinuclear and 
trinuclear compounds represent a large and diverse class of structures which 
may be differentiated among themselves with respect to important parameters 
of biological activity (Farrell, 1996). In fact, antitumour activity of bifunctional 
dinuclear and trinuclear platinum complexes is affected by the nature of the 
coordination sphere, chain length and steric effects within the linker group 
(Farrell et al., 1999).
Dinuclear platinum complexes are a class of compounds of considerable 
interest for their antitumour and DNA-binding properties (Farrell, 1993) and 
the utility of the dinuclear motif in drug design was first demonstrated by 
linking two antitumour active cisplatin molecules by a flexible diamine chain 
(Farrel et al., 1988). Incorporation of the cisplatin synthon into linear trinuclear 
systems was also achieved (Brabec et al., 1999).
Although these molecules did not contam a cis-[PtCl2(amine)n] unit, they 
showed the same cytotoxic and antitumoural effect of cisplatin when used at 
similar doses (Farrell, 1994). It has been demonstrated that the properties of 
monofunctional spheres and an overall 2+ charge violate all previous structure-
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activity relationships for platinum complexes. The complexes cause significant 
DNA (Pt,Pt) interstrand (Zou et al., 1994, Farrell, et al., 1990) as well as (Pt, 
Pt) intrastrand cross-links (Zou et al., 1994). Binding to DNA not only occurs 
at sequences preferred by cisplatin but other sequences, especially alternating 
purine-pyrimidine GCGC sequences, are attacked (Zou et al., 1994; Wu. et al., 
1994; Farrell, et al., 1990). One of these compounds, [{trans- 
PtCl(NH3)2 }2H2N(CH2)„NH2]2+ also called BBR 3005, was also found to 
promote the B -> Z conformational change of poly(dG-dC)*poly(dG-dC) at 
very low binding as evident from circular dichroism studies (Johnson et al., 
1992). This finding is important because it has been demonstrated that DNA 
conformational changes such as unwinding and bending could alter the protein 
recognition of DNA. Particularly, it has been observed that the bending of 
DNA upon cisplatin binding is likely to be responsible for the recognition of 
platinum-lesions by HMG proteins which seems to be, as discussed above 
(DNA repair section), an important determinant for cisplatin cytotoxic activity 
(Lilley, 1992; Pil. and Lippard, 1992). In fact, a number of evidences suggest 
that HMG proteins recognise DNA damaged by BBR 3005 but not as 
efficiently as for cisplatin-damaged DNA. (Farrell et al., 1995), thus indicating 
that this molecule represents the first example of highly cytotoxic platinum- 
based agents which are not recognised by HMG proteins and suggesting that 
the nature of bis(platinum)-DNA adducts allows for a systematic design of a 
“HMG bypass” mechanism. Very interesting was the evidence that BBR 3005 
displays cytotoxicity and antitumour activity in its own right and especially
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retains activity in cell lines resistant to cisplatin (Farrell et al., 1990). Thus, the 
linking of two mononuclear, monofunctional antitumour inactive moieties 
produces formally bifunctional DNA binding agents. In this manner, chemical 
and biological comparison with the classical monuclear cis- and trans- 
[PtCl2(NH3)2] could be made (Farrell et al., 1995).
Most of the reported considerations are also valid for BBR 3464, the first 
representative of the trinuclear platinum complexes class. However, an 
enhanced antitumour activity was found for this drug in comparison to BBR 
3005. BBR 3464, which has recently entered phase I clinical trials, is a novel 
anticancer agent designed on the hypothesis that new clinically useful 
platinum-based anticancer agents should have novel structures unrelated to 
those of agents currently used in the clinic. This trinuclear platinum complex is 
best described as two trans-|TtCl(NH3)^ external units linked by a tetra-amine 
[trans-Pt(NH3)2 {H2N(CH2)6NH2 }2]2+ central unit (Fig. 16). The central unit is 
only able to form non-covalent- hydrogen bonding- interactions with DNA, 
whereas the two external units, contain chloride ions, when aquated, become 
potent positively charged electrophilic intermediates able to covalently interact 
with negatively charged-nucleophilic groups of DNA bases. These particular 
properties of the molecule improve its affinity for the DNA, affect the 
charge/lipophilicity balance and further increase the distance between the two 
Pt-DNA-binding coordinatination spheres, thus determining a mode of DNA 
binding different from that of any other clinically-used DNA-damaging agent.
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Figure 16. Chemical structure of the novel trinuclear platinum complex BBR 
3464.
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An intriguing aspect of BBR 3464 is that, in adding charge and increasing 
chain length, interstrand cross-linking is diminished relative to BBR 3005 and 
long range intrastrand cross-links become equally probable. These types of 
lesions have critical consequences for the biological functions of DNA; the 
resulting conformational alterations in DNA might play an important role in 
considerably altering the antitumour effects of this new platinum complex as 
compared with cisplatin.
In preclinical studies performed by using different experimental models, 
BBR 3464 was found to be very active against human tumour cell lines 
characterised by intrinsic or induced resistance to cisplatin. Moreover, in these 
models an almost complete lack of cross-resistance between cisplatin and the 
novel trinuclear platinum complex was also observed (Pratesi et al., 1997; 
Giuliani et al., 1997; Manzotti et al., 2000). Further studies evidenced that BBR 
3464 retains antitumoral activity in human tumor xenografts and human cancer 
cell lines carrying inactivating mutations in the p53 gene (Pratesi et al., 1999).
These data altogether suggest that this novel trinuclear platinum anticancer 
drug, which is characterised by high activity in a broad spectrum of human 
tumours commonly insensitive to platinum-based chemotherapeutic 
intervention, probably exerts its cytotoxic effect through molecular and cellular 
mechanisms different from those of cisplatin and cisplatin-derivatives. 
However, thus far, the cellular and molecular basis of BBR 3464 efficacy and
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the relevance of factors involved in cisplatin resistance as determinants of 
response to the trinuclear platinum complex are still poorly understood.
1.7 Methods used to explore drug-DNA interactions
Although DNA interacting agents, currently used in clinical practice, are also 
toxic to normal tissues, they possess some degree of selectivity and specificity 
against a variety of human tumours. There are tumours which are particularly 
sensitive to DNA-interacting agents (for example testicular tumours are often 
curable with cisplatin), but the reasons for this peculiar sensitivity are still 
unclear. There is therefore a clear need for an arsenal of cellular, biochemical 
and biophysical techniques for characterising, with an highest approximation, 
how such compounds bind to DNA. In fact, a better understanding of the 
molecular basis of the sensitivity to such agents is necessary before any attempt 
can be made to design molecules which are more selective for different types of 
human neoplasm.
The rapidly growing knowledge of tumour biology, coupled with the use of 
novel molecular biology and pharmacology techniques, makes it possible to 
envisage experimental systems which could test precise hypotheses concerning 
the mechanisms of sensitivity and resistance to antineoplastic agents.
For several years, methods such as optical absorbance/fluorescence 
techniques, calorimetric assays, coupled mass spectroscopy analyses and 
electric dichroism-based procedures gave the possibility to investigate and
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quantitate the overall DNA damage produced by DNA-damaging anticancer 
drugs both in vitro and in living cells. In the past, several studies performed to 
provide a better understanding of the chemical basis of the reaction by which 
DNA-damaging agents bind DNA, indicated that the major site of binding on 
DNA is the guanine N7 position with lesser reaction at guanine O6 and adenine 
N3 .However, the above mentioned techniques do not give the possibility to 
directly confirm these chemical evidences, to ascertain whether a certain degree 
of sequence selectivity in DNA binding exists, to discriminate among the 
different types of DNA lesions or to evaluate if removal of such DNA adducts 
proceeds in a gene specific and/or strand specific manner.
1.7.1 Methods used to determine the sequence specificity of DNA-drug 
covalent binding
The availability of technical approaches to discriminate between the relative 
drug-DNA binding of a given base depending on the DNA sequence in which it 
was located can be very relevant, since one possible way to increase the 
specificity of DNA damaging agents could be to increase the damage towards 
selected DNA sequences which are important for the abnormal proliferation of 
cancer cells. Recently, methods for the determination of the pattern of covalent 
binding to guanine N7 or adenine N3 have been developed, thus making it 
possible to reevaluate existing DNA-damaging agents. The most widely used 
method is a modification of the Maxam-Gilbert DNA sequencing technique
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based on the principle that the covalent binding of the drug to DNA can be 
converted to a strand cleavage either by hot piperidine in case of guanine N7- 
drug adducts or by elevated temperature in the case of adenine N3-drug lesions. 
The method has been successfully applied to obtain information on the pattern 
of guanine N7 and adenine N3 binding of several DNA-damaging agents used 
in cancer chemotherapy such as major groove alkylating agents (nitrogen 
mustards, chloroethylnitrosoureas and alkyltriazenes) and minor groove binders 
(tallimustine and CC-1065). However, this approach has important limitations 
in that it does not allow the determination of DNA-drug adducts which are not 
converted to DNA-strand breaks. For example, cisplatin lesions on guanine N7 
(and adenine N7) as well as guanine O6 alkylations produced by methylating 
agents MNU and MNNG cannot be pinpointed using these procedures as they 
are not converted to DNA-strand breaks after hot piperidine or elevated 
temperature treatment.
To overcome this technical limitation, several techniques have been 
developed and, at present, the sequence specificity of DNA covalent adducts 
produced by all DNA-damaging anticancer agents can be evaluated. Of 
particular relevance are footprinting assays. Initially developed to investigate 
the DNA sequence specificity binding of proteins to DNA, these assays were 
then adapted to characterise both the covalent and the non-covalent DNA 
binding of smaller molecules, including DNA-damaging anticancer agents in 
vitro. These techniques rely on the ability of ligands bound to DNA to protect 
DNA from the digestion of DNase I (Drew, 1984) or radical producing
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chemicals such as methidiiumpropyl-Fe-EDTA (Dervan, 1986). The analysis of 
undigested DNA fragments by sequencing techniques gives information on the 
precise location and binding site of the ligand on the DNA.
In addition to footprinting approaches, the sequence selectivity of DNA 
covalent adducts can be evaluated using enzymes which are stopped by the 
presence of the adducts themselves. The analysis of DNA fragment produced 
by the termination of E. coli exonuclease m  (Exo HI footprinting; Royer- 
Pokora et al., 1981), bacteriophageal and bacterial RNA polymerases 
(monodirectional and bidirectional transcrptional footprinting; Philips and 
Cullinane, 1997) and E. coli DNA polymerase (polymerase inhibition assay; 
Dooley and Weiland, 1997), has been used to pinpoint DNA sequence-specific 
damage produced, in vitro, by several monofunctional alkylating agents 
(Weiland and Dooley, 1991, Broggini et al., 1995) and platinum (II) 
coordination complexes (Royer-Ppkora et al., 1981).
The use of the thermostable Taq DNA polymerase instead of E. coli DNA 
polymerase further improved the polymerase inhibition assay, thus producing a 
method called Taq stop assay.
1.7.1.1 The Taq stop assay
The Taq stop assay (Ponti et al., 1991) is a linear amplification method 
employing the properties of DNA polymerase to investigate the sequence 
selectivity of the interaction between DNA-damaging agents and DNA. The
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use of Taq DNA polymerase, instead of non-thermostable enzymes, gives the 
possibility to perform a number of polymerisation cycles (linear PCR) thus 
increasing the sensitivity of the system and, hence, allows detection of less 
frequent drug-DNA lesions. With respect to other methods, such as 
Exonuclease III, non-thermostable DNA polymerisation inhibition and 
chemical modification assays, this technique is characterised by higher 
simplicity, sensitivity, resolution power and sufficiently low background to 
allow the sequence specificity of DNA adducts to be easily determined both in 
vitro and in intact living cells. In addition, it is important to underline that this 
method is advantageous over other assays in that it is not limited to a single 
type of DNA damage: with the Taq stop approach, virtually all drug-induced 
DNA lesions are detectable.
As shown in Figure 17, an opportunely-selected oligonucleotide primer 
previously labelled is hybridised to a defined sequence of DNA and is extended 
by Taq DNA polymerase up to the drug-induced lesion. DNA-damaging agents 
produce adducts which, directly through steric obstruction or indirectly causing 
distortions in DNA, are able to inhibit polymerisation at the site of adduct 
formation. The forced blockage of the polymerisation caused by the lesions 
generates a pool of radioactively-labelled fragments the length of which is 
shorter than that of the full-length sequence and is determined by the position 
of DNA-drug adduct. Thus an analysis of the Taq stop reaction products on 
DNA sequencing gels allows the sequence specificity to be determined, with 
high precision (± 2 bp), by reference to the appropriate dideoxy sequencing
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Figure 17. Schematic representation of the Taq stop assay. An opportunely- 
selected oligonucleotide primer previously labelled is hybridised to 
a defined sequence of DNA and is extended by Taq DNA 
polymerase up to the drug-induced lesion (★). The forced blockage 
of the polymerisation caused by the lesions generates a pool of 
radioactively-labelled fragments, the length of which is shorter than 
that of the full-length sequence and is determined by the position of 
DNA-drug adduct. By reference to the appropriate dideoxy 
sequencing lanes, the analysis of the Taq stop reaction products on 
DNA sequencing gels allows the sequence specificity to be 
determined with high precision.
DNA template
5 ' ------ T A T C G - 3 '
3 ' ------ A T A G C - 5 '
Taq Stop
untreated DNA (Ctr) + J ’-labelledprim er treated DNA (T) + 5 '-labelledprim er
*5' TATCG-3' (F)
5 ' --- --- T A T C G - 3 '
3 ' ------ A T A G C - 5 '
*5' -- T
linear PCR
5 '  T A T C G - 3 '
3 '  A T M C - 5 '
*5' T
+
5 '  T A T C G - 3 '
3 '  A T A G C - 5 '
*5' T
linear PCR
*5' TATCG-3' (F)
*5' TAT-3' (1)
Sequencing
(Sanger)
ddA ddT
*5' TA (II) *5' T (I)
*5' TAT (III)
ddG ddC
*5' TATCG (V) *5' TATC (IV)
Sequencing gel
T A C G Ctr T
— (V)
— (IV)
—  (i)(in )
—  (ii)
—  (i)
-Figure 17-
(1) Introduction
lanes. In addition, if the drug reactions employed produce single hit kinetics 
(each DNA molecule receives at most one lesion), the intensity of a band 
produced on the DNA sequencing gel is proportional to the extent of the 
covalent adduct at that base position.
The Taq stop assay has been widely used for examining the sequence 
selectivity of damage and repair in genomic DNA of living cells, an 
experimental condition significantly different to that of in vitro studies, in 
which deoxyribonucleic acid is associated with different proteins, packaged in 
higher ordered structures and in the nuclear compartment.
In many studies the DNA target investigated was a-RI DNA (Fig. 18), which 
is formed by approximately 100,000 copies of a 340 bp tandemly repeated 
sequence and represents about 1% of the overall genome (Murray et al., 1992) 
in human cells. Although the 340 bp repeat sequences are not perfectly 
homogeneous but contain a low level (7%) of random base substitutions, they 
are sufficiently homogeneous and in high copy number to allow the 
straightforward determination of the sequence specificity of DNA damaging 
agents. It is important to note that this genomic region does not have any 
function in the control of cellular metabolism, but it represents an optimal 
substrate in Taq stop assays in order to obtain a general picture of the sequence 
selectivity of a DNA damaging agent in a physiological situation.
Finally, results, which are more relevant from a physiological point of view, 
can be obtained determining the sequence specificity of anticancer drug- 
induced DNA lesions at single copy gene level within intact cells. This goal
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Figure 18. The 340 bp a-RI DNÂ consensus sequence.. In bold are indicated.- 
the possible base substitutions present in the different 340 bp a-RI 
DNA monomers compared to the consensus sequence: Dashes 
indicate possible deletions present in the different .340' bp a-RI. 
DNA monomers compared to the consensus sequence. In italic are 
indicated the bases of the EcoRI sites. The underlined sequence 
indicates the position of the 16mer 'sense* primer (-»).
-Figure 18-
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was achieved by developing the single-strand ligation PCR in which an 
improved sensitivity was obtained by modifying the Taq stop assay (Grimaldi 
and Hartley, 1997).
1.7.2 Methods to evaluate induction and removal of drug-induced DNA 
lesions
A number of direct and indirect biophysical and biochemical techniques have 
been developed for the measurement of DNA interstrand cross-links induced 
by bifunctional DNA-damaging agents. Among these, the 'in vitro cross- 
linking' and the alkaline elution assays are the most commonly used. By means 
of the first method Çin vitro' cross-linking assay) it is possible to measure the 
formation of interstrand cross-links after in vitro exposure of any defined DNA 
sequence to any DNA-damaging agent (Grimaldi and Hartley, 1997). The 
alkaline elution assay (Kohn et al., 1976.) is an important approach to evaluate 
the formation and repair of DNA lesions after exposure of living cells to 
anticancer drugs able to produce DNA-DNA interstrand cross-links and DNA- 
protein cross-links. The most important limitations of both these techniques are 
imposed by dealing with the inability to evidence the behaviour of DNA- 
lesions other than those produced by cross-linking agents and the inability to 
evaluate lesion removal in specific regions of the genome. These limitations are 
very important because a large category of DNA-damaging anticancer agents 
induce their cytotoxic effect as a consequence of their ability to form bulky
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adducts rather than to produce cross-links. Moreover, for the rational design of 
new agents, characterised by novel sequence specificity (that may allow some 
degree of gene targeting), it is important to have methods that allow the 
sequence selectivity of binding to be studied in cells to see if the intended 
target sequence is being hit and to what extent individual lesions are repaired.
These problems have been overcome by using PCR-based methods 
exploiting the fact that covalent drug-DNA adducts can block Taq polymerase 
catalytic activity. By means of these PCR-based methods, all possible types of 
drug-DNA interactions can be studied both in vitro and in intact cells at various 
levels of resolution from gene regions (300-3000 bp; quantitative PCR) 
(Grimaldi et al., 1994a; Bingham et al., 1996) right down to the ultimate level 
of detection-individual nucleotides in single-copy genes in mammalian cells 
(Grimaldi, et al., 1994b).
1.7.2.1 Quantitative PCR
For many years the Southern blotting technique was used to study DNA 
damage and repair in living cells exposed to DNA-damaging agents not only in 
the overall genome but also in specific and physiologically relevant regions of 
the cellular DNA. However, an important limitation of this approach was the 
impossibility to perform such investigations at the subgene level. In view of the 
possibility that differential rates of induction and/or removal may occur both in 
different regions of a gene and in a strand-specific manner, the development of
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a reliable quantitative and sensitive method for studying drug effects in small 
regions of a particular gene and/or in the two strands of the same gene region 
was necessary (Bingham et al., 1996).
PCR-based techniques recently developed are equally sensitive, more rapid 
and need less DNA compared with Southern blotting analysis. Moreover, PCR- 
based techniques, give the possibility to map DNA damage and repair at the 
subgene level. Among these assays, quantitative PCR is able to measure the 
aggregate damage on both strands in a gene region of choice. It is sensitive 
enough to be used to look at subgene functional regions such as introns, exons 
and promoters. Currently, a convenient size for amplification is between 300- 
3000 bp. However, with the availability of reagents allowing “long PCR” the 
upper limit may be extended up to 20-30 Kbp allowing quantitative PCR to be 
used to study entire genes, in order to compare, for example, the kinetics of 
DNA damage and removal in genes expressed at a different rale.
The principle of this technique is very simple. As shown in Figure 19, a pair 
of oligonucleotide primers, that define the region of the genome and/or the 
gene selected for the study, is used. In PCR each strand of DNA serves as 
potential template for exponential amplification and the presence of one or 
more adducts will block the amplification of that strand. Therefore, when drug- 
treated DNA is amplified and the reaction is stopped in the exponential phase, 
the amount of PCR product will be reduced compared to untreated DNA and 
the extent of the reduction will be proportional to the amount of damage caused 
by the drug treatment. Moreover, by including a radioactive nucleotide in the
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Figure 19. Schematic representation of the quantitative PCR (QPCR) assay.
An opportunely-selected pair of oligonucleotide primers is used to 
select and amplify a specific DNA sequence. In the PCR reaction 
each strand of such DNA sequence serves as potential template for 
exponential amplification and the presence o f one or more adducts 
(I) will block the amplification of that strand. When drag-treated 
DNA is amplified and the reaction is stopped in the exponential 
phase, the amount of PCR product will be reduced compared to 
untreated DNA and the extent of the reduction will be proportional 
to the amount of damage caused by the drag treatment. The 
sensitivity of the assay can be increased by including a radioactive 
nucleotide in the PCR reaction so that the extent of damage caused 
by a specific treatment (and subsequent repair) can be accurately 
quantified.
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PCR reaction, the extent of damage caused by a specific treatment (and 
subsequent repair) can be accurately quantified.
1.7.2.2 The in vitro cross-linking assay
As mentioned above, the ability to produce interstrand cross-links on DNA 
could be an important molecular determinant for the antitumour activity of 
anticancer drugs. The possibility to rapidly compare the ability of a new DNA- 
damaging agent (for example BBR 3464) to produce interstrand cross-links in 
vitro with respect to a well known agent (for example cisplatin) could be an 
important tool to preliminary characterise its molecular and pharmacological 
properties.
The 'in vitro cross-linking assay' gives the possibility to perform this 
screening step and allows the investigator to evaluate the kinetics of interstrand 
cross-links formation in an opportunely selected naked DNA sequence. As 
shown in Figure 20, a naked DNA sequence previously labelled and containing 
consensus sequences for the formation of interstrand cross-links, is exposed for 
an opportunely selected time to various concentrations of drug. Samples are 
then heat-denatured and loaded onto a non-denaturing agarose gel together with 
two untreated control samples, one o f which was non heat-treated before 
loading. Thermal dénaturation of the untreated control sample induces strand 
separation thus producing radioactive bands with higher electrophoretic 
mobility (single strand form) with respect to the corresponding non-heat
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Figure 20. Schematic representation of the 'in vitro cross-linking' assay. A
naked DNA sequence previously labelled ( ■* —  1 ) and
containing consensus sequences for the formation of interstrand 
cross-links, is exposed for an opportunely selected time to various 
drug doses. Treated samples are then heat-denatured (100°C) and 
loaded onto a non-denaturing agarose gel together with two 
untreated control samples, one of which was non heat-treated before 
loading. Thermal dénaturation of the untreated control sample 
induces strand separation thus producing radioactive bands with 
higher electrophoretic mobility (SS DNA) with respect to the 
corresponding non-heat denatured control sample (DS DNA). In the 
drug-treated samples, the formation of interstrand cross-links (X) 
partially inhibits strand separation thus producing an electrophoretic 
pattern in which double strand form band represents the DNA 
molecule pool in which the separation of the two complementary 
strands was inhibited by the presence of interstrand cross-links 
(XL/DS DNA) whereas single strand form band represents the 
DNA molecule pool in which strand separation was not inhibited by 
the interstrand cross-links (noXL/SS DNA). Moreover, the amount 
of interstrand cross-links present in the DNA molecules is 
proportional to the intensity of the double strand form band and/or 
to the decrease of the single strand form band.
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denatured control sample (double strand form). In samples exposed to the drug, 
the formation of interstrand cross-links partially inhibits strand separation thus 
producing an electrophoretic pattern in which both single strand and double 
strand forms are present. In fact, the double strand form band represents the 
DNA molecule pool in which the separation of the two complementary strands 
was inhibited by the presence of interstrand cross-links. In addition, the amount 
of interstrand cross-links present in the DNA molecules is proportional to the 
intensity of the double strand form band and/or to the decrease of the single 
strand form band.
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Multinuclear platinum compounds represent a new approach to circumvent 
cellular resistance to cisplatin in that they are endowed with a different DNA- 
binding profile compared to their mononuclear counterparts. BBR 3464 has 
been identified as the most active member of this class of compounds. The 
drug is more potent than cisplatin and is active in cisplatin-resistant 
experimental human tumour models. However, the cellular determinants 
responsible for BBR 3464 activity are largely unknown. Moreover, the 
relevance of factors contributing to cisplatin resistance (such as decreased drug 
accumulation, increased detoxification, increased DNA repair and tolerance to 
DNA damage, and decreased cell susceptibility to undergo apoptosis) in 
determining the cellular sensitivity profile to BBR 3464 needs to be 
established.
The present study was undertaken to elucidate possible molecular 
mechanisms responsible for the antitumour activity of BBR 3464. To this 
purpose, the cytotoxic activity of the trinuclear platinum complex was 
evaluated in two pairs of human ovarian cancer cell lines sensitive and with 
experimentally induced resistance to cisplatin. One of the cisplatin-resistant 
cell lines proved to be more sensitive to BBR 3464 than the parental cell line 
and the other one was moderately cross-resistant to BBR 3464. In an attempt to 
identify the cellular characteristics and/or the molecular events responsible for 
the peculiar drug sensitivity profiles observed for the two drugs, we performed 
a detailed characterisation of the cellular models, in terms of ability to 
accumulate the drugs and expression and function of important DNA repair 
pathways such as MMR and NER. A detailed evaluation of the extent and type
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of DNA binding by the drugs in terms of DNA platination, sequence 
preference of DNA adducts and kinetics of accumulation and removal of 
lesions at the single-gene (N-ras) level was also carried out in the different cell 
models.
Due to its ability to modify DNA in a way which is different from that of 
cisplatin, BBR 3464 could evoke different pathways of cellular response to 
DNA damage such as activation of cell cycle checkpoints and triggering of the 
apoptosis pathway, as a function of the genetic background of the tumour 
model. In this study experiments were carried out to verify whether the 
peculiar drug sensitivity profiles observed in our cellular models were 
attributable to a different effect exerted by cisplatin and BBR 3464 on cell 
cycle progression or to their different ability to activate the apoptotic pathway. 
As regards the effects on cell cycle, we investigated the disturbance exerted by 
drugs on the progression of cells throughout the different cycle phases as well 
as the interference with proteins that regulate G2 to M transition. As far as 
programmed cell death was concerned, we determined whether or not each 
drug was able to affect the mitochondrial membrane potential (Av|/mt) and to 
activate caspases, as detected by the presence of degradation products of 
caspase-substrates such as lamin B.
134
(3) Materials and Methods
135
(3) Materials and Methods
3.1 GENERAL PROCEDURES
3.1.1 Drugs
Melphalan was obtained from Sigma (Milan, Italy). Cisplatin was obtained 
from Pharmacia-Upjohn (Milan, Italy). BBR 3464 was obtained from 
Novuspharma S.p A. (Monza, Italy) as (NO3)" salt. Valinomycin was purchased 
from Sigma. Teniposide was purchased from Bristol-M. Squibb as 10 mg/ml 
(15 mM) stock solution.
3.1.1.1 Melphalan preparation
Six hundred-fifty pi of a Perchloric Acid (70%; Carlo Erha Reagenti-Milan, 
Italy)/absolute ethanol (Carlo Erba Reagenti-Milan, Italy) solution [1:200 
(v/v)] were added to 1.3 mg of powdered melphalan. The drug was completely 
dissolved by vortexing and successively diluted with Phosphate Buffered 
Saline (PBS) (Bio-Whittaker Europe-Verviers, Belgium) to a final 
concentration of 20 fig/ml. Melphalan stock solution (20 pg/ml) was stored as 
1 ml aliquots at -20°C. At this temperature the drug proved to be stable for at 
least 7 months.
3.1.1.2 Cisplatin preparation
To obtain a 1 mg/ml (3.3 mM) cisplatin stock solution, 10 ml of PBS were 
added to cisplatin powdered stock and the drug was completely dissolved by 
vigorous vortexing immediately before use.
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3.1.1.3 BBR 3464 preparation
One mg/ml (807.1 pM) BBR 3464 stock solution was prepared as follows: 
an opportune volume of PBS was added to the powder and the drug was 
dissolved by performing 3 ice-cold sonication steps at 55 watt (Branson 
Bonifier 250, Italscientifica-Genoa, Italy) for 15 seconds with 10 seconds of 
pause on ice between each step. The BBR 3464 stock solution was stored at -  
20°C as 100 pi aliquots: at this temperature, the drug solution was stable for at 
least two weeks.
3.1.1.4 Valinomycin preparation
To obtain a 1 mg/ml valinomycin stock solution, 10 ml of distilled water 
were added to 1 0  mg of powdered valinomycin and the drug was completely 
dissolved by vigorous vortexing immediately before use
3.1.2 Human tumour cell lines
OAW42 and OAW42Mer cell lines were kindly supplied by Dr. R.A. Britten 
(Department of Radiation Oncology, University of Liverpool, UK). OAW42 
cell line was derived from the ascites of a patient with a papillary serous 
cystoadenocarcinoma of the ovary (Wilsonc, 1984). The OAW42Mer cell line, 
which is resistant to melphalan and cross-resistant to other alkylators including 
cisplatin, was obtained by exposure of the OAW42 cell line to increasing 
stepwise concentrations of melphalan (Britten et al., 1990).
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Both A2780 and A2780cp8 cell lines were kindly supplied by Dr. R. Ozols 
(FoxChase Cancer Centre Philadelphia, PA, USA). À2780 cell line was 
derived from the ovarian carcinoma of an untreated patient. The corresponding 
cisplatin-resistant A2780cp8 subline, which survived intermittent exposure to 8  
pM cisplatin, was obtained by exposure of the parental A2780 cell line to 
increasing stepwise concentrations of the drug (Behrens et al., 1987). The 
A2780d cell clone was selected in culture from A2780 cell line without drug 
exposure.
The colon carcinoma HCT-H6  cell line was kindly supplied by Dr. M. 
Broggini (Department of Oncology, Istituto di Ricerche Farmacologiche 
"Mario Negri"-Milan, Italy).
LoVo, HeLa and HL-60 cell lines, derived from untreated patients with 
colon carcinoma, uterine cervix carcinoma and leukaemia respectively were 
purchased from American Type Culture Collection (Rockville, MD, USA).
3.1.2.1 Human tumour cell lines growth conditions
All cell lines were maintained as monolayers in 25-cnf flasks (Coming- 
Costar Italia-Milan, Italy) at 37°C in a 5% CO2 humidified atmosphere in an 
air incubator (Mod. BBD 6220, Heraeus-Milan, Italy).
OAW42 and OAW42Mer cells were cultured in D-MEM/F12 medium, 
supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Bio-Whittaker 
Europe), 2 pM L-glutamine (Sigma), 0.25 units/ml insulin (Sigma) and 0.1%
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(v/v) gentamycin (Schering-Plough-Milan, Italy) at a density of 2.5 x 105 cells 
per 25-cm2 flask.
The culture medium for the melphalan-resistant OAW42Mer cell line was 
supplemented with 1 pg/ml of melphalan.
A2780, A2780cp8 and A2780 were maintained as monolayers in RPMI- 
1640 medium (Bio-Whittaker Europe), supplemented with 10% (v/v) FBS, 2 
jiM L-glutamine, 0.25 units/ml insulin, 100 units/ml penicillin (Sigma), 100 
pg/ml streptomycin (Sigma) and 0.1% (v/v) gentamycin, at a density of 0.8 x 
105 cells per 25-cm2 flask.
HCT-116 cells were cultured Using Iscove medium (Bio-Whittaker Europe), 
supplemented with 10% (v/v) FBS, and 0.1% (v/v) gentamycin, at a density of 
0.8 x 10s cells per 25-cm2 flask.
LoVo cell line was maintained in D-MEM/F12 medium, supplemented with 
10% (v/v) FBS, 2 pM L-glutamine, Ix MEM vitamins lOOx (Life 
Technologies Italia-San Giuliano Milanese, Italy) and 0.1% (v/v) gentamycin, 
at a density of 0.8 x 105 cells per 25-cm2 flask.
HeLa cells were cultured using D-MEM/F12 medium, supplemented with 
10% (v/v) FBS, 2 pM L-glutamine and 0.1% (v/v) gentamycin, at a density of 
0.8 x 105 cells per 25-cm2 flask.
HL-60 cell line was maintained as a monolayer at 37°C in a 5% CO2 
humidified atmosphere in an air incubator, using RPMI 1640 medium, 
supplemented with 10% (v/v) FBS, 2 pM L-glutamine and 0.1% (v/v) 
fungizone (Sigma), at a density of 0.8 x 10s cells per 25-cm2 flask.
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All tumour cells were cultured as follow: at set time points, specific growth 
medium was removed from the 25-cm2 flask and the cellular monolayer was 
washed twice with 5 ml 37°C-heated PBS then, 1 ml of a Trypsin-EDTA 
solution (250 mg/litre EDTA, 500 mg/litre Trypsin 1:250) (Bio-Whittaker 
Europe) was added to each flask After a 5 minute-incubation at 37°C with 
gentle shaking, cell detachment was checked under the microscope (Nikon 
TMS, Folabo-Buccinasco, Italy)and trypsin activity was blocked by addition of 
5 ml of complete growth medium. Five ml-suspension containing detached 
cells was transferred in a sterile 15 ml conical tube (Falcon-Becton Dickinson 
Italia-Milan, Italy) and centrifuged at 1,500 ipm for 5 minutes at room 
temperature in a Varifuge 3.OR centrifuge (Heraeus Sepatech). Cell pellet was 
then carefully arid extensively resuspended in 5 ml of growth medium and a 
small aliquot (100 pi) was transferred in a plastic 20 ml-vial (Falcon-Becton 
Dickinson) containing 10 ml of the isoton solution (azide-free balanced 
electrolyte solution; Coulter Scientific, Luton, UK). Single-cell suspension was 
checked under the microscope in a Burker camera, and the number of detached 
cells was calculated by counting in a particle counter (Coulter Counter, Coulter 
Scientific, Luton, UK).
Frozen stocks of human tumour cell lines were prepared as follows. Cells in 
logarithmic growth phase were detached from the flasks and counted as 
previously described. The percentage of viable cells was also determined by 
Trypan blue dye exclusion test by mixing, in a 0.5 ml clean conical tube 
(Eppendorf Italia-Milan, Italy) 5 pi of detached cells suspension, 45 pi of PBS 
and 50 pi of Trypan blue dye (Sigma). Five pi of Trypan blue dye-stained cell
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suspension were placed onto a Burker camera and checked under the 
microscope. The number of viable cells generally exceeded 95%. After 
counting, the cell suspension was centrifuged at 1,500 rpm for 5 minutes at 
4°C. The supernatant was removed and the cell pellet was carefully 
resuspended in. 4°C-cold 'freezing medium' [D-MEM/F12 medium 
supplemented with 40% (v/v) FBS] at a density of 5 x 106 viable cells/ml. One 
ml of such a cellular suspension was then transferred in a 2 ml sterile Nalgene 
tube (Nalgene Company, Rochester, NY, USA) and placed on ice. One ml of 
eryoproteetive medium [basal EAGLE’S medium with HANKS’ BBSS and 
15% (v/v) dimethylsulfoxide (DMSO)] (Bio-Whittaker Europe) was added to 
each tube and after a gentle resuspension, the tube was placed onto a Cryo 1°C 
Freezing Container (Nalgene) and stored at -80°C for the initial freezing step. 
After 16-24 hours, frozen cells were removed from the freezing container and 
stored under liquid nitrogen vapours in the Bamstead/Thermolyne containers 
(Bamstead/Thermolyne, Dubuque, 10, USA).
For cell thawing, frozen cells were incubated in a 37°C water bath (P.B.I 
Intemational-Milan, Italy), transferred into a sterile 15 ml conical tube 
containing 10 ml of complete growth medium and centrifuged at 1,500 rpm for 
5 minutes at room temperature. The cell pellet was then resuspended in 15 ml 
of growth medium and cells were seeded in a 25-cm2 flask.
3.1.3 Nucleic acids quantification
Concentration and quality of solutions containing DNA, RNA or 
oligonucleotides were determined by spectrophotometric analysis as follows.
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In two clean 1.5 ml tube (Eppendorf), a suitable volume of nucleic acid- 
containing solution (generally, 5 and 10 pi) was gently mixed with RNase- or 
DNase-free distilled water to a final volume of 200 pi to obtain a 1:40 and 1:20 
dilutions. As the blank sample, a third clean tube containing 200 pi of RNase- 
or DNase-free distilled water was also prepared. The content of each tube was 
transferred into quartz cuvettes (Perkin-Elmer Italia-Monza, Italy), the cuvettes 
were then placed onto a Lambda 11/Bio spectrophotometer (Perkin-Elmer 
Italia and absorbance values at 260 nm (A260nm) and 280 nm (A280nm) of wave 
length were measured. The A260nm and A280nm values obtained with the blank 
sample were subtracted from the absorbance values obtained with the nucleic 
acid-containing samples, and DNA, RNA or oligonucleotide concentration was 
then calculated using these formulae: 
pg/ml of DNA = (A260nm) x (dilution factor) x (50 pg/ml); 
pg/ml of RNA = (A260nm) x (dilution factor) x (40 pg/ml); 
pg/ml of oligonucleotide = (Aiôonm) x (dilution factor) x (30 pg/ml);
The nucleic acid concentration was expressed as the mean of the values 
(pg/ml) obtained in the two independently-prepared and -measured dilutions.
The quality of nucleic acid solutions was evaluated by calculating the 
A260nm/A280nm ratio. It is well known that for both DNA and oligonucleotide, a 
ratio of 1.8-2 was indicative of a good-quality preparation, whereas high 
quality RNA solutions are characterised by a A260nm/A280nm ratio of 2.
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3.1.4 Protein concentration determination
Protein concentration was determined according to Bradford (Bradford, 
1976).
3.1.4.1 Calibration curve preparation
Solutions of bovine serum albumin (BSA) (1 jig/200 jil, 2 jig/200 pi, 4 
pg/200 pi, 5 pg/200 pi, 10 pg/200 pi and 20 pg/200 pi) were prepared by 
dissolving powdered BSA (Sigma) in distilled water. In a 1.5 ml tube, 200 pi 
of each BSA solution were mixed with 600 pi of distilled water and 200 pi of 
Biorad Protein assay dye (Biorad-Milan, Italy). In the blank sample, 800 pi of 
distilled water were mixed with 200 pi of Biorad Protein assay dye. Samples 
were rapidly transferred into disposable cuvettes (P.B.I. International) and the 
absorbance at 595 nm wave length of each calibration point was measured in 
the spectrophotometer. The absorbance value corresponding the blank sample 
was then subtracted from the values obtained in the BSA-containing samples. 
Each calibration sample was run in triplicate. The calibration curve obtained in 
such a way, gave the possibility to extrapolate the exact absorbance value 
corresponding to a 1 pg of proteins present in the solution.
3.1.4.2 Protein concentration quantification
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Concentration of extracted proteins was determined by mixing in a 1.5 ml 
tube 1 pi of protein extracts with 200 pi of Biorad Protein assay dye and 
distilled water to a final volume of 1 ml. Samples were rapidly transferred into 
disposable cuvettes and the absorbance at 595 nm wave length was measured 
in the spectrophotometer. By dividing the obtained absorbance value for that 
corresponding to 1 pg of proteins (obtained from the calibration curve), it was 
possible to calculate the protein concentration of each sample. Also in this 
case, each sample was run in triplicate.
3.1.5 Agarose gel preparation
All of the agarose gel electrophoresis experiments were carried out using 
Hoefer horizontal electrophoresis units (Amersham-Pharmacia Biotech Italia- 
Cologno Monzese, Italy).
Gels of different sizes and percentages (w/v = grams of powdered agarose 
per 1 0 0  ml of running buffer) were prepared in clean glass bottles by mixing 
suitable amounts of powdered agarose (Sigma) in Ix TAE [0.04 M Tris- 
Acetate (Sigma), 0.001 M EDTA (Life Technologies)] or Ix TBE [0.09 M 
Tris-Borate (Sigma), 0.002 M EDTA] running buffers. Agarose was dissolved 
by heating in a microwave cooker (Philips mod. 810; Philips Italia-Milan, 
Italy), cooled to about 50°C, transferred onto the casting tray and, after the 
insertion of a clean comb, left to polymerise at room temperature. When 
polymerisation was completed, the comb was removed and solidified agarose 
gel was transferred into the running tray and submerged with running buffer.
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3.1.6 SDS-polyacrylamide gel preparation
All of the SDS-polyacrylamide gels used for protein separation (16 
centimetres high/16 centimetres length/1.5 millimetres thick) were prepared as 
described by Laemmli et. al. (1970) and run in a Hoefer SE 600 vertical 
electrophoresis slab unit (Amersham-Pharmacia Biotech Italia).
Resolving gel (30 ml) was prepared in a 50 ml conical tube (Falcon- Becton 
Dickinson) by mixing a suitable volume of 40% (w/v) polyacrylamide stock 
solution (acrylamideiNjN'-metliylenebisacrylainidc molar ratio = 29:1) (Sigma) 
with 0.3 ml of 10% (w/v) SDS solution (Sigma) [final concentration = 0.1% 
(w/v)], 7.5 ml of 1.5 M Tris-HCl pH 8 . 8  solution (Sigma) (final concentration 
= 375 mM), 300 pi of 10% (w/v) ammonium persulfate (Sigma) [final 
concentration = 0.1% (w/v)] and 18 pi of TEMED (Sigma) [final concentration 
= 0.06% (v/v)], and subsequently poured into the gap between glass plates 
(previously washed with absolute ethanol) leaving sufficient space for the 
stacking gel (the length of the teeth of the comb plus 1 centimetre: about 3 
centimetres). The poured resolving polyacrylamide gel solution was 
immediately and carefully overlaid with 0.1% (w/v) SDS solution (the overlay 
prevents oxygen from diffusing into the gel and inhibiting polymerisation) and 
the gel was placed in a vertical position at room temperature to polymerise. 
When polymerisation was complete (within 30-45 minutes), the overlay was 
poured off and the top of the gel. was carefully washed several times with 
distilled water to remove any unpolymerised acrylamide. The stacking gel (10 
ml) containing 5% (w/v) polyacrylamide (acrylamide :N,N'-
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methylenebisacrylamide molar ratio = 29:1), 0.1% (w/v) SDS, 125 mM Tris- 
HCl pH 6 .8 , 0.1% (w/v) ammonium persulfate and 0.1% (v/v) TEMED was 
prepared in a 15 ml conical tube and poured directly onto the surface of the 
polymerised resolving gel. A clean comb was immediately inserted into the 
stacking gel solution and the gel was placed in vertical position to polymerise. 
When polymerisation was complete, the comb was removed, the wells were 
washed with distilled water to remove any unpolymerised acrylamide and the 
gel was mounted in the electrophoresis apparatus containing TGS running 
buffer [25 mM Tris base, 250 mM Glycine (Sigma), 0.1% (w/v) SDS, pH 8.3] 
in both upper and lower buffer reservoirs.
3.1.7 Sequencing gel preparation
The sequencing gel (50 centimetres length/40 centimetres wide/0.4 
millimetres thick) was prepared and run into a S3S sequencing unit (Owl 
Scientific Inc., Woburn, MA, USA). Before their assembly, glass plates were 
cleaned by extensive washes with distilled water and absolute ethanol to avoid 
the formation of air bubbles when the gel was poured. To prevent the gel from 
sticking tightly to both plates and reduce the possibility that the gel tears when 
it is removed from the mold, the surface of the smallest glass plate which will 
contact the gel was treated with Gel Slick silicone solution (J.T. Baker, 
Phillipsburg, NJ, USA) according to the manufacturer's recommendations.
Sequencing polyacrylamide gel was prepared in a glass beaker by mixing 
polyacrylamide (acrylamide:N,N-methylenbisacrylamide molar ratio -  19:1)
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(Sigma), powdered urea (Sigma), lOx TBE buffer (0.9 M Tris-Borate, 0.02 M 
EDTA) and distilled water in order to achieve, in a final volume of 90 ml, a 6 % 
(w/v) polyacrylamide/7 M urea/lx TBE solution. To completely dissolve 
powdered urea, the mixture was incubated several minutes in a heated water- 
bath with occasional agitation, and polyacrylamide solution was then filtered 
through a 0.2 pm filter membrane. After addition of ammonium persulfate and 
TEMED [final concentrations of 0.05% (w/v) and 0.02% (v/v) respectively], 
polyacrylamide solution was poured into the gap between the glass plates. The 
fiat side of the shark's tooth comb was immediately inserted for approximately 
0 . 5  centimetres into the gel solution and clamped by using bulldog binder clips. 
The gel was placed in the horizontal position and allowed to polymerise over 
night at room temperature. Before the gel mold was transferred to the 
electrophoretic unit containing Ix TBE in the upper and lower reservoirs, the 
shark's tooth comb was carefully removed from the top of the gel, the flat 
loading surface of the gel was washed with Ix TBE to remove any fragments 
of polyacrylamide and a cleaned shark's tooth comb was reinserted with its 
teeth just sticking into the loading surface of the gel. The sequencing gel was 
heated to about 60°C before sample loading by means of a pre-run at constant 
power of 57 watt by using an Alex 300 power supply (M-Medical-Florence, 
Italy).
3.1.8 Non-denaturing polyacrylamide gel preparation
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Non-denaturing, polyacrylamide gels (16 centimetres high/16 centimetres 
length/1.5 millimetres thick) were prepared and run in a Hoefer SE 600 vertical 
electrophoresis slab unit (Amersham-Pharmacia Biotech Italia).
Polyacrylamide gel solution (30 ml) containing 5% (w/v) polyacrylamide 
(acrylamide : N,N-methylenebisacrylamide molar ratio = 29:1), Ix TBE 
buffer, 0.07% (w/v) ammonium persulfate and 0.035% (v/v) TEMED was 
prepared in a 50 ml conical tube and subsequently poured into the gap between 
glass plates (previously washed with absolute ethanol). A clean comb was 
immediately inserted and the gel was placed in vertical position to polymerise. 
When polymerisation was completed, the comb was removed, the wells were 
washed with Ix TBE buffer to remove any unpolymerised acrylamide and the 
gel was mounted in the electrophoresis apparatus containing Ix TBE running 
buffer in both upper and lower reservoirs.
3.1.9 Preparation of the pSP73 vector-containing E. coli library
In order to obtain a permanent and stable source of pSP73 vector, the 
following procedures were performed.
3.1.9.1 Preparation of competent JM 109 E. coli cells for transformation
Fifty pi of sterile JM 109 È. coli cellular suspension (Promega Italia-Milan, 
Italy) were mixed, in a sterile 50 ml conical tube, with 10 ml of sterile LB 
medium [1% (w/v) Bacto-Tryptone (Life Technologies Italia), 0.5% (w/v)
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Bacto-Yeast extract (Life Technologies Italia), 1% (w/v) NaCl (Sigma), pH 
7.0] and allowed to grow in a 37°C-heated shaking incubator (GFL3031; 
Folabo) at 225 rpm over night. One ml of such liquid bacterial culture was then 
transferred into a sterile 500 ml bottle containing 100 ml of sterile LB medium 
and the bottle was placed into the 37°C-heated shaking incubator at 225 rpm.
To harvest bacterial cells in logarithmic growth phase, 2 hours later, 1 ml of 
liquid culture was transferred, under a laminar flow (Bluebeam 4; Arredi 
Tecnici Villa-Caronno Pertusella, Italy), in a disposable cuvette and the 
absorbance at 600 nm of wave length was read on the spectrophotometer. E. 
coli concentration in the liquid culture was calculated by considering that 1 
Aéoonm unit corresponds to about 8  x 106 bacterial cells/ml. When Aeoonm of the 
liquid culture reached 0.3 units (corresponding to 240 x 106 cells/ml; 24 x 10* 
cells in 1 0 0  ml) the bacterial suspension was transferred, under a laminar flow, 
in two ice-cold sterile 50 ml conical tubes and the cell growth was stopped by 
placing the tubes on ice for 15 minutes. E. coli cells were pelleted by a 3,000 
rpm centrifugation at 4°C for 10 minutes and, after the removal of LB medium, 
cell pellets were pooled in the same tube by gentle resuspension in 1 0  ml of 
ice-cold sterile 0.1 M CaCfe solution (Sigma). After addition of 40 ml of ice- 
cold sterile 0.1 M CaCb solution, bacterial suspension was incubated on ice for 
30 minutes and subsequently centrifuged at 3,000 rpm for 10 minutes at 4°C. 
The supernatant was then removed and the cell pellet was carefully 
resuspended in 5 ml of an ice-cold sterile 0.1 M CaCl2-15% (v/v) glycerol 
(Sigma) solution. Such a bacterial suspension was incubated on ice for 24 
hours. At the end of incubation, the bacterial suspension was mixed by gentle
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pipetting, divided in 500 pl-aliquots (4.8 x 10* cells/ml; 2.4 x 109 cells in each 
500 pl-aliquot) in sterile 0.5 ml Nalgene tubes, frozen by snap freezing in 
liquid nitrogen and stored at -80°C.
Fifty pi (240 x 106 cells) of freshly-prepared competent cells were 
transformed with 50 ng of a DNA vector able to confer ampicillin resistance 
and 1/ 1 0 0 , 0 0 0  (dilution factor, 1 0 5) of the bacterial suspension was plated as 
described in the 2.1.9.2 section. Transformation efficiency, calculated on the 
basis of the formula [(num ber  of colonies) x (103) x (dilution factor) / 50 
ng], was expressed as the "number of colony forming units (CPU) per pg of 
plasmid DNA". Generally, 10*-10* CFU per pg of plasmid DNA were 
indicative of a good preparation of competent bacterial cells.
3.1.9.2 Transformation of bacteria
In an ice-cold 10 ml Falcon 2059 tube (Falcon-Becton Dickinson), 240 x 10* 
of competent bacterial cells (50 pi; section 2.9.1) were diluted to a final 
volume of 100 pi with 0.1 M CaCb and 50 ng (5 pi) of purified pSP73 vector 
were then added. The mixture was gently mixed by tapping and the tube was 
chilled on ice for 30 minutes, incubated for 90 seconds at 42°C in a water bath 
and for 2 minutes on ice. After a 5-minute incubation at room temperature, 900 
pi of LB medium were added and tube was placed into a 37°C-heated shaking 
incubator at 225 rpm for 1.5 hours. The tube was then centrifuged at 3,000 rpm 
for 5 minutes at room temperature, 950 pi of supernatant LB were removed
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and bacterial cell pellet was resuspended in the remaining 50 pi, plated onto 
90-mm dish (Coming-Costar Italia-Milan, Italy) containing selective solid LB 
medium [liquid LB medium, 1.5% (w/v) agar (Life Technologies), 50 pg/ml 
ampicillin (Mead-Johnson-Rome, Italy)] and incubated over night at 37°C. 
Each colony, representing ampicillin-resistant/transformed growing bacterial 
cells, was picked-up with a sterile disposable loop, dissolved in a 50 ml conical 
tube containing 10 ml of liquid LB medium supplemented with ampicillin (50 
pg/ml final concentration) and allowed to grow over night at 37°C with 225 
rpm shaking.
3.1.9.3 Small scale preparation of plasmid DNA ("miniprep")
To confirm the presence of pSP73 . plasmid in ampicillin-resistant liquid 
culture, 8  ml of the bacterial suspension were used for "miniprep" by using 
Wizard Plus SV Minipreps Kit (Promega Italia) according to the 
manufacturer's instructions. Plasmid DNA concentration was determined 
spectrophotometrically as described in the section 3.1.3.
Electrophoretic analysis was performed on 1% (w/v) agarose mini gel 
prepared and run in Ix TAE buffer. About 500 ng of extracted and original 
DNA vectors were loaded and separated at 90 volt (SE300 power supply; 
Amersham-Pharmacia Biotech.) at room temperature for 1 hour in the presence 
of 500 ng of X-BsteII molecular weight marker (Sigma). DNA fragments were 
visualised by placing the gel onto the UV-transilluminator (260 nm wave 
length) (Biorad) after a 30-minute staining with 1 pg/ml ethidium bromide (Life
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Technologies Italia)-Ix TAE buffer staining and a 30-minute Ix TAE buffer 
destaining.
3.1.9.4 Storage of pSP73 vector-transformed bacteria
In a 2 ml sterile Nalgene tube, 1. 6  ml of ampicillin-resistant liquid bacterial 
culture and 0.4 ml of sterile pure glycerol (final concentration (v/v) = 20%) 
were mixed by a vortex mixer and frozen by snap freezing in liquid nitrogen 
and stored at -80°C.
3.1.10 Large scale preparation of plasmid DNA ("maxiprep")
By means of a sterile spatula, frozen bacterial cells were scraped from the 2 
ml sterile Nalgene tube and dissolved in 10 ml of 50 pg/ml ampicillin 
containing-LB medium (contained in a 50 ml conical tube) and allowed to 
grow at 37°C in a shaking incubator at 225 rpm. After 8  hours, 10 ml liquid 
culture was mixed with 100 ml of fresh 50 pg/ml ampicillin containing-LB 
medium into a 500 ml glass bottle and cells were left to grow over night at 
37°C and 225 rpm.
Bacterial cells were pelleted by a 30-minute centrifugation at 4,000 rpm at 
4°C and, after removal of LB medium, plasmid DNA was purified with the 
Qiagen Plasmid Maxi Kit (Qiagen-Hilden, Germany) according to the 
manufacturer's instructions.
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Concentration and quality of the plasmid DNA were evaluated as described 
in the section 3.1.3.
3.1 SPECIFIC PROCEDURES
3.2.1 Cytotoxic activity of cisplatin and BBR 3464 on cell lines: the growth 
inhibition assay
After harvesting in logarithmic growth phase, cells were seeded in 6 -well 
plates (Coming-Costar Italia) in 2 ml of fresh media at the following densities: 
5 x 104 cells/well for OAW42 and OAW42Mer and 4 x 104 cells/well for 
A2780, A2780d and A2780cp8. The plates were then incubated at 37°C in a 
5% CO2 humidified atmosphere in the air incubator for 24 hours. As regards 
the OAW42Mer cell line, it is important to stress that melphalan was not added 
to the growth medium for at least 2  passages before initiation of the growth 
inhibition experiment.
Immediately before cell treatment, cisplatin (3.3 mM) and BBR 3464 (807.1 
pM) stock solution were diluted in specific growth media to obtain the 
different 1 Ix working solutions of the two drugs. Two hundred pi of each drug 
1 ix  working solution were added to each well (containing attached cells and 2  
ml of medium) in order to expose the cells to Ix final drug concentration in a 
final volume of 2.2 ml. For untreated control samples, 200 pi of fresh medium 
was added to each well. After a 1-hour incubation of cultures at 37°C in a 5% 
CO2 humidified atmosphere in air incubator, drug-containing medium was
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removed from each well and cells were washed three times with PBS (3 ml for 
each well). Five ml of fresh medium were then added to each well and plates 
were incubated at 37°C in a 5% CO2 humidified atmosphere in air incubator. 
After 72 hours, medium was removed from each well, cells were washed three 
times with PBS (3 ml for each well) and detached from the plates by a 5- 
minute incubation at 37°C with Trypsin-EDTA solution (1 ml for each well). 
Trypsin activity was stopped by addition of a 10% (v/v) FBS-PBS solution (5 
ml for each well) and cells were transferred in the isoton solution. Single-cell 
suspensions were obtained by repeated pipetting, checked under the 
microscope and counted in a particle counter.
Each experimental sample was run in triplicate and the results were 
expressed as the number of cells in treated samples compared with control 
samples. Each experiment was repeated at least three times.
3.2.2 Expression of mismatch repair (MMR) and nucleotide excision 
repair (NER) proteins 
Basal level expression of some of the most important proteins involved in 
MMR and NER DNA repair pathways were determined in OAW42, 
OAW42Mer, A2780, A2780d and A2780cp8 cell lines by Western blot 
analysis.
3.2.2.1 Nuclear extracts preparation
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Proteins were extracted from cell nuclei by using a modification of the 
method described by Dignam (Dignam et al., 1983).
OAW42, OAW42Mer, A2780, A2780d, A2780cp8, HCT-116, LoVo and 
HeLa cell lines in logarithmic growth phase were detached from the flasks by 
means of Trypsin-EDTA solution, transferred in a 15 ml conical tube and 
pelleted by a 5-minute centrifugation at 1,500 rpm at 4°C. To obtain a single­
cell suspension, cell pellets were dissolved by repeated pipetting in 1 0  ml of 
PBS. Cell suspension was checked under the microscope, and a small aliquot 
( 1 0 0  pi) was transferred in the isoton solution and counted in the particle 
counter.
An aliquot of cell suspension containing about 5 x 10* cells was then 
transferred in a 1.5 ml conical tube and cells were pelleted by a 15-second 
centrifugation at 12,000 rpm at 4°C (5417 R Centrifuge) (Eppendorf Italia). 
After removal of PBS, cell pellets were again washed twice with PBS. At the 
end of the last wash, PBS was removed and, in order to destroy the cellular 
membrane but not the nuclear membrane, cells were resuspended by gentle 
pipetting in 400 pi of ice-cold/slightly hypotonic lysis buffer A [10 mM Hepes 
pH 7.9 (Sigma), 10 mM KC1 (Sigma), 0.1 mM EDTA pH 8 , 0.1 mM EOT A 
(Sigma), 1 mM Dithiothreitol (DTT) (Sigma), 0.5 mM PMSF (Sigma), 5 pg/ml 
Aprotinin (Sigma)]. Cell suspensions were incubated on ice for 15 minutes, 
then 25 pi of 10% (v/v) Nonidet P-40 (Sigma) were added and the tubes were 
vigorously vortexed for 10 seconds. To separate cytoplasmic proteins from 
crude intact nuclear, the homogenates were centrifuged for 30 seconds at 
12,000 rpm at 4°C. After removal of the supernatant containing cytoplasm
155
(3) Materials and Methods
proteins, crude intact nuclei pellets were resuspended in 1 0 0  pi of the ice 
cold/high ionic strength lysis buffer C (20 mM Hepes pH 7.9,400 mM NaCl, 1 
mM EDTA pH 8 , 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 5 pg/ml Aprotinin) 
which is able to disrupt the nuclear membrane and to selectively extract nuclear 
proteins. The tubes were vigorously rocked at 4°C for 15 minutes on a shaking 
platform (RotoMix; P.B.I. International), then the homogenates were 
Centrifuged 5 minutes at 12,000 rpm at 4°C and supernatants containing the 
nuclear proteins were transferred in a clean 1.5 ml conical tube.
Protein concentration was determined as described in section 3.1.4, and 
nuclear extracts were stored at -80°C as 50 fig aliquots.
3.2.3 Western blot analysis
Equivalent amounts of nuclear extracts were fractionated, blotted onto solid 
support and immunoassayed to qualitatively evaluate the expression of MMR 
proteins (hMLHl, hPMS2 and hMSH2) and NER protein ERCC1 in OAW42, 
OAW42Mer, A2780, A2780cp8 and A2780d cell lines. Nuclear extracts from 
HeLa (hMLHl+, hPMS2+, and hMStB4), LoVo (hMLHl*, hPMS2+, and 
hMSH2") and HCT-116 (hMLHV, hPMS2", and hMSH2 *) cells were used as 
controls for MMR proteins basal expression.
3.2.3.1 SDS-polyacrylamide gel electrophoresis
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An 8 % (w/v) polyacrylamide resolving gel (linear range separation = 36-94 
KDa) was used to obtain the separation of hMLHl, hMSH2 and hPMS2 
proteins (8 6 , 100 and 110 KDa respectively). An aliquot of OAW42, 
OAW42Mer, A2780, A2780d and A2780cp8 nuclear extracts containing 100 
pg of proteins were mixed with 20 pi of 'Colour markers for SDS-PAGE and 
Protein transfer' spanning a molecular weight range of 6.5-205 KDa (Sigma) in 
a 1.5 conical tube. An equal volume of 2x SDS loading buffer (100 mM Tris- 
HC1 pH 6 .8 , 4% (w/v) SDS, 0.2% (w/v) bromophenol blue (Sigma), 20 (v/v) 
glycerol and 200 mM DTT) was then added. Tubes were heated at 100°C for 5 
minutes (Modular-Thermostat; P.B.I. International), chilled on ice for an 
additional 5 minutes, centrifuged at 4°C at 12,000 rpm for 5 seconds and 
loaded onto the SDS-PAGE system.
Proteins were fractionated running the gel at constant voltage (55 volt over 
night) or 8  volt/centimetres for stacking gel and 15 volt/centimetres when the 
dye front was moved into the resolving gel at room temperature by means of a 
Biorad 200/2.0 power supply (Biorad). The run was stopped when the 6 6  KDa 
band of the colour marker reached the bottom of the gel.
The same procedure, with the exception of the resolving gel percentage 
(12% w/v) corresponding to a 14-60 KDa linear range of separation, was used 
to separate ERCC1 (36 KDa) protein. In this case, the run was stopped when 
the 45 KDa band of the colour marker reached the bottom of the gel.
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3.23.2 Transfer of fractionated proteins from SDS polyacrylamide gel to 
nitrocellulose filter
Protein blotting was performed in a ‘Trans-Blot Cell’ electrophoresis protein 
transfer unit (Biorad). When the SDS-PAGE was approaching the end of its 
run, four pieces of Whatman 3MM (Whatman International LtD., Maidstone, 
UK) and one piece of nitrocellulose filter (Hybond ECL, Amersham-Pharmacia 
Biotech.) to the exact size of the resolving gel were cut and soaked for at least 
5 minutes in transfer buffer [50 mM Tris base, 100 mM Glycine, 0.01% (w/v) 
SDS, 20% (v/v) methanol (Carlo Erba Reagenti), pH 7.5]. At the end of the 
run, the glass plates holding the SDS-polyacrylamide gel were removed from 
the electrophoresis tank, the glass plates were opened and, by means of a 
scalpel, the stacking gel was removed. The resolving gel was placed exactly on 
the top of nitrocellulose filter and then sandwiched between two pairs of 
transfer buffer wetted-Whatman 3MM papers. Possible air bubbles trapped 
were displaced by repeated rolling with a pipette tip. The sandwich was then 
placed between two transfer buffer wetted-porous pads and two plastic 
supports and the entire construction was immersed in the electrophoresis 
transfer tank containing transfer buffer with the nitrocellulose filter placed 
toward the anode.
Transfer of the protein from the gel to nitrocellulose membrane was carried 
out at room temperature for 2  hours at 60 volt (constant voltage) by means of a 
Biorad 200/2.0 power supply.
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S.2.3.3 Immunological detection of nitrocellulose-immobilised proteins
At the end of the transfer, the nitrocellulose filter was recovered from the 
sandwich and, in order to verify the correct protein blotting, it was stained for 5  
minutes in a clean tray containing a “Ponceau S red dye” solution (Sigma) with 
gentle agitation at room temperature. When the bands of proteins were visible, 
the filter was destained with several washes of distilled water at room 
temperature.
On the basis of the molecular weight marker position, membrane slices 
containing proteins corresponding to about 36 KDa (ERCC1), 57 KDa (tubulin 
P), 8 6  KDa (hMLHl), 100 KDa (hMSH2) and 110 KDa (hPMS2) were excised 
with a scalpel and placed in separate clean trays. To completely destain the 
Ponceau S red dye bound to the proteins, nitrocellulose slices were washed 
three times for 2 0  minutes at room temperature on a shaking platform with 
blocking solution [5% (w/v) dried-nonfat milk (Regilait-Barcelona, Spain), 
0.1% (v/v) Tween-20 (Sigma) and PBS], filter slices were then incubated at 
room temperature on a shaking platform in blocking solution to mask potential 
nonspecific antibodies binding sites and, thus, to reduce general background. 
After 1 hour, blocking solution was removed and filter slices were incubated 
over night at 4®C on a shaking platform with the specific antibody-containing 
solution. Detection of proteins of interest was achieved by using polyclonal 
antibodies anti hMLHl, hMSH2 and hPMS2 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) or monoclonal antibodies anti ERCC1 and tubulin p 
(NeoMarkers, Fremont, CA, USA), diluted to a final concentration of 1 pg/ml
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in blocking solution. At the end of the over night incubation, primary 
antibodies were removed and filter slices were washed 3 times for 20 minutes 
with T-PBS wash solution [0.1% (v/v) Tween-20 in PBS] at room temperature 
on a shaking platform. Nitrocellulose filters were then incubated at room 
temperature on a shaking platform with the secondary antimouse or antirabbit 
Ig horseradish peroxidase-linked whole antibodies (Amersham Pharmacia 
Biotech.) diluted 1:1000 in blocking solution. After a 1-hour hybridisation, 
secondary antibodies were removed and filter slices were washed three times 
for 20 minutes at room temperature on a shaking platform with T-PBS wash 
solution followed by a rapid wash with PBS. Antibodies bound to proteins of 
interest on nitrocellulose slices were detected by means of the enhanced 
chemoluminescence system (ECL) (Amersham-Pharmacia Biotech.) according 
to the manufacturer's instructions using Hyperfilm MP films (Amersham- 
Pharmacia Biotech.).
3.2.4 Evaluation of ERCC1 gene expression by RT-PCR analysis
Basal levels of expression of ERCC1 gene in the OAW42, OAW42Mer, 
A2780, A2780d and A2780cp8 cells were quantified by RT-PCR analysis.
3.2.4.1 Cell preparation
Cells in logarithmic growth phase were detached from the flasks by means of 
sterile Trypsin-EDTA solution, transferred into a sterile a 15 ml conical tube
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and pelleted by a 5-minute centrifugation at 1,500 rpm at 4°C. Single-cell 
suspension was obtained by resuspending cell pellets in 10 ml of sterile PBS, 
the suspension was checked under the microscope, and a small aliquot ( 1 0 0 - 
500 pi) was transferred in the isoton solution and counted in the particle 
counter.
An aliquot of cell suspensions containing about 5-10 x 106 cells was then 
transferred in a sterile 1.5 ml tube, cells were pelleted by a 15-second 
centrifugation at 12,000 rpm at 4°C. After removal of PBS, cell pellets were 
washed twice with 1 ml of sterile PBS. At the end of the last wash, PBS was 
removed and total RNA was extracted from the cells.
3.2.4 2 Total RNA extraction
All extraction and manipulation steps were performed under sterile 
conditions using Diethylpirocarbonate (DEPG) (Sigma)-treated or 'RNase-free' 
certified chemicals and plastic disposable materials.
Total cellular RNA was obtained from fresh or frozen cell pellets by means 
of the Trizol Reagent' (Life Technologies Italia) according to the 
manufacturer's instructions. The amount of extracted RNA was determined 
spectrophotometrically.
Quality of isolated RNA was checked by gel electrophoresis analysis carried 
out by using a 1 % (w/v) agarose mini gel ( 1 0  centimetres length/ 6  centimetres 
wide) prepared in Ix TAE buffer. An aliquot corresponding to about 1 pg of 
extracted ribonucleic acid was mixed in a RNase-free 0.5 ml tube with an equal
161
(3) Materials and Methods
volume of sequencing gel loading buffer [95% (v/v) Formamide (Sigma), 20 
mM EDTA pH 8 , 0.05% (w/v) bromophenol blue and 0.05% (w/v) xylene 
cyanol (Sigma)], heated at 100°C for 3 minutes (in order to completely destroy 
possible RNA secondary structures), chilled on ice for further 3 minutes and 
loaded. RNA samples were run at a constant voltage of 90 volts for 1 hour at 
room temperature. The gel was then stained for 30 minutes at room 
temperature with gentle shaking in the ethidium bromide staining solution 
(lpg/ml ethidium bromide prepared in Ix TAE buffer) and destained for 
further 30 minutes at room temperature with gentle shaking in Ix TAE buffer. 
RNA was visualised by means of the UV transilluminator and photographed on 
a 667 Polaroid film (Polaroid LtD-St. Albans, UK). The presence of well 
defined and visible bands corresponding to both 28S and 18S ribosomal RNA 
was indicative of a good RNA preparation.
Total RNA extracted from each of the cell lines was stored at -80°C as Ipg 
aliquots.
3 2.4.3 Synthesis of first strand cDNA by reverse transcription reaction
Total RNA extracted from each cell line was reverse transcribed by using 
'RNA PCR Core Kit’ (Perkin-Elmer Italia). In a RNase-free 0.5 ml reaction 
tube (Perkin-Elmer Italia), 1 pg of total RNA was mixed with 2.5 pM random 
hexamers, 20 units of RNase inhibitor, 2.5 mM MgCh, ImM each dNTP, Ix 
PCR buffer (10 mM Tris-HCl pH 8:3, 50 mM KC1), 50 units of MuLV reverse 
transcriptase and RNase-free water to a final volume of 20 pi. Tubes were
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incubated at room temperature for 15 minutes (to allow annealing between 
random hexamers and RNA). First strand cDNA synthesis and MuLV reverse 
transcriptase inactivation were then obtained by a 42°C-incubation for 30 
minutes and a 5-minute heating at 95°G, respectively, in a hot-bonnet thermal 
cycler (MJ Research/M-Medical-Florence, Italy). Samples were stored at 4°C 
until they were used in PCR reactions.
3.2.4.4 PCR reactions
Primers used were synthesised and supplied in lyophilised form by M- 
Medical:
•  ERCC1 sense (5’-GTGCAGTCGGCCAGGATACAC-3’; Tm = 62°C) 
corresponding to position 233-252 of human ERCC1 mRNA;
• ERCC1 antisense (5’-GTCCTCCTGGAGTGGCCAAG-3’; Tm = 65°C) 
corresponding to position 706-726 of human ERCC1 mRNA;
• P-Actin sense (5 ’-GGGAATTCAAAACTGGAACGGTGAAGG-3 ’ ; Tm = 
60°C) corresponding to position 1336-1362 of human P-Actin mRNA;
• p-Actin antisense (5 ’ -GGAAGCTTATCAAAGTCCTCGGCCACA-3 ’ ; Tm 
= 61 °C) corresponding to position 1405-1431 of human P-Actin mRNA;
For each primer, 100 pM stock solution was prepared by dissolving the 
lyophilised primer in an opportune volume of Ix TE pH 8  (10 mM Tris-HCl, 1 
mM EDTA) by extensive vortexing. Oligonucleotide concentration was
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checked spectrophotometrically as described in section 3.1.3. The successive 
dilutions were prepared in distilled water.
Non-competitive quantitative PCR amplification was performed using the 
'RNA PCR Core Kit' (Perkin-Elmer Italia) as follows. In DNase-free 0.5 ml 
PCR reaction tubes, 125 ng of total RNA reverse transcribed in first strand 
cDNA were mixed with 1 pM sense and antisense ERCC1 primers, 0.1 pM 
sense and antisense P-Actin primers, 0.625 units of AmpliTaq DNA 
polymerase, Ix PCR buffer, 2 mM MgCk and DNase-free water to a final 
volume of 25 pi. Tubes were then placed in a hot-bonnet thermal cycler and 
both 494 bp ERCC1 and 96 bp p-Actin PCR products were obtained 
performing 1 cycle at 95°C for 5 minutes followed by 30 cycles each formed 
by a dénaturation step of 1 minute at 95°C, an annealing step of 30 seconds at 
65°C [Ta = (Tm sense primers + Tm antisense primers/4) + 3°C] and an 
extension step of 30 seconds at 72°C followed by a final extension cycle of 5 
minutes at 72°C.
It is important to stress that these experimental conditions were selected, on 
the basis of preliminary experiments performed, to ensure that the PCR was 
still in the exponential phase when the reaction was stopped.
3.2.4.4.1 Gel electrophoresis and densitometric quantification of PCR 
products
Twenty-five pi of PCR solution were mixed with 5 pi of 6x gel loading 
buffer (0.25% (w/v) of both bromophenol blue and xylene cyanol, 30% (v/v)
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glycerol in distilled water) and samples were loaded onto 3% (w/v)-lx TAE 
buffer agarose gel. Electrophoretic separation was performed at 90 volts in Ix 
TAE buffer and was stopped when bromophenol blue dye reached the bottom 
of the gel. Agarose gel was then stained for 30 minutes at room temperature 
with gentle shaking in the ethidium bromide-Ix TAE buffer staining solution 
and destained for a further 30 minutes at room temperature with gentle shaking 
in Ix TAE buffer. PCR products were visualised on the UV-transilluminator 
and photographed on a 665 Polaroid film. Negative copy of the film was 
developed by using 18% (w/v) sodium sulphite (Sigma) according to the 
manufacturer's instructions and it was used for densitometric quantification of 
the PCR products by means of a HP ScanJet Ilcx/t scanner (HewlettPackard 
Italia-Milan, Italy) and IQ software (Molecular Dynamics Ltd., Kemsing, UK).
3.2.5 Evaluation of the “alternatively-spliced form/full-length form” ratio 
of ERCC1 mRNA by RT-PCR analysis
The ratio between alternatively spliced form lacking exon VIII (AexVIII) 
and full-length form of the ERCC1 mRNA in the OAW42, OAW42Mer, 
A2780, A2780d and A2780cp8 cells was evaluated by RT-PCR analysis.
3.2.5.1 PCR reactions
Primers used were synthesised and supplied in lyophilised form by M- 
Medical:
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•  ERCC1 sense (5’-GAGCTGGCTAAGATGTGTATCC-3 ’; Tm = 60°C) 
corresponding to position 692-713 of human ERCC1 mRNA;
• ERCC1 antisense (5’-AGGCCAGATCTTCTCTTGATGC-3’; Tm = 60°C) 
corresponding to position 938-959 of human ERCC1 mRNA;
• P-Actin sense (5’-ACACTGTGCCCATCTACGAGG-3'; Tm = 60°C) 
corresponding to position 555-575 of human P-Actin mRNA;
• p-Actin antisense (5’-AGGGGCCGGACTGCTCATACT-3 ’; Tm = 62°C) 
corresponding to position 1155-1175 of human p-Actin mRNA;
For each primer, 100 pM stock solution was prepared by dissolving the 
lyophilised primer in an opportune volume of Ix TE pH 8 by extensive 
vortexing. Oligonucleotide concentration was checked spectrophotometrically 
as described in section 3.1.3. The successive dilutions were prepared in 
distilled water.
First strand cDNA previously synthesised (3.2.4.3 section) was used as 
template in non-competitive quantitative PCR amplification. PCR reactions 
were carried out as described in the 3.2.4.4 section with the exception that an 
annealing temperature of 60°C [(Ta = Tm sense primers + Tm antisense 
primers/4)] instead of 65°C [Ta = (Tm sense primers + Tm antisense 
primers/4) + 3°C] was used.
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3.2.S.2 Gel electrophoresis and densitometric. quantification of PCR 
products
ERCC1 full-length form (267 bp), ERCC1 alternatively spliced (AexVIII) 
form (196 bp) and p-actin (621 bp) PCR products were separated, visualised 
and quantified exactly as described in the 2.2.4.4.1 section with the exception 
that a 1,5% (w/v) agarose gel instead of a 3% (w/v) agarose gel was used.
3.2.6 Microsatellite instability (MIN) analysis
MIN analysis was carried out to evaluate the MMR functional status in 
OAW42, OAW42Mer, A2780, A2780d and A2780cp8 cell lines.
3.2.6.1 Genomic DNA extraction
Genomic DNA was extracted from the five cell lines as described by Sunters 
(Sunters et al., 1996) with minor modifications.
OAW42, OAW42Mer, A2780, A2780d and A2780cp8 cells in logarithmic 
growth phase were detached from the flasks with Trypsin-EDTA solution, 
transferred into a 15 ml conical tube and pelleted by a 5-minute centrifiigation 
at 1,500 rpm at 4°C. Single-cell suspension was obtained by resuspending cell 
pellets in 10 ml of PBS, checked under the microscope, and a small aliquot 
(100-500 pi) was transferred in the isoton solution and counted in the particle 
counter. An aliquot of cell suspensions corresponding to about 1 x 106 cells
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was then transferred in a 1.5 ml tube and cells were pelleted by a 15-second 
centrifugation at 12,000 rpm at 4°C. After removal of PBS, cell pellets were 
washed twice with 1 ml of sterile PBS and, at the end of the last wash, PBS 
was removed. Cell pellets were gently resuspended with 340 pi of lysis buffer 
[400 mM Tris-HCl pH 8, 60 mM EDTA pH 8, 150 mM NaCl, 1% (w/v) SDS, 
10 pg/ml RNase A (Sigma)] and incubated at 37°C for 30 minutes. One 
hundred pi of 5 M sodium perchlorate (Sigma) were then added to each sample 
and tubes were firstly mixed in a shaking platform for 20 minutes at room 
temperature before being incubated for 20 minutes at 65°C with occasional 
agitation. Samples were cooled at room temperature, 580 pi of -20°C-cold 
chloroform (Carlo Erba Reagenti) were added and tubes were mixed in a 
shaking platform at room temperature. After 20 minutes, samples were 
centrifuged at 12,000 rpm for 10 minutes at 4°C and the upper phase 
containing DNA was transferred in a clean 1.5 ml tube. To precipitate genomic 
DNA, 2 volumes of -20°C-cold absolute ethanol were added to each tube. 
Cellular DNA was pelleted by a 12,000 rpm centrifugation at 4°C for 3 
minutes and DNA pellets were washed twice with -20°C-cold 70% (v/v) 
ethanol, air dried and dissolved in an opportune volume of DNase-free water 
by an over night incubation at 4°C on a shaking platform.
DNA concentration was determined spectrophotometrically. DNA quality 
was checked by electrophoretic analysis on a 1% (w/v) agarose mini gel 
(prepared and run in Ix TAE buffer) in which about 1 pg of each DNA sample 
was separated at 90 volts at room temperature for 1 hour and visualised by UV-
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transilluminator after a 30 minutes-ethidium bromide-Ix TAE buffer staining 
and 30 minutes Ix TAE buffer destaining.
3.2.6.2 Primers
Oligonucleotides used for MIN analysis were synthesised and supplied in 
lyophilised form by M-Medical:
Locus D2S123:
Sense: 5’-ACAGGATGCCTGCCTTTA-3’ (Tm = 53°C);
Antisense; 5’-ACTTTCCACCTATGGGAC-3 ’ (Tm = 57°C);
Locus D17S250:
Sense: 5 ’-AGAATCAAATAGACAAT-3 ’ (Tm = 47°C);
Antisense: S’-GCTGGCCATATATATATTTAAACCO’ (Tm = 59°C);
Locus BAT26:
Sense: 5’-GACTACTTTTGACTTCAGCC-3’ (Tm = 55°C);
Antisense: 5’-CCATTCAACATTTTTAACCC-3’ (Tm = 53°C);
Locus BAT40:
Sense: 5’-TAACTTCCTACACCACAAC-3’ (Tm = 53°C);
Antisense: 5’-AGAGCAAGACCACCTT-3’ (Tm = 530C);
Locus D6S261:
Sense: 5'-GTGAAACCCTGTCTCACTGC-3* (Tm = 61°C);
Antisense: 5’-GGATTTAtÀGGACCATGCCA-3’ (Tm = 63°C);
Locus D3S1283:
Sense: 5’-GGCAGTACCACCTGTAGAAATG-3’ (Tm = 57°C);
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Antisense: 5’-GAGTAACAGAGGCATCGTGTATTC-3' (Tm = 53°C); 
Locus EDH17B:
Sense: 5’-GTGACCCACGAAACACAGG-3’ (Tm = 59°C);
Antisense: 5 * -C AGAAGGTGAAGAAÇTC ATCC A-3 ’ (Tm = 58°C);
Locus GATAI IB 12:
Sense: 5’-AACAAAACAAAACAAAACAAACA-3’ (Tm = 50°C); 
Antisense: 5 ’-GGTGGAAATGCCTCATGTAG-3 * (Tm = 57°C);
Locus GGAA2E02:
Sense: 5’-AGGAAAGAGAAAGAAAGGAAGG-3 ' (Tm = 56°C);
Antisense: 5’-TATATGATGAAAGTATATTGGGGG-3’ (Tm = 56°C); 
Locus D6S1035:
Sense: 5’-ACTTGAATCCAGGCATTCAG-3’ (Tm = 55°C);
Antisense: 5’-AAAACTCAAGCTCAGAAAGGC-3’ (Tm = 56°C);
For each primer, stock solution and successive dilutions were prepared as 
described in the 3.2.4.4 section.
3 2.6.3 PCR reactions
In clean 0.5 ml PCR reaction tubes, 20 ng of genomic DNA isolated from 
each of the five cell lines under investigation were mixed with 1 pM of both 
sense and antisense primers, 3 pCi of [a-32P]-dCTP (3,000 Ci/mmole) 
(Amersham-Pharmacia Biotech Italia), 200 pM of each dNTP (Takara 
Biomedicals, Japan), Ix Ex-Taq PCR buffer (2 mM MgCk, 10 mM Tris-HCl 
pH 8.3, 50 mM KC1) (Takara Biomedicals) and distilled water to a final
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volume of 5 fil. Tubes were placed in the hot-bonnet thermal cycler and heated 
at 95°C for 5 minutes. Five pi of an aqueous solution containing 0.5 units of 
Ex-Taq DNA polymerase (Takara Biomedicals) was then added to each tube 
and; samples were subjected to the amplification reaction for 30 cycles each 
composed of a dénaturation step of 30 seconds at 94°C, an annealing step of 30 
seconds at a temperature, equivalent to the mean melting temperature of the 
sense and antisense primers plus 5°C [(Tm primer sense + Tm primer 
antisense/2) + 5°C], and an extension step of 30 seconds at 72°C, followed by 
one extension cycle of 7 minutes at 72°C.
At the end of the amplifications, 10 pi of sequencing gel loading buffer were 
added to each tube and samples were stored at -20°C when not immediately 
subjected to electrophoretic separation.
3.2.6.4 Sequencing gel electrophoresis
Sequencing gel was prepared as described in the 3.1.7 section.
PCR samples were heated at 95 °C for 5 minutes, chilled on ice for a further 
5 minutes and then quickly centrifuged at 4°C. Sequencing gel pre-run was 
stopped and each well was washed with Ix TBE to remove any trace of urea. 
Four pi of each heat-denatured PCR sample were then loaded. Electrophoretic 
separation was performed at a constant power of 57 watt and was stopped 
when bromophenol blue dye reached the bottom of the gel.
At the end of the electrophoresis run, the gel mold was removed from the 
apparatus and, after that the polyacrylamide gel was cooled to room
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temperature, glass plates were carefully separated. Sequencing gel was 
detached from the non silicone-treated glass plate by means of Whatman 3 MM 
papers and, after that a sheet of Saran Wrap was placed on the top, the gel was 
dried at 80°C in a 583 Gel Dryer (Biorad). After 40 minutes, the sequencing 
gel was removed from the dryer and placed in a Hypercassette (Amersham- 
Pharmacia Biotech.) with intensifying screens and autoradiographed by 
exposure to x-ray film (Hyperfilm; Amersham-Pharmacia Biotech.) over night 
at -80°C.
The presence of instability at different loci was independently evaluated by 
three different observers.
3.2.7 Intracellular drug accumulation
Each experimental sample was run in triplicate. Cellular platinum levels 
were expressed as micrograms of platinum per cell number where the cell 
number being determined by counting parallel cultures. The experiments were 
repeated at least three times.
3.2.7.1 Sample preparation
After harvesting in logarithmic growth phase, 2 x 106 cells were seeded in 
90-millimetres dishes (Coming-Costar Italia) containing 10 ml of fresh 
medium. Dishes were incubated at 37°C in a 5% CO2 humidified atmosphere 
in air incubator for 24 hours. As regards the OAW42Mer cell line, it is
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important to stress that melphalan was not added to the growth medium for at 
least 2 passages before initiation of the experiment.
Immediately before cell treatment, cisplatin (3.3 mM) and BBR 3464 (807.1 
pM) stock solution were diluted in specific growth media to obtain the 
different l lx  working solutions of the two drugs. One ml of each l lx  drug 
working solution were added to each dish (containing attached cells and 10 ml 
of medium) in order to expose.the cells to Ix final drug concentration in a final 
volume of 11 ml. For untreated control samples, 1 ml of fresh medium was 
added. After a 1-hour incubation of cultures at 37°C in a 5% CO2 humidified 
atmosphere in air incubator, drug-containing medium was removed from each 
dish, then cell monolayers were washed three times by immersing 90-mm 
dishes in ice-cold PBS, air dried and harvested at room temperature.
3.2.7.2 Atomic absorption spectrometry
Analysis for platinum content was performed by atomic absorption 
spectrometry (model 3,300) (Perkin-Elmer Italia) in the laboratories of the 
Department of Medical Sciences, Université degli Studi di Torino-Novara, 
Italia.
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3.2.8 Platinum bound to genomic DNA
Each experimental sample was run in triplicate. The levels of platinum 
bound to cellular DNA were expressed as picograms of platinum per 
micrograms of DNA. The experiments were repeated at least three times.
3.2.8.1 Sample preparation
After harvesting in logarithmic growth phase, 107 cells of OAW42, 
OZW42Mer, A2780, A2780d and A2780cp8 cell lines were seeded onto 75 
cm2 culture flasks (Coming-Costar, Milano) in 15 ml of fresh medium and 
placed in the incubator for 24 hours. As regards the OAW42Mer cell line, it is 
important to stress that melphalan was not added to the growth medium for at 
least 2 passages before starting the experiment.
Immediately before cell treatment, cisplatin (3.3 mM) and BBR 3464 (807.1 
pM) stock solution were diluted in specific growth media to obtain the 
different l lx  working solutions of the two drugs. One point five ml of each 
l lx  drug working solution were added to each flask (containing attached cells 
and 15 ml of medium) in order to expose the cells to Ix final drug 
concentration in a final volume of 16.5 ml. For untreated control samples, 1.5 
ml of fresh medium was added. After a 1-hour incubation of cultures at 37°C in 
a 5% CO2 humidified atmosphere in air incubator, drug-containing medium 
was removed from each flasks and cell monolayers were washed twice with 20 
ml of PBS and, subsequently, detached with 2 ml of Trypsin-EDTA solution at
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37°C for 5 minutes. In each flask, trypsinisation was blocked by addition of 20 
ml of 10% (v/v) FBS-PBS solution, then cell suspension were centrifuged in a 
50 conical tube at 1,500 rpm for 5 minutes at 4°C and washed twice with 30 ml 
of PBS. Cells pellets were then resuspended in 1 ml of PBS and transferred in a 
1.5 ml tube. Single-cell suspension was checked under the microscope and a 
small aliquot (100-500 pi) was transferred in the isoton solution and counted in 
the particle counter.
Single cell suspension was pelleted by a 30-second centrifugation at 12,000 
rpm at 4°C and, after PBS removal, genomic DNA was isolated from the cells, 
quantified and checked as described in the 3.2.6.1 section.
3.2.S.2 Coupled Plasma Mass Spectroscopy
Analysis of platinum bound to genomic DNA of each cell sample was 
performed by means of coupled plasma mass spectroscopy as described by 
Bonetti et al. (1996). The analysis was carried out in the laboratories of the 
Department of Pharmacology, Université degli Studi di Verona-Verona, Italia.
3.2.9 Evaluation of BBR 3464 and cisplatin ability to produce interstrand 
Cross links in viitû
BBR 3464 and cisplatin ability to induce interstrand cross-links on a naked 
plasmid DNA was evaluated according to the method described by Hartley et
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al. (1991) with some modifications using the pSP73 vector (2464 bp) as 
template.
3.2.9.1 Linearisation of the pSP73 vector template with the Hindlll 
restriction enzyme
In a 1.5 ml tube, an aliquot containing 30 pg of pSP73 plasmid was mixed 
with 60 units of Hindlll restriction enzyme (Promega Italia), Ix of digestion 
buffer specific for Hindlll (Buffer E) (Promega Italia) and distilled water to a 
final volume of 100 pi. The mixture was then incubated at 37°C in a water 
bath. After a 1 hour, the reaction was stopped by addition of 5 pi of 0.5 M 
EDTA, pH 8. The linearisation of the vector template was verified as described 
in the 3 .1.9.3 section by loading about 200 ng of digested vector with the same 
amount of undigested plasmid DNA and 500 ng of X-BstEII molecular weight 
marker.
3.2.9.2 Purification of Hindlll-digested pSP73 vector
Digestion mixture was diluted to a final volume of 400 pi with distilled 
water. An equal volume of phenol (Sigma)/chloroform/isoamilic alcohol (Carlo 
Erba Reagenti) solution [25:24:1, (v/v/v)] was then added. The tube was 
extensively mixed by tapping and centrifuged at 12,000 rpm at 4°C for 5 
minutes, then the aqueous upper phase, containing plasmid DNA, was 
recovered and placed in a clean 1.5 ml tube and an equal volume of
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chloroform/isoamilic alcohol solution [24:1, (v/v)] was added. After mixing, 
the tube was centrifuged and the aqueous upper phase was recovered and 
placed in a clean 1.5 ml conical tube. To precipitate plasmid DNA, the aqueous 
phase was mixed with sodium acetate, pH 5.2 (Sigma), (0.3 M final 
concentration) then, after addition of 2 volumes of -20°C-cold 100% ethanol, 
the solution was mixed for a few seconds using the vortex and placed at -80°C 
for 1 hour. The sample was then centrifuged at 12,000 rpm at 4°C for 30 
minutes, and, after ethanol removal, pelleted DNA was washed twice with 70% 
(v/v) ethanol and dried for 3 minutes by means of a speed-vacuum centrifuge 
(Heraeus Centrivac). Dried pSP73 vector was then dissolved in distilled water 
and quantified spectrophotometrically.
3.2.93 Removal of 5* terminal phosphate groups
In a 1.5 ml tube, an aliquot containing 20 pg (12.5 pmoles) of Hindlll- 
linearised vector was mixed with 20 units of calf intestinal alkaline 
phosphatase (CIAP) (Promega), Ix CIAP buffer (Promega) and distilled water 
to a final volume of 50 pl. Dephosphorylation reaction was performed by a 3- 
hour incubation at 37°C in a water bath. The reaction was blocked by addition 
of EDTA, pH 8, to a final concentration of 5 mM and a 1-hour incubation at 
65°C. Dephosphorylated DNA was then purified and quantified as described in 
the 3.2.9.2 section.
177
(3) Materials and Methods
3 2.9.4 Labelling of linearised vector at 5' termini
In a 0.5 ml tube, 10 ng (6.25 pmoles) of linearised-dephosphorylated pSP73 
vector were mixed with 40 units of T4 polynucleotide kinase (Takara 
Biomedicals), 60 p Ci [y-32P]-ATP (3,000 Ci/mmole) (Amersham-Pharmacia 
Biotech), Ix T4 polynucleotide kinase buffer (Takara Biomedicals) and 
distilled water to a final volume of 50 pi. Labelling reaction was performed by 
incubating the tube at 37°C for 1 hour. T4 polynucleotide kinase was then 
inactivated by incubating the mixture at 95°C for 5 minutes.
Labelled DNA was purified and recovered as described in the 3.2.9.2 section 
with some modifications. To completely remove untransferred 32P groups, 
labelled DNA pellet was washed 4 times with 70% ethanol; the dried DNA 
pellet was dissolved in distilled water (50 pi) and cpm corresponding to 1 pi of 
this DNA solution were evaluated by “Cerenkov counting” at the p-counter 
(Tri-Carb Liquid Scintillation Analyzer; Camberra-Packard Italia-Milan, Italy). 
Assuming a DNA recovery of 50% after purification steps, a solution at a 
concentration of 100 ng/pl with a specific activity of 50,000-100,000 cpm/ng 
was generally obtained.
3 2.9.5 Treatment of labelled-pSP73 with cisplatin and BBR 3464
For each experimental point, 100 ng of labelled DNA were mixed in a 0.5 ml 
tube with appropriate concentrations of cisplatin, or BBR 3464, Tris-HCl pH 8
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(10 mM final concentration) and distilled water to a final volume of 40 jil. Two 
untreated control samples were also prepared omitting the addition of the 
drugs. Treatment reactions were performed for 1 hour at 37°C in the dark and 
were stopped by addition of an equal volume (40 pi ) of stop solution [0.6 M 
sodium acetate pH 5.2,20 mM EOT A pH 8 and 100 pg/ml salmon sperm DNA 
(Sigma)]. Plasmid DNA from treated and untreated samples was precipitated as 
described in the 3.2.9.2. section.
3.2.9 6 Gel electrophoresis analysis
DNA pellets obtained from drug-treated samples and one untreated control 
sample (control D) were dissolved in 10 pi of ‘strand separation buffer* (30% 
(v/v) DMSO (Sigma), 1 mM EDTA pH 8, 0.04% (w/v) bomophenol blue and 
0.04% (w/v) xylene cyanol), the DNA pellet from the other untreated control 
sample (control UD) was dissolved in 10 pi of ‘native gel loading buffer* (6% 
(w/v) saccarose (Sigma), 0.04% (w/v) bomophenol blue and 0.04% (w/v) 
xylene cyanol). All samples were subjected to Cerenkov counting to verify the 
amount of DNA recovered for each experimental point after ethanol 
precipitation.
Before loading, tubes corresponding to drug-exposed samples and control 
(D) sample were denatured for 5 minutes by incubation at 95°C and chilled on 
ice for an additional 5 minutes. The untreated control sample (UD) was directly 
loaded onto a 25 centimetres-wide/25 centimetres-length 1% (w/v) agarose gel 
prepared in Ix TAE buffer.______
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Electrophoretic separation was performed in Ix TAE as running buffer at a 
constant voltage of 30 volts at room temperature. After 16 hours, 
electrophoresis was stopped, gel was placed onto Whatmann 3 MM papers and, 
after that a sheet of Saran Wrap was placed on the top, the gel was dried at 
80°C in the gel drier. After 2 hours, the agarose gel was removed from the 
dryer and placed in a Hypercassette with intensifying screens and 
autoradiographed by exposure to X-ray film over night at -80°C.
Quantification of the bands was performed by densitometric scanning of the 
X-ray film.
3.2.10 Evaluation of the sequence specificity of BBR 3464 and cisplatin 
induced DNA covalent adducts: the Taq stop assay
The Taq stop assay was performed as described by Bubley et al. (1994), with 
some modifications, to determine the sequence preference of DNA lesions 
produced by the novel trinuclear platinum complex, with respect to cisplatin, 
by using in vitro drug-treated naked plasmid and genomic DNA as well as 
genomic DNA isolated after exposure of intact cells to the drugs as templates.
3.2.10.1 Taq stop assay on in vitro treated naked pSP73 plasmid DNA
pSP73 vector was obtained as described in the 3.1.10 section.
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3.2.10.1.1 pSP73 vector linearisation, purification and quantification
In a 0.5 ml tube, a volume corresponding to 30 pg of pSP73 plasmid were 
mixed with 60 units of Haell restriction enzyme (Promega Italia), Ix of 
digestion buffer specific for Haell (Buffer B) (Promega Italia) and distilled 
water to a final volume of 100 p i  The mixture was then incubated at 37°C in a 
water bath. After a 1 hour, the reaction was stopped by addition of 5 pi of 0.5 
M EDTA, pH 8, and the linearisation of the plasmid was verified as described 
in the 3.2.9.1 section. Purification of Haell-linearised pSP73 vector was carried 
out as described in the 3.2.9.2 section. After spectrophotometric quantification, 
plasmid DNA concentration was adjusted with distilled water to a final 
concentration of 40 ng/25 fmole/pl.
3.2.10.1.2 In vitro drug treatment of Haell-digested plasmid DNA
For each experimental sample, 4 pi of linearised pSP73 vector, 
corresponding to 100 finoles (160 ng), were mixed in a 0.5 ml tube with 
opportunely selected concentrations of cisplatin or BBR 3464, 2.6 pi of 100 
mM Tris-HCl pH 8 (final concentration = 10 mM) and distilled water to a final 
volume of 26 pi. Untreated control samples were prepared by adding PBS 
instead of the drugs. Damaging reactions were performed by incubating the 
tubes at 37°C in a water bath in the dark for 2 hours and then stopped by snap 
freezing in liquid nitrogen. Frozen samples were stored at -80°C until they 
were used in linear PCR reactions.
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3.2.10.1.3 Labelling of Sp6 primer at 5* termini
Sp6 primer (5 ’-GATTTAGGTGACACTATAG-3 ’ ; Tm = 48°C)
corresponding to position 2447-1 of the pSP73 vector consensus sequence (Fig. 
21) was synthesised and supplied in the lyophilised form by M-Medical. One 
hundred |iM stock solution and successive dilutions were prepared as described 
in the 3.2.4.4. section.
In a 0.5 ml tube, a volume corresponding to 300 pmole of Sp6 primer was 
mixed with
20 units of T4 polynucleotide kinase, 30 p Ci [y-32P]-ATP (3,000 Ci/mmole), 
Ix T4 polynucleotide kinase buffer and distilled water to a final volume of 20 
pi. Labelling reaction was performed by incubating the tube at 37°C for 1 hour. 
T4 polynucleotide kinase was then inactivated by incubating the mixture at 
95°C for 5 minutes. The labelled primer was then stored at -20°C until it was 
used in linear PCR and/or in sequencing reactions.
3.2.10.1.4 Sequencing of the pSP73 vector
Sequencing of the pSP73 plasmid region included between Sp6 primer 
annealing region and Haell-restricted site was performed by means of the 
AmpliCycle kit (Perkin-Elmer Italia) according to the method described by Lee 
et al. (Lee et al, 1991), that is a modification of the dideoxy chain termination 
procedure described by Sanger et al. (Sanger et al., 1977).
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Figure 21. Sequence of the pSP73 plasmid DNA region subjected to 
determination of the sequence specificity of cisplatin- and BBR 
3464-induced lesions by Taq stop assay. The underlined sequence 
indicates the position of thé Sp6 'sense' primer (->). In bold are 
indicated the bases of the Haell site.
,2391 ÂTTGTCGTTA GAACGCGGCT ACAATTAATA
ÿ '- Ÿ t.  ^  - " fc s: A* ,S 1
CATAACCTTA
2431 TGTATCATAC ACATACGATT TAGGTGACAC TATAGARCCA
7 GATCTGATAT CATCGATGAA TTCGAGCTCG GTACCCGGGG
47 ATCCTCTAGÂ GTCGACCTGC ÀGGCATGCAA GCTTCAGCTG
87 CTCGAGGCCG GTCTCCCTAT AGTGAGTCGT ATTAATTTCG
127 ATAAGCCAGG TTAACCTGCA TTAATGAATC GGCCAACGCG
167 CGGGGAGAGG CGGTTTGCGT ATTGGGCGCT CTTCCGCTTC "
207 CTCGCTCACT GACTCGGTGC GCTCGGTCGT TCGGCTGCGG
247 CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGGTTAT
287 CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC
-Figure 21-
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In a clean 0.5 ml tube, 30 pil of 'reaction mix' were prepared by mixing an 
aliquot of the DNA plasmid, corresponding to 30 fmole (49 ng), with 1.5 
pmole of 32P-labelled Sp6 primer, 3 pi of lOx Cycling mix (final concentration 
= Ix) and distilled water. Four 0.5 ml PCR reaction tubes were placed on ice 
and labelled with A, T, G and C letters, then, 2 pi of A-termination mix, T- 
termination mix, G-termination mix and C-termination mix were poured on the 
A, T, G, C-labelled tubes respectively. At the end, 6 pi of 'reaction mix' were 
transferred to each of the four labelled tubes. Sequencing reactions were 
carried out by placing the tubes in the hot-bonnet thermal cycler and 
performing a linear PCR amplification composed of 1 cycle at 95°C for 1 
minute followed by 25 cycles, each consisting of a dénaturation step of 1 
minute at 95°C, an annealing step of 1 minute at 48°C (Ta = Tm) and an 
extension step of 1 minute at 72°C. At the end of the amplifications, 4 pi of 
sequencing gel loading buffer were added to each sequencing tube and samples 
were stored at -20°C if not immediately subjected to electrophoretic 
separation.
3.2.10.1.5 Linear PCR reactions (Taq stop reactions)
In order to inactivate the drugs, 13 pi of drug-treated and untreated samples 
(containing 50 fmole of pSP73 vector; section 3.2.10.1.2) were placed in a 0.5 
ml PCR reaction tube, heated at 95°C for 5 minutes and then rapidly chilled on 
ice for further 5 minutes. After a brief 12,000 rpm-centrifugation at 4°C, 30
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pmole (2 pi) of 32P-labelled Sp6 primer, 1 unit of Ex-Taq DNA polymerase, 
200 pM of each dNTP, Ix PCR Buffer, 5% (v/v) DMSO and distilled water, to 
a final volume of 20 pi were added to each 13 pl-DNA sample. Linear PCR 
reactions were carried out by placing the tubes in the hot-bonnet thermal cycler 
and performing 30 cycles, each consisting of a dénaturation step of 20 seconds 
at 95°C, an annealing step of 1 minute at 48°C (Ta = Tm) and an extension step 
of 1 minute at 72°C. At the end of the amplifications, 6 pi of sequencing gel 
loading buffer were added to each tube and samples were stored at -20°C if not 
immediately loaded onto sequencing gel.
3.2.10.1.6 Sequencing gel electrophoresis
pSP73 sequencing and Taq stop reactions were loaded and separated in the 
same sequencing gel as described in the 3.1.7 and 3.2.6.4 sections.
3.2.10.2 Taq stop assay on in vitro treated naked genomic DNA
DNA was isolated from A2870 cells as described in the 3.2.6.1 section.
3.2.10.2.1 EcoRI genomic DNA digestion, purification and quantification
In a 1.5 ml tube, an aliquot corresponding to 60 pg of cellular DNA was 
mixed with 300 units of EcoRI restriction enzyme (Promega Italia), Ix of 
digestion buffer specific for EcoRI (Buffer H) (Promega Italia) and distilled
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water to a final volume of 300 pi.The mixture was then incubated at 37°C in a 
water bath for 18 hours. The reaction was stopped by the addition of 5 pi of 0.5 
M EDTA, pH 8. The DNA digestion was verified as described in 3.2.9.1 
section by loading about 500 ng of both digested and undigested genomic 
DNA. Purification was carried out as described in the 3.2.9.2 section. After 
spectrophotometric quantification, DNA concentration was adjusted with 
distilled water to a final concentration of 750 ng/pl.
3.2.10.2.2 In vitro drug treatment of EcoRI-digested cellular DNA
For each experimental sample, 4 pi of digested genomic DNA corresponding 
to 3 pg were mixed in a 0.5 ml tube with opportunely selected concentrations 
of cisplatin or BBR 3464, 2.6 pi of 100 mM Tris-HCl pH 8 (final concentration 
= 10 mM) and distilled water to a final volume of 26 pi. Untreated control 
samples were prepared by adding PBS instead of the drugs. Damaging 
reactions were performed by incubating the tubes at 37°C in a water bath in the 
dark for 2 hours and then stopped by snap freezing in liquid nitrogen. Frozen 
samples were stored at -80°C until they were used in linear PCR reactions.
3.2.10.2.3 Labelling of the 16mer primer at S’ termini
16mer primer (5’-AATTCTCAGTAACTTC-3’; Tm = 41°C) corresponding 
to position 1-16 of the 340 bp repeat (also called a-RI DNA) consensus
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sequence of the alphoid cellular DNA region (Fig. 18) was synthesised and 
supplied in the lyophilised form by M-Medical. One hundred pM stock 
solution and successive dilutions were prepared as described in the 3.2.4.4 
section. The primer was labelled as described in the 3.2.10.1.3 section.
3.2.10.2.4 Sequencing of the a-RI DNA region
Sequencing of the a-RI DNA region upstream of the 16mer primer was 
performed as described in the 3.2.10.1.4 section with the following variants:
• 32P-labelled 16mer primer instead of 32P-labelled Sp6 primer;
• 300 ng of naked whole genomic DNA (corresponding to about 30 fmole of 
340 bp a-RI DNA repeat) instead of 30 fmole (49 ng) of pSP73 vector;
• 51°C as annealing temperature (Ta = Tm + 10°C) instead of 48°C (Ta = 
Tm).
3.2.10.2.5 Linear PCR reactions (Taq stop reactions)
Taq stop reactions were performed by using 13 pi of drug-treated and 
untreated samples (containing 1.5 pg of genomic DNA). The procedure was 
identical to that described in the 3.2.10.1.5 section with the exception that 36 
cycles instead of 30 cycles and an annealing temperature of 35°C (Ta = Tm -  
6°C) instead of 48°C (Ta = Tm) were used.
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3.2.10.2.6 Sequencing gel electrophoresis
Sequencing and Taq stop reactions were loaded and separated in the same 
sequencing gel as described in the 3.1.7 and 3.2.10.1.6 sections.
3.2.10.3 Taq stop assay on genomic DNA isolated after drug treatment of 
intact cells
3.2.10.3.1 Drug treatment of A2780 living cells
After harvesting in logarithmic growth phase, for each experimental point 
106 A2780 cells were seeded in 6-well plates (Coming-Costar Italia) in 3 ml of 
fresh complete medium and incubated at 37°C in a 5% CO2 humidified 
atmosphere in air incubator. After 24 hours, the complete medium was 
removed, cell monolayers were washed twice with 3 ml of PBS. Two ml of 
FBS-free medium were then added to each well.
Immediately before cell treatment, cisplatin (3.3 mM) and BBR 3464 (807.1 
pM) stock solution were diluted in FBS-free specific growth medium to obtain 
the different l lx  working solutions of the two drugs. Two hundred pi of each 
l lx  drug working solution were added to each well (containing attached cells 
and 2 ml of medium) in order to expose the cells to Ix final drug concentration 
in a final volume of 2.2 ml. For untreated control samples, 200 pi of fresh 
FBS-free medium was added to each well. After a 2-hour incubation at 37°C in 
a 5% CO2 humidified atmosphere in air incubator, drug-containing medium
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was removed from each well, cells were washed three times with PBS (3 ml for 
each well) and detached from the plates by 5 minutes-incubation at 37°C with 
trypsin-EDTA solution. Trypsinisation was blocked by addition of 5 ml of 10% 
(v/v) FBS-PBS solution, then cell suspension was centrifuged in a 15 ml 
conical tube at 1,500 rpm for 5 minutes at 4°C and washed twice with 5 ml of 
PBS. Cells pellets were then resuspended in 1 ml of PBS and transferred in a
1.5 ml tube. Single-cell suspension was checked under the microscope and a 
small aliquot (100 pi) was transferred in the isoton solution and counted in the 
particle counter.
Single cell suspension was pelleted by 30-second centrifugation at 12,000 
rpm at 4°C and, after PBS removal, genomic DNA was isolated from the cells, 
quantified and checked as described in 3.2.6.1 section.
3.2.10.3.2 EcoRI genomic DNA digestion, purification and quantification
Cellular DNA extracted from drug-treated and -untreated cells was digested 
with EcoRI restriction enzyme, purified, quantified and dissolved in distilled 
water to a final concentration of 750 ng/pl exactly as described in the
3.2.10.2.1 section.
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3.2.10.3.3 Genomic DNA sequencing, Taq stop reactions and sequencing 
gel electrophoresis.
Sequencing and Taq stop reactions were performed, exactly as described in 
the 3.2.10.2.4 and 3.2.10.2.5 sections, on cellular DNA isolated from treated 
and untreated living cells.
Sequencing gel was prepared and run as described in the 3.2.10.2.6 section.
3.2.11 Assessment by quantitative PCR (QPCR) of gene-specific 
accumulation and repair of cisplatin- and BBR 3464-induced DNA 
damage
The formation and removal of drug-induced lesions in a 523 bp region 
including the intron 1 of the human N-ras gene was assessed by means of the 
QPCR assay essentially according to Bingham et al. (1996), with some 
modifications.
3.2.11.1 Primers
To select and amplify the 523 bp fragment a N-ras sense primer (5’- 
CCTAAATCTGTCCAAAGCAGAGGC-3’; Tm = 63°C) and a N-ras 
antisense primer (5’-CAGCAAGAACCTGTTGGAAACCAG-3’; Tm = 63°C) 
corresponding to positions 1-24 and 500-523 of the intron 1 of the human N- 
ras gene (Fig. 22), respectively, were used. These oligonucleotides were 
synthesised and supplied in the lyophilised form by M-Medical. Stock solution
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Figure 22. Sequence of the Intron I of the human N-ras gene. The underlined 
sequences indicate the positions of the N-ras 'sense' (->) and 
'antisense' (<-) primers.
6
Figure 22
(3) Materials and Methods
and successive dilutions were prepared as described in the section 3.2.4.4 
section.
3.2.11.2 Measurement of DNA lesions induced by cisplatin and BBR 3464 
DNA in vitro
The formation of drug-induced platinum DNA lesions was assessed on 
naked whole genomic DNA exposed in vitro to cisplatin or BBR 3464.
3.2.11.2.1 Treatment of naked genomic DNA
For each experimental sample, 1 pg of naked genomic DNA, extracted from 
A2780 cells as described in the 3.2.6.1 section was mixed in a 0.5 ml tube with 
opportunely selected concentrations of cisplatin or BBR 3464, 10 pi of 100 
mM Tris-HCl pH 8 (final concentration = 10 mM) and distilled water to a final 
volume of 100 pi. Untreated control samples were prepared by adding PBS 
instead of the drugs. Damaging reactions were performed by incubating the 
tubes at 37°C in a water bath in the dark for 1 hour and then stopped by snap 
freezing in liquid nitrogen. Frozen samples were stored at -80°C until they 
were used in QPCR reactions.
3.2.11.2.2 Quantitative PCR (QPCR)
To inactivate the drugs, 8 pi of drug-treated and untreated samples 
(containing 80 ng of whole naked genomic DNA; section 3.2.11.2.1) were
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placed in a 0.5 ml PCR reaction tube, heated at 95°C for 5 minutes then rapidly 
chilled on ice for a further 5 minutes. For untreated control samples, an 
additional experimental point containing 4 pi (40 ng) of whole naked genomic 
DNA and 4 pi of distilled water was also set up. After a brief 12,000 rpm- 
centrifugation at 4°C, 0.5 pM of both N-nzs sense and antisense primers, 0.6 
units of Ex-Taq DNA polymerase, 120 pM of each dNTP, Ix of Ex-Taq PCR 
buffer, 0.3 pCi of [ct-32P]-dCTP (3,000 Ci/mmole) and distilled water to a final 
volume of 30 pi were added. Tubes were then placed in the hot-bonnet thermal 
cycler and subjected to the amplification reaction composed of 1 cycle at 95°C 
for 2 minutes followed by 26 cycles each consisting of a dénaturation step of 1 
minute at 95°C, an annealing step of 1 minute at 61°C [Ta = (Tm sense primer 
+ Tm antisense primer/2) -  2°C] and an extension step of 1 minute at 72°C 
followed by a final extension cycle of 4 minutes at 72°C. It is important to 
stress that this thermal profile was selected on the basis of preliminary 
experiments, to ensure that the PCR was still in the exponential phase when the 
reaction was stopped. Samples were stored at 4°C until they were subjected to 
electrophoretic separation.
3.2.11.2.3 Polyacrylamide gel electrophoresis
To separate the 523 bp DNA band, a 5% (w/v) polyacrylamide-1 x THE 
buffered non-denaturing gel (resolution power = 80-500 bp) was prepared as 
described in the 2.1.8 section. Six pi of 6x gel loading buffer were then added
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to each 30 pl-PCR tube and samples were loaded onto the gel. Electrophoretic 
run was performed at a constant voltage of 120 volts at room temperature. 
When the bromophenol blue dye reached the bottom of the gel (after about 4 
hours from the start of the run), electrophoresis was stopped and the 
polyacrylamide gel was detached from the glass plates by means of Whatman 
3MM papers. After that a sheet of Saran Wrap was placed on the top, the gel 
was dried at 80°C for 20 minutes, placed in a Hypercassette with intensifying 
screens and autoradiographed by exposure to X-ray film over night at -80°C.
3.2.11.2.4 Quantification of PCR products
The amount of 523 bp DNA fragments present in each experimental sample 
was quantified by densitometric analysis. The results were expressed as the 
integrated volume value of treated samples compared with that of untreated 
control samples.
3.2.11.3 Induction and removal of platinum DNA-adducts on living cells
The kinetics of induction and removal of platinum DNA-adducts was 
assessed on genomic DNA isolated from intact cells after treatment with 
cisplatin or BBR 3464.
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3.2.11.3.1 Induction of DNA lesions in intact cells
After harvesting in logarithmic growth phase, 106 OAW42, OAW42Mer, 
A2780 or A2780cp8 cells, resuspended in 3 ml of growth media, were seeded 
in 60-millimetre dishes and incubated at 37°C in a 5% CO2 humidified 
atmosphere in an air incubator. After 24 hours, the complete media was 
removed, cell monolayers were washed twice with 3 ml of PBS and then 2 ml 
of FBS-free media were then added to each dish.
Immediately before cell treatment, cisplatin (3.3 mM) and BBR 3464 (807.1 
pM) stock solution were diluted in FBS-free specific growth medium to obtain 
the different 1 Ix working solutions of the two drugs. Two hundred pi of each 
drug working solution were added to each well (containing attached cells and 2 
ml of medium) in order to expose the cells to Ix final drug concentration in a 
final volume of 2.2 ml. For untreated control samples, 200 pi of fresh FBS-free 
medium was added to each well. After a 5-hour incubation at 37°C in a 5% 
CO2 humidified atmosphere in air incubator, drug-containing medium was 
removed from each dish and cells were washed three times with PBS (3 ml for 
each dish). Cellular samples destined to be used in repair studies (Tô, T24 and 
T48) were overlaid with 3 ml of complete media and incubated at 37°C for an 
additional 6, 24 or 48 hours, whereas cells destined for the measurement of 
platinum DNA lesions were collected immediately at the end of treatment (To).
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3.2.11.3.2 Cell harvesting and genomic DNA extraction
At each time point, the growth medium was removed from the dishes and, 
after three washes with 3 ml of PBS, monolayers were harvested from the 
plates by means of a sterile cell scraper (Coming-Costar Italia), transferred to 
1.5 ml tubes and pelleted by a 3,000 rpm centrifugation at 4°C for 10 minutes. 
Cell pellets were washed twice with 1.5 ml of PBS and resuspended in 1 ml of 
PBS. Single-cell suspension was checked under the microscope and cell 
number was determined for each sample by transferring a small aliquot (100 
pi) in the isoton solution and counting it in the particle counter.
Single cell suspensions were then pelleted by a 30-second centrifugation at
12,000 rpm at 4°C and, after PBS removal, cellular pellets were resuspended in 
lysis buffer [50 mM KC1, 10 mM Tris-HCl pH8, 0.45% (v/v) Nonidet P-40, 
0.45% (v/v) Tween-20, 60 pg/ml proteinase K (Sigma)], with a 'number of 
cells/volume of lysis buffer' ratio of 106 cells/160 pi, corresponding to 6,250 
cell equivalents/pl.
Cellular proteins were degraded by incubating samples with proteinase K for 
2 hours at 60°C. Tubes were then heated at 95°C for 15 minutes in order to 
completely denature and precipitate both proteinase K and degraded cellular 
proteins. Insoluble material containing cellular debris and denatured proteins 
was collected in the bottom of the tubes by a 12,000 rpm centrifugation at 4°C 
for 5 minutes. The DNA-containing aqueous phases were carefully removed 
and transferred into 0.5 ml tubes and diluted 1:100 in distilled water to achieve
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a solution at a final concentration of 62.5 cell equivalents/jil. Samples were 
stored at 4°C until they were used in QPCR reactions.
3.2.11.3.3 Quantitative PCR (QPCR)
QPCR was performed as described in the 3.2.11.2.2 section with the 
following exceptions:
• 95°C-heating for 5 minutes of drug-treated and untreated samples to 
inactivate drugs was not performed;
• for drug-treated samples, an aliquot of 20 pi (corresponding to 1,250 
cell/equivalents of genomic DNA) instead of an aliquot of 8 pi 
(corresponding to 80 ng of cellular DNA) was used;
• for untreated control samples, two aliquots of 20 pi and 10 pi 
(corresponding to 1,250 and 625 cell equivalents of genomic DNA 
respectively) instead of two aliquots of 8 pi and 4 pi (corresponding to 80 
ng and 40 ng of cellular DNA respectively) were used.
3.2.11.3.4 Polyacrylamide gel electrophoresis and quantification of PCR 
products
Electrophoretic separation of PCR samples and quantification of 523 bp 
fragments were performed exactly as described in the 3.2.11.2.3 and 3.2.11.2.4 
sections.
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3.2.12 Treatment of OAW42 and OAW42Mer cell lines with cisplatin and 
BBR 3464 for the analysis of cell cycle disturbance and apoptosis
After harvesting in logarithmic growth phase, 2 x 106 OAW42 and 
OAW42Mer cells were seeded in 75-cm2 flasks with 20 ml of fresh growth 
medium and were then incubated at 37°C in a 5% CO2 humidified atmosphere 
in air incubator for 24 hours.
To expose cell lines to IC50 concentration of cisplatin (8.3 pM and 83 pM 
for OAW42 and OAW42Mer cell lines, respectively) and BBR 3464 (5.2 pM 
and 0.36 pM for OAW42 and OAW42Mer cell lines, respectively), 807.1 pM 
cisplatin (3.3 mM) and BBR 3464 (807.1 pM) stock solutions were diluted in 
growth medium to prepare different llx  working solutions (cisplatin = 91.3 
pM and 913 pM for OAW42 and OAW42Mer cell lines respectively; BBR 
3464 = 57.2 pM and 3.96 pM for OAW42 and OAW42Mer cell lines 
respectively) and 2 ml of the different 1 Ix drug working solutions were added 
to each flask. For untreated control samples, 2 ml of fresh growth medium was 
added to each flask. After a 1 -hour incubation at 37°C in a 5% CO2 humidified 
atmosphere in air incubator, drug-containing medium was removed from each 
flask, cell monolayers were washed three times with 20-30 ml of PBS. Twenty 
ml of fresh growth medium was added to each flask and cultures were then 
incubated at 37°C in a 5% CO2 humidified atmosphere in air incubator for 
additional 24 (T24 samples), 48 (T48 samples) or 72 (T72 samples) hours. At 
different intervals after drug treatment, the growth medium, containing floating
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cells, was removed from the flasks and transferred in 50 ml conical tubes 
whereas attached cell monolayers were washed twice with 10 ml of PBS and 
detached by a 5-minute incubation at 37°C with trypsin-EDTA solution (2 ml 
for each flask). Trypsinisation was stopped by addition of a 10% (v/v) FBS- 
PBS solution (10 ml for each flask). Cellular suspensions were then pooled 
with the corresponding floating cells in 50 ml conical tubes and centrifuged at
1,500 rpm for 5 minutes at room temperature.
After 2 PBS washes, cell pellets were resuspended in 1 ml of PBS and 
transferred in 1.5 ml conical tubes. Single-cell suspensions were checked under 
the microscope and counted in a particle counter by mixing a small aliquot of 
cell suspension (generally 50 pi) with isoton solution.
Each experimental sample was split into various aliquots (containing an 
appropriate number of cells) for the different assays. Cells aliquots destined to 
be used in assays for which fresh cells were not required, were collected by a
12,000 rpm-centrifugation at 4°C for 30 seconds and frozen by snap freezing in 
liquid nitrogen and stored at -80°C.
3.2.12.1 Cell cycle analysis by flow cytometry
For T24, T48, and T72 (untreated control sample, cisplatin- and BBR 3464- 
treated samples) experimental points, 1 x 106 (0.5 ml) of fresh OAW42 and 
OAW42Mer cells were fixed by a drop-to drop addition of cellular suspension 
to 4.5 ml of -2O°C cold-70% ethanol present in a 5 ml Nalgene tube. Fixed 
cells were stored at -20°C until they were subjected to the flow cytometric 
analysis. Immediately before analysis, fixed cells were collected by a 1,500
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rpm-centrifugation at 4°C for 5 minutes, transferred into a 1.5 ml tube and 
washed twice with 0.5 ml of PBS. Cell pellets were then resuspended in 0.5 ml 
of the solution A [50 pg/ml propidium iodide (Sigma), 50 mg/ml RNase A and 
0.05% (v/v) Nonidet P-40] and stained at 4°C. After 30 minutes, drug-induced 
cell cycle perturbations were assessed by analysing the stained cellular 
suspension with a FACScan flow cytometer (Becton Dickinson, Sunnyvale, 
CA, USA). At least 30,000 "events" were read and the percentages of cells in 
Go/i, S and G2/M phases were evaluated on DNA plots by CellFit software 
(Becton Dickinson) according to the SOBR model (Becton Dickinson).
3.2.13 Apoptosis induction studies
The possibility that activation of programmed cell death pathway occurred in 
the drug-treated OAW42 and OAW42Mer cell lines was investigated 
evaluating different endpoints.
3.2.13.1 Evaluation of the mitochondrial membrane potential (Av|/mt)
Since the disruption of mitochondrial membrane potential has been linked to 
the induction of apoptosis by different stimuli, possible changes of the Av|/mt in 
the OAW42 and OAW42Mer cell lines treated with the two drugs were 
investigated.
These potential alterations were studied by means of a flow cytometry 
method (Salvioli et al., 1997) using the Aymt-sensitive dye JC-1 (5.5'b.b'- 
tetrachloro-1.113.31 -teraethylbenzimidazolyl carbocyanine iodide) (Molecular
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Probes, Inc., Eugene, OR, USA). After cellular internalisation, the dye forms 
590 nm wave length-emitting JC-1 aggregates at relatively high Av|/mt whereas, 
in the absence of or at relatively low Av|/mt, internalised JC-1 exists as a 527 nm 
wave length-emitting monomeric form.
Forty eight hours after exposure to cisplatin or BBR 3464, (T48), untreated 
and drug-treated OAW42 and OAW42Mer cells (0.5 x 106 cells) were 
collected by a 1,500 rpm-centrifugation for 5 minutes at room temperature. A 
positive control for A\\imt disruption was prepared by treating cells with 
valinomycin, a K+ ionophore that uncouples oxidative phosphorylation. Zero 
point five x 106 cells of OAW42 and OAW42Mer cells were collected by a
1,500 rpm-centrifugation for 5 minutes at room temperature. To this purpose 
pellets of untreated OAW42 and OAW42Mer cells were resuspended in 0.9 ml 
of complete growth medium, then 0.1 ml of a 50 pM valinomycin solution 
(final concentration = 5 pM) were added and cells were placed at 37°C. After 
30 minutes cells were collected by a 1,500 rpm-centrifugation for 5 minutes at 
room temperature, washed twice with 1 ml of PBS and pelleted again.
Pellets of untreated, drug-treated and valinomycin-treated cells were 
carefully resuspended in 0.9 ml of complete growth medium, then 0.1 ml of a 
100 pg/ml JC-1 (final concentration = 10 pg/ml) solution were added and 
samples were incubated at 37°C in the dark. After 15 minutes, cells were 
centrifuged at 1,500 rpm for 5 minutes at room temperature and, after the 
removal of JC-1-containing medium, samples were washed once with 1 ml of 
PBS, resuspended in 1 ml of PBS and analysed by flow cytometry.
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A FACScan flow cytometer was used to analyse a minimum of 30,000 cells 
per sample. Data were acquired in list mode and evaluated using Lysis II 
software (Becton Dickinson). Forward and side scatter were used to gate the 
viable population of cells. JC-1 monomers emit at 527 nm wave length (FL-1 
channel, green range of visible light) whereas JC1-aggregates emit at 590 nm 
wave length (FL-2 channel, orange range of visible light). Duplicate samples of 
untreated control cells were used for compensation (FL-1 -  FL-2) and flow 
cytometry profiles from these cells defined the 590 nm cut-off for drug treated 
samples.
3.2.13.2 Evaluation of apoptotic morphology by fluorescent microscopy
Untreated and cisplatin- and BBR 3464-treated OAW42 and OAW42Mer 
cells (0.5 x 106 cells) harvested at 48 and 72 hours from the end of treatment 
(T48 and T72), were collected by a 1,500 rpm-centrifugation for 5 minutes at 
room temperature and stained with solution A (1 ml for 1 x 106 cells) as 
described in the 3.2.12.1 section. An aliquot of 30,000 stained cells was 
cytocentrifuged onto a glass slide for 3 minutes at 500 rpm (Cytospin 3) 
(Shandon Italia-Milan, Italy) at room temperature and, after that the cover slide 
was placed on the top of cells, glass slides were observed under fluorescence 
microscopy (excitation wave length = 588 nm, emission wave length = 610 
nm) by using Zeiss fluorescence miscroscope (Carl Zeiss Italia-Arese, Italy). 
The percentage of apoptotic cells was determined by scoring at least 500 cells 
on each sample.
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3.2.13.3 Evaluation of the genomic DNA fragmentation
The accumulation of DNA oligonucleosomal fragments was evaluated by a 
specific 'DNA agarose gel electrophoresis' assay essentially as described by 
Orlandi et al. (2001).
3.2.13.3.1 Preparation of a positive control of apoptosis induction
After harvesting in logarithmic growth phase, 3 x 106 HL-60 cells were 
seeded in 75-cm2 flask with 20 ml of fresh growth medium and were then 
incubated at 37°C in a 5% CO2 humidified atmosphere in air incubator for 24 
hours.
Immediately before treatment, the 15 mM teniposide stock solution was 
diluted in growth medium to prepare a l lx  solution (330 pM) and 2 ml of such 
llx  teniposide solution were added to the flask. After a 8-hour incubation at 
37°C in a 5% CO2 humidified atmosphere in air incubator, cells were pelleted 
by a 5-minute centrifugation at room temperature for 5 minutes.
After 2 PBS washes, cell pellets were resuspended in 1 ml of PBS, 
transferred in the 1.5 ml conical tubes and, single-cell suspensions were 
checked under the microscope and counted in a particle counter by mixing a 
small aliquot of cell suspension (generally 50 pi) with isoton solution.
Aliquots of 3 x 106 cells were collected by a 12,000 rpm-centrifugation at 
4°C for 30 seconds and, after PBS removal, were frozen by snap freezing in 
liquid nitrogen and stored at -80°C until they were used for genomic DNA 
extraction.
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3.2.13.3.2 Cellular DNA extraction
Frozen OAW42 and OAW42Mer cell pellets (3 x 106 cells), obtained from 
untreated and cisplatin- and BBR 3464-treated samples at 48 and 72 hours 
from the end of treatment (T48 and T72), experimental points and the same 
amount of frozen teniposide-treated HL-60 cells were resuspended in 1 ml of 
lysis buffer [10 mM EDTA pH 8, 5 mM Tris-HCl pH 8, 0.5% (v/v) Triton X- 
100 (Sigma)] and incubated on ice for 30 minutes. Samples were centrifuged at
12,000 rpm for 30 minutes at 4°C then supernatant, containing low molecular 
weight DNA, was separated from the pellet, corresponding to high molecular 
weight DNA, and transferred in a 15 ml conical tube. Low molecular weight 
DNA samples were first digested for 1 hour at 37°C by addition of 0.5 ml of a
1,500 units/ml RNase A solution (final concentration = 500 units/ml). Then, 
0.5 ml of the digestion solution [4% (w/v) SDS, 2 mg/ml proteinase K] were 
added and samples were incubated for 3 hours at 50°C. At the end of 
incubation, 2 ml of Ix TE pH 8-saturated phenol solution (Sigma) were added 
to each sample and tubes were centrifuged at 4,000 rpm for 5 minutes at 4°C. 
Supernatant aqueous phases were carefully removed and transferred in 15 ml 
tubes and 2 ml of Ix TE pH 8-saturated phenol/chloroform/isoamyl alcohol 
[25:24:1 (v/v/v)] solution were added. Samples were then centrifuged at 4,000 
rpm for 5 minutes at 4°C and 1.8 ml of supernatant aqueous phase was 
carefully transferred in a 15 ml tube. Two hundred pi of 3 M sodium acetate 
pH 5.2 (final concentration = 0.3 M) and 5 ml (2.5 volumes) of absolute 
ethanol were added to each DNA sample and, tubes were centrifuged at 4,000
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rpm for 5 minutes at 4°C. DNA pellets were then washed with 5 ml of 70% 
(v/v) ethanol, air dried and dissolved over night at 4°C in Ix TE pH 8 .
3.2.13.3.3 Agarose gel electrophoresis
Purified-low molecular weight cellular DNA obtained from 3x10* cells was 
mixed with 4 pi of 6 x gel loading buffer (final concentration = Ix) and loaded 
onto a 35 centimetres-length/20 centimetres-wide 1.5% (w/v) agarose gel 
prepared in Ix TBE buffer together with 3 pg of 1Kb DNA ladder marker 
(Sigma). Electrophoretic separation was performed by using Ix TBE as 
running buffer at a constant voltage of 50 volts for 5 hours at room 
temperature. Agarose gels were stained with ethidium bromide (10 pg/ml 
ethidium bromide, Ix TBE buffer) for 20 minutes onto a shaking platform and, 
after a 20-minute destaining in IX TBE buffer on a shaking platform, the 
resultant DNA ladder was visualised and photographed under the UV 
transilluminator.
3.2.13.4 Western blot analysis
3.2.13.4.1 Protein extract preparation
Frozen OAW42 and OAW42Mer cell pellets (3 x 10* cells) obtained from 
untreated and cisplatin- and BBR 3464-treated samples at 24, 48 and 72 hours 
from the end of drug treatment (T^, Tw, and T72) were lysed on ice by gentle 
resuspension in 200 pi of ice-cold RIPA buffer (20 mM Tris-HCl pH 7.4, 150
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mM NaCl, 5 mM NaF (Sigma), 2 mM PMSF and 10 jag/ml of the protease 
inhibitors aprotinin, leupeptin and pepstain). Tubes containing lysates were 
centrifuged at 12,000 rpm for 20 minutes at 4°C. Supernatants were then 
separated from pellet debris and transferred in 0.5 ml tubes. Protein content 
was quantified as described in the 3.1.4 section and protein extracts were stored 
at -80°C as 100 pg aliquots.
3.2.13.4.2 SDS PAGE
Protein extract fractionation was performed exactly as described in the
3.2.3.1 section with the only exception that a 12% polyacrylamide resolving 
gel was used.
3.2.13.4.3 Transfer of fractionated proteins from SDS-polyacrylamide gel 
to nitrocellulose filter
SDS PAGE-fractionated proteins were electroblotted onto nitrocellulose 
membrane using the same procedure described in the 3.2.3.2 section.
3.2.13.4.4 Immunological detection of nitrocellulose-immobilised proteins
Immunological detection of p53 (53 KDa), p21wafl (21 KDa), Bax (21 KDa), 
Bcl-2 (25 KDa), cyclin Bi (62 KDa), p34 cdc2 (also named cdk 1) (34 KDa) and 
lamin B (66 KDa for full-length product, 45 KDa for cleavage product) 
proteins was carried out as described in the 3.2.3.3 section using the primary 
monoclonal or polyclonal antibodies anti-p53, anti-Bax, anti-Bcl-2, anti cyclin
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B|, anti-cdkl, anti-lamin B (Santa Cruz Biotechnology) and anti-p21wafl 
(Oncogene Science, Cambridge, MA, USA) at final concentrations of 1 pg/ml, 
respectively, and antimouse or antirabbit Ig horseradish peroxidase-linked 
whole antibodies diluted 1:2,500 as secondary antibodies.
To ensure equal loading of proteins on the gel, the monoclonal anti-tubulin p 
antibody (final concentration = 1 pg/ml) was used to detect the levels of such a 
protein on each blot.
To probe the same filter with alternative antisera, the probed membranes 
were immersed in a 50 ml tube containing 20-40 ml of 50°C-heated stripping 
solution (100 mM p-mercaptoethanol (Sigma), 2% (w/v) SDS, 62.5 mM Tris- 
HCl pH 6.7) and incubated for 30 minutes at 50°C. Stripped filters were 
washed twice with large volumes of T-PBS wash solution for 20 minutes at 
room temperature, then the procedure for immunological detection described in 
the 3.2.3.3 section was started.
3.2.14 in vitro cyclin Bi-associated cdkl kinase activity assay
The kinase activity of the cyclin Bi-cdkl complexes extracted from OAW42 
and OAW42Mer after drug treatment was assessed in vitro as described by 
Orlandi et al. (2001).
3.2.14.1 Protein extraction
Frozen OAW42 and OAW42Mer cell pellets (1 x 106 cells) obtained from 
untreated and cisplatin- and BBR 3464-treated samples at 24, 48 and 72 hours
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from the end of treatment ( T 2 4 ,  T 4 8 ,  and T 7 2 )  were lysed on ice by gentle 
resuspension in 500 pi of ice-cold lysis buffer for kinase assay [1% (v/v) 
Nonidet P-40, 10 pg/ml aprotinin, 10 pg/ml leupeptin, 1 mM AEBSF (Sigma), 
1% (w/v) BSA prepared in PBS]. Cell lysates were clarified by a 15,000 rpm- 
centrifugation for 30 minutes at 4°C then the containing-protein supernatant 
was transferred in a 1.5 ml tube and placed on ice.
3.2.14.2 Immunoprécipitation
Five hundred pi of cellular lysate were mixed with 3 pg of the mouse 
monoclonal anti-cyclin Bi antibody (Santa Cruz) and 100 pi of a 20% (v/v) 
protein A-Sepharose slurry (Amersham-Pharmacia Biotech.). The formation of 
immune complexes was carried out by a 4°C-incubation on a shaking platform. 
The protein A-Sepharose/anti-cyclin Bi antibody/ cyclin Bi-cdkl ternary 
immune complexes were then collected to the bottom of the tube by a 12,000 
rpm-centrifugation for 2 minutes at 4°C. After the supernatant phase removal, 
immune complexes pellets were washed twice with 100 pi of lysis buffer for 
kinase assay and then twice with the same volume of lysis buffer for kinase 
assay minus BSA.
3.2.14.3 Kinase activity assay
Ten pi of 2x kinase buffer [40 mM Tris-HCl pH 7.5, 20 mM MgCh (Sigma), 
10 pM ATP (Sigma)], 8 pi of a 375 ng/pl (3 pg) solution of histone HI 
(Boehringer Mannheim Italia-Monza, Italy), 10 pCi of [y-32P]-ATP (3,000
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Ci/mmole) and distilled water to a final volume of 20 p.1 were added to each 
immune complex pellet. The tubes were incubated at 30°C in a hot-bonnet 
thermal cycler for 20 minutes, then the reaction was stopped by adding an 
equal volume (20 pi) of 2x SDS loading buffer. Before loading onto SDS 
PAGE, samples were heated at 100°C for 5 minutes and then placed on ice for 
an additional 5 minutes.
3.2.14.4 SDS PAGE
SDS-polyacrylamide gel electrophoresis was carried out exactly as described 
in the 3.2.12.4.2 section. At the end of the run, and after the separation of glass 
plates, the stacking gel was removed by means of a razor blade whereas the 
resolving gel was transferred onto a plastic film, covered on the top with a 
sheet of Saran Wrap, placed onto a Hypercassette without intensifying screens 
and autoradiographed for different times at room temperature (short exposure 
times) or at 4°C (long exposure times) by using X-ray films.
Bands corresponding to the cyclin Bi-cdkl kinase activity of the different 
samples were quantified by densitometric analysis. Kinase activities of 
untreated control and drug-treated samples were normalised on the number of 
cells in the G2-M compartment and expressed in arbitrary densitometric units.
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4.1 Cytotoxicity of cisplatin and BBR 3464
The cytotoxic activity of BBR 3464 was studied in comparison to cisplatin in 
a panel of human ovarian cancer cell lines by means of the growth inhibition 
assay. Cells were exposed to increasing concentrations of the two agents for 1 
hour and the effect of the drugs was determined as variation in the cell number 
of treated samples (with respect to untreated control samples) after an 
additional 72 hours in drug-free medium. The concentrations of cisplatin and 
BBR 3464 able to inhibit cellular proliferation by 50% (IC5o) were extrapolated 
from the dose-effect curves.
A very interesting behaviour was found in the OAW42/OAW42Mer cell line 
pair, one sensitive and one with experimentally induced resistance to cisplatin, 
in which an opposite pattern of sensitivity to the two drugs was observed (Fig. 
23 and Tab. IV). In fact, in respect of the parental-cisplatin sensitive OAW42 
cell line, OAW42Mer cells were 10 times less sensitive to cisplatin but 14 
times more sensitive to the novel trinuclear platinum complex BBR 3464. The 
pronounced collateral sensitivity of BBR 3464 seemed to be specific for this 
cell line pair. In fact, results obtained in a second pair of human ovarian 
carcinoma cell lines, A2780 and A2780cp8, one sensitive and one with 
experimentally induced resistance to cisplatin, indicated that a certain degree of 
cross-resistance between cisplatin and BBR 3464 was present, although the 
resistance index for the trinuclear platinum in the A2780cp8 was much lower 
than observed for cisplatin (2.5 vs 14-fold) (Tab. IV).
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Figure 23. Sensitivity of OAW42, OAW42Mer, A2780, A2780d and 
A2780cp8 cells to cisplatin and BBR 3464 (1 hour exposure). The 
sensitivity was assessed by the growth inhibition assay. Cells were 
counted 72 hours after drug removal. Values represent the mean (± 
S.D.) of three independent experiments.
o o<NO
IOJ1UOOJO %
o o
o o
|0J)U03 JO %
oo
00 OO 00
<N
3rrm
02CQCQ
o<N 8 OOO o o(N o
|0J)U03j0%
00 00 00
c
. i  Hmu I
o<N g o
|OJ)UOO JO %
C
is
pl
at
in
 
(p
M
) 
BB
R 
34
64
 
(p
M
)
-F
ig
ur
e 
23
-
Table IV. Cytotoxic activity of cisplatin and BBR 3464 in human ovarian 
cancer cell lines. Drug activity is expressed in terms of 
concentration able to inhibit cell growth by 50% ( I C 5 0 ) .
Values represent the mean (± S.D.) of three independent 
experiments. The resistance factor is the ratio of IC50 
OAW42Mer/IC5o OAW42 or IC50 A2780d/IC5o A2780 or IC50 
A2780cp8/IC5o A2780.
I1
!
u
O
'
8
'
OKu
u
=5
°
' ' ' :' " :■  ' ■ ■
o mO  CM
en
+1
°«n
m
s<oen
O
o
©
S o  8
?, g  $
O o  S
°  °  °
ma
© r- ©
i—< r f  ""d"
ËMMNNMVvm .
oo ^  s  s  „• ■ ■ ■ ■ CN ■ •“ * OO (*"*$ _• |/^c i 00 ©  un
5  !  5  5 1
-8
o  ' g  ■$  H I
-T
ab
le 
IV
-
(4) Results
The sensitivity profile to the two platinum-based anticancer agents was also 
determined in the A2780d cell clone which was selected in culture without 
drug exposure and characterised by alterations of the mismatch repair pathway 
(see section 4.2). Results obtained in the growth inhibition assay indicated that, 
in comparison to the parental cisplatin-sensitive A2780 cells, this cell clone 
was characterised by a moderate degree of resistance to cisplatin but it 
maintained the same sensitivity to the novel trinuclear platinum complex BBR 
3464 (cisplatin I C 5 0  for A2780 cells = 4.3±0.34 pM, cisplatin I C 5 0  for A2780d 
cells = 20±3.25 pM; BBR 3464 I C 5 0  for A2780 cells = 0.08+0.008 pM, BBR 
3464 I C 5 0  for A2780d cells = O.O77±O.O3 pM).
4.2 Status of mismatch repair (MMR) and nucleotide excision repair 
(NER) systems in the cellular models
To verify whether the cytotoxic activity of BBR 3464 and cisplatin in our 
cell lines was influenced by the functional status of two of the most important 
DNA repair pathways, intracellular levels of the MMR enzymes, hMSH2, 
hMLHl, hPMS2, and of the NER enzyme ERCC1 were assessed by western 
blot analysis. In addition, microsatellite instability analysis was performed to 
ascertain the functional status of MMR. Again, RT-PCR experiments were 
carried out to evaluate ERCC1 gene expression and the molecular ratio 
between ’alternatively-spliced form’ lacking exon VIII (AexVIII) and ‘full- 
length form' of ERCC1 transcript.
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4.2.1 MMR
In western blotting experiments, nuclear extract from HeLa cells was used as 
a positive control for expression of the three MMR proteins hMLHl, hPMS2 
and hMSH2, nuclear extract from LoVo cells line was used as negative control 
lacking hMSH2 expression, and nuclear extract from HCT-116 cells was used 
as negative control lacking the expression of both hMLHl and hPMS2 proteins 
(Fig. 24).
As regards the 100-KDa hMSH2 protein, data obtained after immunostaining 
indicated that it was expressed in all the tested ovarian cancer cell lines. A 
different pattern of expression was observed for both 86-KDa hMLHl and 
110-KDa hPMS2 proteins. In fact, a lack of expression of the two human MutL 
homologues was observed in the cisplatin-resistant OAW42, A2780d and 
A2780cp8 cell lines, whereas these proteins were expressed in the parental 
cisplatin-sensitive counterparts OAW42 and A2780 cell lines (Fig. 24). It is 
important to underline that these differences in the expression of the three 
MMR proteins among the five cell lines were not due to a different loading of 
the gel, as demonstrated by the comparable intensity of an 81 KDa-non specific 
band.
To verify whether the lack of such proteins was responsible for a functional 
inactivation of the MMR machinery in the cisplatin-resistant cells, the MMR 
efficiency was assessed in the five cell lines by means of the microsatellite 
instability assay at nine different loci (Fig. 25). These loci were selected on the 
basis of data previously published which indicate such microsatellite sequences
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Figure 24. Structural analysis of the DNA mismatch repair (MMR) system by 
Western blotting assay of hPMS2, hMSH2 and hMLHl protein 
expression in OAW42, OAW42Mer, A2780, A2780d and 
A2780cp8 cells. HeLa, LoVo and HCT-116 cell lines were used as 
specific controls for MMR protein expression. The non-specific 
lower band in the hMLHl blot (n.s.b.) represented a control of 
protein loading.
hPMS2
hMSH2
hMLHl
-Figure 24-
Figure 25. Functional analysis of the DNA mismatch repair (MMR) system by 
microsatellite instability assay in OAW42 (1), OAW42Mer (2), 
A2780d (3), A2780cp8 (4) and A2780 (5) cell lines.
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(4) Results
as the most indicative for a deficiency in MMR activity in human ovarian 
cancer tissues. Results obtained from sequencing gels corroborated those 
obtained with western blot analysis (Tab. V). In fact, conversely from what 
was observed in the MMR-proficient/cisplatin sensitive OAW42 and A2780 
cells, a marked instability of the microsatellite sequences at seven/eight of the 
nine loci considered (78-89%) was detected in cisplatin-resistant cell lines 
lacking the expression of hMLHl and hPMS2 proteins (OAW42Mer, 
A2780cp8 and A2780d). Specifically, data obtained from the analysis of 
microsatellite sequences indicated that the electrophoretic pattern 
corresponding to OAW42Mer cells was markedly different from that obtained 
for OAW42 cells at BAT 26, D2S123, D17S250, D3S1283, D6S261, 
GGAA2E02, and D6S1035 loci, whereas no differences were found between 
the two lines for the microsatellite sequences corresponding to EDH17B and 
GATAI 1B12 loci (Fig. 25 and Tab V). Moreover, the electrophoretic pattern 
observed for the cisplatin resistant A2780d cell clone indicated a marked 
instability of the microsatellite sequences corresponding to BAT 26, BAT40, 
D2S123, D17S250, D3S1283, D6S261, GGAA2E02 and D6S1035 loci. 
Microsatellite instability at the same loci (with the only exception of 
GGAA2E02 locus) was also detected for the other cisplatin-resistant cell line 
A2780cp8 (Fig. 25 and Tab V).
Overall, data obtained from analysis of the structural and functional status of 
the MMR suggest that, while the loss of MMR activity is an important event in 
determining cellular resistance to cisplatin, the functional status of MMR does 
not seem to be involved in the cellular response to BBR 3464.
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Table V. Summary of the microsatellite instability analysis data. Symbols: 
microsatellite instability detected; - = microsatellite instability 
undetected; N.E. = not evaluated locus.
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4.2.2 NER
The intracellular mRNA and protein levels of the ERCC1 gene were 
evaluated by western blotting and quantitative non-competitive RT-PCR 
analyses, respectively, in OÀW42, OAW42Mer, A2780, A2780d and 
A2780cp8 cell lines.
Results of western blot experiments indicated that this NER protein was 
present in all cell lines, although at a variable extent of expression. The 
amounts of ERCC1 enzyme present in the five cellular samples were then 
quantified by densitometric analysis and expressed as arbitrary densitometric 
units (a.d.u.), after normalisation with P-tubulin levels for the different gel 
loading.
As shown in Fig. 26, the level of the ERCC1 protein detected in the 
cisplatin-resistant OAW42Mer cell line was 3-fold higher than that observed in 
the OAW42 parental cell line (3.15 a.d.u and 1 a.d.u, respectively) (Tab. VI), 
whereas quite similar levels of ERCC1 expression were observed in A2780, 
A2780d and A2780cp8 cell lines (2.4, 2.9 and 1.9 a.d.u, respectively) (Tab. 
VI).
The results obtained in the quantitative non-competitive RT-PCR analysis 
(that was performed by using total RNA extracted from each cell line, a couple 
of primers able to select and amplify the 494 bp full-length ERCC1 mRNA 
molecule and a pair of primers that specifically amplify a 96 bp region of P- 
actin mRNA) corroborated the western blotting data. In fact, results from 
densitometric analysis of the gel photograph (Fig. 27) (expressed as arbitrary
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Figure 26. Analysis of the DNA nucleotide excision repair (NER) system.
Western blotting analysis of ERCC1 protein in OAW42, 
OAW42Mer, A2780, A2780d and A2780cp8 cells.
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Table VI. Summary of the ERCC1 protein levels present in OAW42,
OAW42Mer, A2780, A2780d and A2780cp8 cells [expressed 
arbitrary densitometric units (a.d.u.)].
i _  _ _ _ _  _ _ _ _ _  _ . _
OAW42 1.0
OAW42Mer 3.15
A2780 2.4
. A2780d 2.9
A2780cp8 1.9
-Table VI-
Figure 27. RT-PCR analysis of ERCC1 gene expression in OAW42, 
OAW42Mer, A2780, A2780d and A2780cp8 cell lines.
ERCC1
P-actin
-Figure 27-
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densitometric units after normalisation with p-actin levels for the different gel 
loading) indicated that ERCC1 mRNA levels present in the OAW42Mer cells 
were almost 3 times higher than those measured in the parental OAW42 cells 
(3.25 and 1 a.d.u, respectively) (Tab. VII), whereas a similar ERCC1 gene 
expression was detected in A2780, A2780d and A2780cp8 cells (3.3, 3.7 and 
3.0 a.d.u, respectively) (Tab. VII). Moreover, results from this assay indicated 
that the up-regulation of ERCC1 expression in OAW42Mer cells occurred at 
the transcriptional or post-transcriptional level.
Since it has been reported that in cisplatin sensitive cell lines the low activity 
of the ERCC1 enzyme can be ascribable both to the downregulation of the 
ERCC1 gene expression (regulation at the transcriptional level) and to an 
increased ratio between alternatively-spliced (biologically inactive) and full- 
length (biologically active) forms of ERCC1 mRNA (regulation at post- 
transcriptional level), the amount of the alternatively-spliced ERCC1 mRNA 
form lacking exon VIII (AexVIII) was measured by a quantitative non 
competitive RT-PCR approach in our cellular models. Amplification reactions 
were carried out using a pair of primers able to select and amplify both full- 
length (267 bp) and AexVIII (196 bp) ERCC1 mRNA molecules together with 
a pair of primers that specifically amplify a 621 bp region of p-actin mRNA 
(Fig. 28).
Results from the densitometric analysis of the gel photograph (Fig. 28) 
(expressed as arbitrary densitometric units after normalisation with p-actin 
levels for the different gel loading) (Tab. VIII) indicated that the amount of
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Table VII. Summary of the ERCC1 gene expression levels (full-length
mRNA) in OAW42, OAW42Mer, A2780, A2780d and A2780cp8 
cells [expressed as arbitrary densitometric units (a.d.u.)].
C e ll lin e s
O A W 4 2 1
Ô A W  4 2 M e r 3
A 2 78 0 3.6
A 2 7 8 0 d 3
A 2 7 8 0 c p 8 3.7
-Table VII-
Figure 28. RT-PCR analysis of alternatively-spliced (AexVIII) and full-length 
(F-L) ERCC1 mRNA forms in OAW42, OAW42Mer, A2780, 
A2780d and A2780cp8 cell lines.
p-actin
F-L
AexVIII
Table VIII. Summary of the ratios between alternatively-spliced (AexVIII) and 
full-length ERCC1 mRNA forms in OAW42, OAW42Mer, A2780, 
A2780d and A2780cp8.
Cell lines
OAW42 0.322
OAW42Mer 0.1
A2780 0.213
A2780d 0.206
A2780cp8 0.285
-Table VIII-
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AexVIII ERCC1 mRNA present in the parental OAW42 cells was greater than 
that detected in OAW42Mer cells, and the 'AexVIII form/full-length form' ratio 
in OAW42 cells was almost 3-fold higher than that found in OAW42Mer cells 
(OAW42Mer 'AexVIII form/full-length form' ratio = 0.1, OAW42 'AexVIII 
form/full-length form' ratio = 0.322) (Tab. VIII). Conversely, comparable 
'AexVIII form/full-length form' ratios were detected in the A2780, A2780d and 
A2780 cp8 cell lines (ratios: 0.213, 0.206, 0.285, respectively) (Tab. VIII). 
Overall, our data suggest that the lower amount of ERCC1 enzyme found in the 
OAW42 cells compared to OAW42Mer cells, could be attributable to a high 
rate of post-transcriptional rearrangements as well as to a reduced transcription 
of the ERCC1 gene.
4.3 Evaluation of intracellular platinum accumulation
To verify whether the opposite pattern of sensitivity to cisplatin and BBR 
3464 observed in the OAW42/OAW42Mer cell line pair, in comparison to the 
A2780/A2780cp8 cell line pair, can be explained in terms of a different 
accumulation of the two drugs in the cells, experiments were carried out to 
evaluate the intracellular platinum content in the different cell models after 
exposure to the two drugs. To this purpose, OAW42, OAW42Mer, A2780 and 
A2780cp8 cell lines were incubated for 1 hour with equimolar concentrations 
of cisplatin and BBR 3464 (0.3, 3.3 and 33.3 pM) and then intracellular
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platinum content was measured by atomic absorption spectrometry and 
expressed as micrograms of platinum per 106 cells (fig Pt/106 cells).
The data obtained with this assay indicated that the accumulation of BBR 
3464 was consistently higher than that of cisplatin. In fact, the quantity of 
platinum accumulated after exposure to the novel trinuclear platinum complex 
was from 2 to 20-times higher than that measured after treatment with cisplatin 
in the different cell lines (Fig. 29 and Tab. IX).
Data obtained after cisplatin treatment indicated that the levels of platinum 
found in the resistant OAW42Mer and A2780cp8 cells were lower than those 
detected in the corresponding parental sensitive OAW42 and A2780 cells at all 
the tested doses. Specifically, for the OAW42 and OAW42Mer cell line pair, 
the differences were minimal at the lower drug concentrations (Tab. IX) 
whereas at the highest drug concentration (33.3 pM) the amount of 
intracellular platinum content was significantly different (p<0.05. Student t 
test) between sensitive and resistant cells (Tab. IX). As regards the second pair 
of ovarian cell lines, the amount of platinum accumulated in the A2780 cells 
was significantly higher (p<0.05. Student t test) than that observed in 
A2780cp8 cells, at all cisplatin concentrations used, although the maximum 
difference was evident at the highest cisplatin dose (33.3 pM) (Tab. IX).
After exposure to different concentrations of BBR 3464, a lower platinum 
accumulation consistently was observed in the A2780cp8 cell line as compared 
to its parental counterpart A2780 cell line (Tab. IX). These differences were 
significant (p<0.05. Student t test) at the two highest BBR3464 concentrations
216
Figure 29. Cellular accumulation of platinum after a 1-hour exposure to 
cisplatin and BBR 3464 as assessed by atomic absorption 
spectrometry in OAW42 (□  ), OAW42Mer (■  ), A2780 (■  ) and 
A2780cp8 (■  ) cell lines. Values represent the mean (± S.D.) of 
three independent experiments.
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Table IX. Summary of the data regarding cellular accumulation of platinum in 
OAW42, OAW42Mer, A2780, and A2780cp8 cells. Data are 
expressed as micrograms of platinum per 106 cells (pg Pt/106 cells).

(4) Results
Results obtained after exposure of OAW42 and OAW42Mer cells to the 
novel trinuclear platinum complex indicated that the amount of platinum 
accumulated in the two cell lines was similar at the concentration of 0.3 pM 
and 3.3 pM (Tab. IX). Conversely, after treatment with the highest BBR 3464 
concentration, a significantly (p<0.05, Student t test) lower platinum 
accumulation was detected in OAW42Mer cells than in OAW42 cells (Tab. 
IX).
4.4 Evaluation of platinum bound to cellular DNA
Since genomic DNA has been described as the most important cellular target 
for both cisplatin and BBR 3464, we assessed whether the different activity 
profiles observed for the two drugs were due to a different capacity of the 
drugs to penetrate the nucleus and covalently bind cellular DNA.
The amount of platinum bound to DNA was measured by mass spectroscopy 
analysis following exposure of OAW42, OAW42Mer, A2780 and A2780cp8 
intact cells to equimolar concentrations of the two platinum-based drugs (10, 
40, 400 pM of cisplatin and 1, 10, 40 pM of BBR 3464), and it was expressed 
as picograms of platinum per micrograms of DNA (pg Pt/pg DNA).
Results obtained from such experiments showed that, after exposure to 
cisplatin, the extent of DNA platination found in resistant OAW42Mer and 
A2780cp8 cell lines was lower than that observed in sensitive cells at all drug 
concentrations used (Fig. 30 and Tab. X).
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Figure 30. Platinum bound to genomic DNA after a 1-hour exposure to 
cisplatin and BBR 3464 as assessed by mass spectroscopy analysis 
in OAW42 (D ), OAW42Mer (■ ), A2780 (■) and A2780cp8 #  
cell lines. Values represent the mean (± S.D.) of three independent 
experiments.
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Table X. Summary of the data regarding platinum bound to genomic DNA of 
in OAW42, OAW42Mer, A2780, and A2780cp8 cells. Data are 
expressed as picograms of platinum per micrograms of genomic 
DNA (pg Pt/pg DNA).
»&
CN
<N
+1
xf-
oo
o
uri
+1
O n
i n 19
1.
71
35
13
12
.5
15
2.
61
2.
4
37
3.
71
20
.7
21
11
.9
14
5.
51
21
55
0.
22
15
4
+1
r -
00
CN 17
3.
21
48
.9
22
5.
11
15
vO
%
o 40 o 40 o 40 o 40
PS
fiQ
e a
6 6
i
pk
un
o
+1
(N
CN
m
oo
o
+1
(N
in
<N
NO
+1
m
00
O
o
+1
r n
o
+1
oo
NO
CN
+1
in
un
(N
+1
<N
in
+1
in
ON
14
4.
51
2.
9
1.
51
0.
8 ON
o
4-1
ON
CN 7
21
3.
6
s
. =L
f
o 40 40
0 O 40 40
0 o 40 40
0 o 40 40
0
1
O
A
W
42
O
A
W
42
M
er
A
27
80
A
27
80
cp
8
(4) Results
After treatment with BBR 3464, significant (p<0.05. Student t test) lower 
levels of platinum bound to genomic DNA were found in the BBR 3464- 
resistant cells (OAW42) than in BBR 3464-sensitive cells (OAW42Mer) at all 
drug concentrations tested (Tab. X). These differences were constant, with a 
ratio between pg Pt/pg DNA of sensitive cells and pg Pt/pg DNA of resistant 
cells -  2, at all BBR 3464 concentrations tested (Tab. X).
In the A2780 and A2780cp8 cell line pair, a similar trend was observed only 
at the highest BBR 3464 concentration (with a ratio between pg Pt/pg DNA of 
A2780 and pg Pt/pg DNA of A2780cp8 = 2). In fact, at lower BBR 3464 
concentrations, no marked difference between sensitive and resistant cells was 
detected (Tab. X).
Results from these experiments also indicated that the ability of the novel 
trinuclear platinum complex to covalently bind genomic DNA was greater than 
that of cisplatin. In fact, when we compared the extent of platinum bound to 
DNA after treatment of the four cell lines with 10 and 40 pM cisplatin to that 
measured after exposure of the cells to the same concentrations of BBR 3464, 
we found higher values (from 10 to 40 times), in terms of picograms of 
platinum bound per micrograms of DNA, for the novel trinuclear platinum 
complex.
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4.5 Evaluation of interstrand cross-links formation
The ability of BBR 3464 to produce DNA interstrand cross-links in vitro in a 
dose-dependent manner was compared to that of cisplatin by using the naked 
pSP73 vector as substrate. This DNA plasmid was selected on the basis of its 
low content of guanines, which are the DNA nucleotides most frequently 
covalently attached by platinum-based drugs, in the attempt to reduce the 
possible background of the assay due to higher DNA packaging and/or 
fragmentation. Experiments were carried out by treating the DNA vector for 1 
hour at 37°C in the dark with different concentrations of cisplatin or BBR 
3464. Damage reactions were then stopped by ethanol precipitation, and treated 
and untreated samples, previously denatured by thermal treatment (with the 
exception of one of the two untreated control samples) were loaded onto an 
agarose gel. It is important to stress that the drug concentrations used in these 
experiments were selected on the basis of the results obtained from several 
preliminary experiments which were performed to identify the drug doses able 
to guarantee an optimal balance between dose-dependent induction of DNA 
interstrand cross-links and general background of the assay.
Figure 31 shows a representative agarose gel electrophoresis experiment of 
dose-dependent accumulation of drug-induced DNA interstrand cross-links. 
Untreated control samples, subjected or not subjected to heat dénaturation 
before gel loading (CTR D and CTR UD respectively) are characterised by 
single DNA bands with different electrophoretic mobility. Specifically, the 
signal corresponding to the CTR UD sample, which consists of double-
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stranded DNA molecules not exposed to the thermal treatment (DS DNA), is 
characterised by an electrophoretic mobility lower than that of the heat- 
denatured control sample (CTR D). The latter sample represents the sum of 
single-stranded plasmid DNA molecules (SS DNA).
In drug treated samples, which were all heat denatured before gel loading, it 
is possible to appreciate the appearance of a band (DS/XL DNA) characterised 
by an electrophoretic mobility similar to that of the DS DNA present in the 
CTR UD sample. In fact, this DS/XL DNA band represents the sum of double 
stranded plasmid molecules in which the strand separation induced by thermal 
treatment was inhibited by drug-induced formation of interstrand cross-links.
Results reported in figure 31 indicate that the intensity of the DS/XL DNA 
bands obtained after treatment with different concentrations of cisplatin or 
BBR 3464 does not increase in a dose-dependent manner. Conversely, it is 
possible to observe a dose-dependent decrease in the amount of the bands 
formed by single-stranded non cross-linked (SS/noXL) DNA molecules. These 
latter molecules are characterised by an electrophoretic mobility similar to that 
of the SS DNA band present in the CTR D samples. This particular behaviour 
can be explained by considering the fact that relatively high drug 
concentrations are able to induce several alterations in the pSP73 vector 
chemical-physical properties thus producing undesired collateral phenomena, 
such as elevated rates of DNA packaging and/or fragmentation, with a 
consequent increase of the gel background. To obtain quantitative information 
on the ability of BBR 3464 and cisplatin to form DNA interstrand cross-links, 
this methodological problem was circumvented by calculating indirectly the
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Figure 31. Evaluation of interstrand cross-links induction on naked pSP73 
vector after a 1-hour in vitro exposure to cisplatin and BBR 3464. 
Ctr UD = untreated control sample not subjected to thermal 
dénaturation before loading; Ctr D = untreated control sample 
subjected to thermal dénaturation before loading; DS DNA = 
double stranded DNA; SS DNA = single stranded DNA; DS/XL 
DNA = double stranded-cross-linked DNA; SS/noXL DNA = 
single stranded-not cross-linked DNA.
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(4) Results
extent of such DNA lesions at the different drug concentrations on the basis of 
the disappearance of the SS/noXL DNA band in drug-treated samples with 
respect to the untreated control sample (CTR D).
Data obtained from densitometric analysis in cisplatin-treated samples (Tab. 
XI) indicate that after a 1-hour exposure, a considerable decrease (38%) of the 
SS/noXL DNA band intensity, due to the formation of DNA interstrand cross­
link lesions, was already detectable at the lowest drug concentration (0.5 pM). 
The extent of DNA interstrand cross-links increased in a dose-dependent 
manner (58% and 99.3%, at 2 and 6 pM respectively) up to the highest drug 
concentration (8 pM) where an almost complete disappearance of the signal 
corresponding to the SS/noXL DNA band was observed.
After a 1-hour exposure of the pSP73 plasmid to BBR 3464 (Fig. 31), a 
dose-dependent decrease of the SS/noXL DNA band and a corresponding 
increase of the DS/XL DNA band were detected at drug concentrations up to 
0.01 pM. Conversely, at the highest concentration of the trinuclear platinum 
complex (0.05 pM), the strong decrease of the SS/noXL DNA band was not 
accompanied by a correspondent increase of the DS/XL DNA band. However, 
it was indicative of an elevated extent of DNA interstrand cross-links 
formation (62%) (Tab. XI).
These results indicate that the ability of BBR 3464 to form in vitro DNA 
interstrand cross-links is quite similar to that of cisplatin. However, from a 
quantitative point of view, results indicate that the affinity of the novel 
trinuclear platinum compound for the DNA is significantly greater than that of
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Table XI. Summary of data regarding interstrand cross-links induction on 
naked pSP73 vector. Data are expressed as percentage value of 
band signal in drug-treated samples with respect to untreated-heat 
denatured control sample.
Sample Drug Concentrations
:
Untreated Control D / 100
Treated cisplatin 0.5 62
Treated cisplatin 2 42
Treated cisplatin 6 0.7
Treated cisplatin 8 0
Treated BBR 3464 0.001 88
Treated BBR 3464 0.005 77
Treated BBR 3464 0.01 50
Treated BBR 3464 0.05 38
-Table XI-
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cisplatin. In fact, the concentration of BBR 3464 necessary to produce on the 
plasmid DNA a number of interstrand cross-link lesions able to reduce the 
intensity of the SS/noXL DNA band of about 50%, was 140-times lower than 
that required for cisplatin (0.01 pM vs 1.4 pM). It is important to stress that 
these findings are in agreement with those obtained after measurement of 
platinum bound to genomic DNA after exposure of intact cells to the two drugs 
(section 4.4).
4.6 Sequence selectivity of adduct formation of BBR 3464 and cisplatin
In an attempt to qualitatively characterise the molecular lesions induced by 
BBR 3464 to DNA, the Taq stop assay was used for the evaluation of the 
sequence specificity of DNA adducts generated by the novel trinuclear 
platinum complex in comparison to that of cisplatin. The sequence specificity 
of damage induced by the two platinum-based compounds was evaluated on 
DNA template molecules characterised by an increasing structural complexity 
and in experimental conditions progressively closer to the physiological 
environment.
The first experiments of Taq stop assay were carried out on naked pSP73 
plasmid DNA exposed to the two drugs in vitro. As already mentioned, such 
DNA vector represents an excellent substrate to investigate the effect of in 
vitro treatment with potent electrophilic intermediates, like cisplatin and BBR 
3464, on the basis of its low content of possible nucleophilic targets such as 
guanine and/or adenine DNA nucleotides.
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An opportunely selected amount of purified plasmid DNA was exposed in 
vitro to different concentrations of cisplatin and BBR 3464 for 2 hours at 37°C 
in the dark. Such drug concentrations were chosen on the basis of the results of 
preliminary experiments that were carried out to define the amount of cisplatin 
and BBR 3464 at which the single-hit kinetics (each DNA molecule receives at 
most one lesion) was achieved. Such kinetics (which represent an important 
parameter to be considered in order to obtain significant information from this 
technique) are satisfied when a clear dose-dependent increase in the signal of 
the bands (corresponding to the sites whose Taq DNA polymerase activity was 
prematurely halted by drug-induced DNA adducts) is observed.
Drug exposed DNA vector was used as template in linear PCR together with 
the 32P-labelled Sp6 primer. The same primer was also utilised to perform 
pSP73 sequencing reactions by means of a PCR-based dideoxy method. 
Samples from Taq stop and sequencing reactions were then simultaneously 
loaded onto the sequencing gel and the sequence selectivity of the DNA 
lesions, generated by drug treatment, was exactly (±2 bp) pinpointed by 
comparing the position of the bands (representing the nucleotide at which Taq 
polymerase was stopped by the drug-generated adduct) and the dideoxy 
sequencing lanes.
It is important to stress that the sequence selectivity of DNA lesions induced 
by the two platinum-based compounds on the plasmid was evaluated in a small 
region of the template. In fact, the labelled Sp6 primer was able to select and 
amplify (in a linear fashion) a selected -190 bp portion of the pSP73 vector 
included between the primer annealing region and the artificial Taq stop site
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generated by cutting the vector with the Haell restriction endonuclease (Fig. 
21).
Figure 32 shows a representative picture of a sequencing gel in which Taq 
stop and sequencing reactions, carried out on naked pSP73 plasmid DNA, were 
depicted. Results obtained with this assay indicate that the two platinum-based 
anticancer drugs share almost the same sequence preference of adduct 
formation. In fact, after a 2-hour exposure to various concentrations of each 
drug, the presence of three distinct bands (I, II and III) was clearly detectable in 
the polyacrylamide gel. These radioactive spots represent the pool of DNA 
fragments characterised by a number of base pairs lower than that present in 
the full-length fragment due to the premature stops of Taq DNA polymerase 
activity caused by the drug-induced lesions at the 3'-AG-5' (band I) and 3'-GG- 
5' (bands II and III) dinucleotide sites. The presence of weak bands at the same 
sites in the untreated DNA control sample was also detected. This phenomenon 
is thought to be a technical problem of the assay, as already reported by other 
authors (Bubley et al., 1994; Grimaldi et al., 1994b). In fact, such background 
signals seem to be generated by intrinsic obstructions to Taq polymerase, since 
they constitutively appear in the same positions and may be due to secondary 
structures of DNA blocking to some extent the progress of Taq polymerase in 
the first round of the PCR. However, all attempts to overcome the effects of 
such secondary structures, such as the inclusion of the co-solvent DMSO into 
the PCR mixtures, failed to remove these bands.
Results reported in Figure 32 indicate that the intensity of the three bands 
corresponding to the Taq stop sites generated by cisplatin is significantly
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Figure 32. Detection of adducts induced by BBR 3464 and cisplatin in naked 
pSP73 vector after a 2-hour in vitro drug exposure. The sites of 
DNA lesions are indicated as I-III. The corresponding adduct sites 
on the DNA template (as determined from the consensus sequence) 
are underlined.
Cisplatin (pM) BBR 3464 (pM)
T A C G  Ct r  0.01 0.1 0.5 1 2 0.01 0.05 0.1 0.5 1
Full length
3’-AAGC-5
-Figure 32-
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different. Specifically, the signal corresponding to the band I was greater than 
those corresponding to the bands II and II, thus suggesting that the number of 
lesions generated by cisplatin at the 3'-AG-5' dinucleotide on the 3 -AAGC-5' 
(band I) sequence was higher than those produced at 3'-GG-5' dinucleotides on 
3-TGGA-5' (band II) and 3'-CGGT-5' (band III) sequences. Moreover, results 
indicate that cisplatin affinity for the 3'-GG-5' site is greater when such a 
dinucleotide is located in the 3'-CGGT-5' (band III) instead of that in the 3'- 
TGGA-5' (band II) DNA sequence, thus suggesting that the affinity with which 
this drug is able to covalently bind the same target site (for example, the 3'- 
GG-5' dinucleotide) can also be influenced by neighbouring nucleotides.
Superimposable results were detected in BBR 3464-treated samples (Fig. 32) 
with the only difference being that a lack of dose-dependent increase in band 
intensities at sites II and III was found. This phenomenon can be explained by 
a lack of the single-hit kinetics (Hartley and Wyatt, 1997). In fact, as the drug 
concentration increases the percentage of template DNA molecules bearing 
more than one lesion will also increase and Taq polymerase will be blocked at 
the first lesion met (the one closest to the primer). This explanation seems to be 
applicable to the results obtained at the BBR 3464 concentrations of 0.1 and 
0.5 pM. As regards the highest drug dose (1 pM), it is possible to assume that 
the extent of damage on plasmid DNA molecules was sufficient to completely 
inhibit linear PCR reactions, probably by preventing the annealing step 
between Sp6 primer and the template strand of the pSP73 vector (Fig. 32).
Although the Taq stop assay was not intended to quantify DNA adducts, 
results from the sequencing gel shown in Figure 32 clearly indicate that the
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efficiency of BBR 3464 to generate DNA adducts was greater compared than 
that of cisplatin. In fact, by considering the results obtained at concentrations of 
the two platinum-based compounds at which the requirement of single-hit 
kinetics was satisfied, it is possible to observe that in order to generate bands of 
comparable intensity at the three sites, the required cisplatin dose is almost 2 
times higher than that of BBR 3464.
The sequence specificity of DNA lesions produced by the two platinum- 
based anticancer drugs was also evaluated on a more structurally complex 
DNA substrate. To this purpose, genomic DNA isolated from A2780 ovarian 
cancer cells was treated in vitro with different cisplatin and BBR 3464 
concentrations for 2 hours at 37°C in the dark and then subjected to linear PCR 
amplification. Also in this case, drug concentrations were chosen on the basis 
of the results obtained in preliminary experiments carried out to ascertain the 
presence of single-hit kinetics in the system.
In the assay, a 16mer primer, previously labelled with 32P at the 5' termini, 
was used to select, amplify and sequence a particular region of the cellular 
genome named alphoid DNA (a-DNA). The alphoid DNA is a satellite 
sequence that represents approximately 1% of the entire mammalian genome. 
Although this sequence does not play any significant role in controlling cellular 
metabolism, it can be considered an excellent target template for Taq stop 
assays in order to obtain very important information regarding the sequence 
specificity of DNA lesions generated by DNA damaging agents. In fact, in 
each mammalian cell, a-DNA is formed by about 100,000 copies of a 340 bp
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tandemly repeated sequence named a-RI DNA, and it is separable in the 340 
bp fragments by digestion with the EcoRI restriction endonuclease (Fig. 18). 
The sequence of such a DNA repeat is not perfectly homogeneous but contains 
random base substitutions (Fig. 18) which are 7% on average for each 340 bp 
repeat (Murray et al., 1992). However, the high copy number of this 340 bp 
monomer allows the straightforward determination of the sequence specificity 
of DNA damaging agents by Taq stop experiments. In fact, the use of thermal 
cycling to linearly amplify the products associated to the high copy number of 
template molecules dramatically increases the sensitivity of the system.
Data obtained from these Taq stop assays (Fig. 33) are in accord with those 
collected from experiments carried out using plasmid DNA molecules as the 
template. Results obtained from sequencing gel indicate the presence of six 
bands, all of them constituted by DNA molecules shorter than the full-length 
fragment and generated by premature blockage of the Taq polymerase activity, 
due to the presence of drug-induced adducts at 3,-GG-5', 3,-GA-5' and 3 -AG-5' 
dinucleotides. Results also indicate that the electrophoretic pattern obtained 
using naked genomic DNA exposed in vitro to the two drugs is more complex 
than that obtained using in v/Vro-treated plasmid DNA, probably as a 
consequence of the higher structural complexity of the DNA template. In these 
experiments, bands which did not show a clear dose-dependent increase of 
intensity (or in which the lack of such dose-dependent increase was not 
explainable by a lack of single-hit kinetics) as well as bands that in drug- 
treated samples exhibited an intensity comparable to that of untreated control 
sample were not considered as Taq stop sites.
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Figure 33. Detection of adducts induced by BBR 3464 and cisplatin in naked 
genomic DNA after 2-hour in vitro drug exposure. The sites of 
DNA lesions are indicated as I-VI. The corresponding adduct sites 
on the DNA template (as determined from the consensus sequence) 
are underlined and possible base substitutions (Murray et al., 1992) 
are indicated in bold type.
Cisplatin (pM) BBR 3464 (pM)
Full length
144
133
113 —
( £ )  80 —
A C G
Mm
NI 3 -GTTACC-5’ GC GA
3 -TCGGÇGAA‘5 ’ 
T G GG
mmmmi
3 ’-TGTGAGAA-5 
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-Figure 33-
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As already observed in Taq stop experiments carried out on plasmid DNA 
vector, also in this case it was possible to appreciate that the affinity of each 
drug for a specific dinucleotide seems to be influenced by neighbouring 
sequences. However, it is important to stress that the sequence heterogeneity 
among the copies of the 340 bp a-RI monomer has led to variability in the 
sequences which represent potential targets for adduct formation. As a 
consequence, the intensity of a band representing a specific stop site is 
probably the result of the sum of different adducts generated at the same 
position but on separated a-RI molecules. For example, the band 
corresponding to the site VI (Fig. 33) could be formed by molecules 
representing the products of premature Taq stop at different possible sites 
located in the same sequence, such as the 3’-GG-5' dinucleotide in a-RI 
monomers containing the 3,-GGTACC-5' sequence or 3'-AG-5' and 3'-GA-5' 
dinucleotides in a-RI monomers containing, in the same position, the 3'- 
GGTAGA-5' sequence.
Results obtained in these experiments indicate that the DNA damaging 
power of BBR 3464 is stronger than that of cisplatin. In fact, by considering 
the Taq stop site I, it is possible to observe that bands of comparable intensity 
were obtained with cisplatin concentrations (samples 5 and 10 pM) that are 10- 
50-fold greater than those of BBR 3464 (samples 0.1 and 1 pM) (Fig. 33).
The sequence specificity of adducts generated by cisplatin and BBR 3464 
was then investigated under more physiological conditions by assessing the
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position of drug-induced Taq stop sites in the alphoid region of genomic DNA 
isolated after exposure of intact A2780 ovarian cancer cells to different 
concentrations of cisplatin or BBR 3464.
Drug concentrations were chosen on the basis of preliminary experiments 
carried out to verify whether single-hit kinetics were operative in the system.
Results, obtained from the sequencing gel shown in Figure 34, indicated that 
the two platinum-based compounds share almost the same sequence preference 
of adduct formation and that the DNA damaging power of BBR 3464 is greater 
than that of cisplatin. These findings are in accord with those obtained from 
Taq stop experiments carried out with naked plasmid pSP73 vector and 
genomic DNA treated in vitro. Specifically, five bands (I to V) corresponding 
to lesions generated at 3’-GG-5', 3'-GA-5' and 3,-AG-5' dinucleotides by 
cisplatin and BBR 3464 are clearly detectable. Only at site III there is a 
cisplatin-induced adduct which is not present in BBR 3464-treated samples. 
Also in this case, it is important to stress that each band representing a specific 
stop site is probably the result of the sum of different adducts generated at the 
same position but on separated a-RI molecules, as a consequence of the 
sequence heterogeneity among the different 340 bp monomers.
By comparing the results obtained from Taq stop assays carried out on naked 
genomic DNA treated in vitro to those on genomic DNA isolated from drug- 
treated living cells, it was possible to appreciate that some of the stop sites 
were detected in both situations. This finding would indicate that the sequences 
damaged by the two drugs are, at least in part, similar in the two different
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Figure 34. Detection of adducts induced by BBR 3464 and cisplatin in 
genomic DNA isolated after a 2-hour exposure of intact A2780 cells 
to cisplatin and BBR 3464. The sites of DNA lesions are indicated 
as I-V. The corresponding adduct sites on the DNA template (as 
determined from the consensus sequence) are underlined and 
possible base substitutions (Murray et al., 1992) are indicated in 
bold type.
Cisplatin BBR 3464
(pM) (pM)
3 ’ -GTT ACCT CTT ATCC-5 
GC GA CGTA
->-(1111 3’-AAGCQOCT-3 
GG G T
3’-IGAACTTTGIGAGAA-5 
AA TC TC C
-Figure 34-
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experimental environments, although 10 to 60-fold greater drug concentrations 
are needed to produce the same level of DNA damage under in vivo conditions.
4.7 Evaluation of the accumulation and repair of DNA damage induced by 
BBR 3464 and cisplatin at the single-gene level
The kinetics of induction and removal of DNA lesions generated by cisplatin 
and BBR 3464 was measured at a single gene level using the quantitative PCR 
assay. As for the Taq stop assay, also in quantitative PCR the ability of drug- 
induced DNA adducts to halt Taq polymerase activity is exploited. However, 
differently from the Taq stop methodology, the quantitative PCR assay gives 
the possibility to accurately quantify the extent of DNA lesions generated by 
DNA damaging agents in a specific region of the genome. In particular, an 
opportunely selected pair of primers was used in PCR reactions to select and 
exponentially amplify a 523 bp sequence within the Intron I of the N-ras gene 
(Fig. 22). N-ras is an actively transcribed single copy gene which plays a 
relevant role in controlling cell cycle progression and which was already used 
as target substrate in similar studies (Bingham et al., 1996; Koberle et al., 1996 
and 1997; O'Neill et al., 1999).
In order to obtain reliable quantitative information regarding the extent of 
the lesions generated on the cellular genome by DNA damaging agents, some 
fundamental experimental parameters were accurately set up. Specifically, the 
optimal amount of DNA substrate and the appropriate number of PCR cycles 
were defined in preliminary experiments.
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To assess the sensitivity and reproducibility of the quantitative PCR 
technique, experiments were carried out using, as template, naked genomic 
DNA extracted from A2780 ovarian cancer cells and then exposed in vitro to 
various concentrations of cisplatin and BBR 3464 for 2 hours at 37°C in the 
dark. To ensure that amplification reactions were still in the exponential phase 
when stopped, the system was set up as follows. PCR samples containing a 
constant amount (300 ng) of damage-free DNA substrate were subjected to a 
different number of cycles and the amount of the radioactive product was 
quantified. After that the appropriate number of cycles was chosen, DNA 
substrate titration was performed in order to define the appropriate amount of 
DNA template to use in the successive experiments.
Figure 35A shows quantitative PCR results obtained by amplifying 80 ng of 
untreated and drug-treated naked genomic DNA for 26 cycles. Results 
indicated that the extent of signal amplification inhibition and, as a 
consequence, the level of lesions present in the N-ras gene, were dependent on 
drug concentration for both agents and confirmed the higher efficiency of BBR 
3464 in inducing DNA lesions than cisplatin. In fact, the concentration of BBR 
3464 required to induce a 50% amplification inhibition was 14 times lower 
than that of cisplatin (0.013 pM vs 0.183 pM) (Fig. 35B). In addition, it is 
important to stress that the intensity of the band corresponding to the untreated 
control sample containing 80 ng of DNA substrate is almost two-fold higher 
than that of control sample containing 40 ng of DNA template thus indicating 
that PCR was stopped when reactions still were in the exponential range.
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Figure 35. (A) A representative quantitative PCR experiment on naked 
genomic DNA (N-ras) after 1-hour in vitro exposure to cisplatin 
and BBR 3464. Controls: 0, 40 and 80 ng of untreated DNA. (B) 
Quantification of PCR reactions for the N-n%? gene. The ordinate 
shows the relative amplification expressed as percentage of control. 
Values represent the mean (± S.D.) of three independent 
experiments.
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The effect of DNA damage present in the N-ras gene on PCR signal 
amplification was then evaluated in the four ovarian cancer cell lines 
immediately following a 5-hour exposure of intact cells to cisplatin or BBR 
3464 and after an additional 6, 24 or 48 hour in drug-free medium. The 
experiments were carried out with IC50 of cisplatin in all cell lines. In the case 
of BBR 3464, 10 x IC50 was used, since in A2780, A2780cp8, and OAW42Mer 
cells the IC50 values of the trinuclear platinum compound were too low to 
produce a level of DNA damage reliably detectable by the PCR technique. 
Also in this case, preliminary experiments were performed to set up the 
experimental conditions of the system. Figure 36 shows a representative 
experiment of quantitative PCR in which 1,250 cell equivalents of genomic 
DNA isolated from untreated and drug-treated OAW42Mer living cells were 
used as template and subjected to thermal cycling for 26 cycles. Again, it is 
important to stress that the intensity of the band corresponding to the untreated 
control sample containing 1,250 cell equivalents of DNA substrate is almost 
two-fold higher than that of control sample containing 625 cell equivalents of 
DNA template thus indicating that PCRs were stopped when reactions still 
were in the exponential range.
Data obtained from quantitative PCR in OAW42 cells (Fig. 37), evidenced a 
strong inhibition of signal amplification (3.8% of control) at the end of the 5- 
hour exposure to cisplatin (To). The level of inhibition remained almost the 
same 6 and 24 hours from the end of drug treatment (2.9% and 2.5% of control 
at Tô and T 2 4 ,  respectively) whereas at 48 hours the extent of amplification
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Figure 36. A representative example of quantitative PCR analysis on genomic 
DNA (N-ras gene) after a 5-hour drug exposure of OAW42Mer 
cells to I C 5 0  of cisplatin and 10 x I C 5 0  of BBR 3464 and after an 
additional 6, 24 or 48 hours of incubation in drug-free medium. 
Controls: Ct/2 = 625 cell equivalents, Ct = 1,250 cell equivalents.
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Figure 37. Quantification of PCR reactions for the N-ray gene following a 5- 
hour incubation to IC50 of cisplatin @ ) and 10 x IC50 of BBR 3464 
(D) in OAW42, OAW42Mer, A2780 and A2780cp8 cell lines. The 
ordinate shows the relative amplification expressed as percentage of 
control. Values represent the mean (± S.D.) of three independent 
experiments.
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increased to 67% of control, thus indicating that a large number of adducts 
generated by cisplatin in the 523 bp region of N-ras gene Intron I were 
removed. Similar results were obtained after exposure of OAW42 cells to BBR 
3464. Specifically, at the end of drug-treatment (To) amplification was 
dramatically inhibited (3.4% of control) and additional lesions were 
accumulated in the following 6 and 24 hours (To and T2 4 : 1.2% and 1% of 
control, respectively). Differently from what was observed after cisplatin 
exposure, a large number of adducts was not removed after 48 hours of 
recovery in drug-free medium, so that the extent of amplification was 
significantly (p<0.05) lower and limited to 33.5% of control.
Immediately after OAW42Mer cells exposure to cisplatin (To), a strong 
inhibition of the signal amplification (6.2% of control) was observed and the 
accumulation of DNA lesions proceeded up to 6 hours (T^) from drug 
withdrawal (2.8% of control). DNA damage was then partially repaired after 
24 hours ( T 2 4 )  of recovery in drug-free medium (21% of control), and only 
very few adducts were still present after 48 hour from the end of drug-exposure 
(95.8% of control) (Fig. 37). Similar kinetics of DNA adduct accumulation and 
removal was observed after treatment of OAW42Mer cells with BBR 3464. 
Specifically, a large number of DNA lesions was already present at the end of 
drug-treatment (To) and additional adducts were accumulated after 6 hours 
from drug withdrawal (Tg). At these time points, the signal amplification was 
limited to 3.9% and 2% of control, respectively. Removal of DNA lesions was 
already started after 24 hour ( T 2 4 :  38% of control) and almost completed after 
48 hours (T4 8: 96% of control). These data indicate that no significant
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differences between cisplatin-sensitive and -resistant cell lines in the level of 
amplification inhibition or in extent of unrepaired damage are present. After 
drug exposure, some differences were observed only in the kinetics of DNA 
adducts processing after treatment with equitoxic concentrations of cisplatin. 
This was also true for BBR 3464.
As regards the second ovarian cancer cell line pair, in cisplatin-treated 
A2780 cells the maximum inhibition of signal amplification (9.6% of control) 
was found at the end of drug exposure (To) whereas a progressive removal of 
DNA lesions, with a consequent increase in the extent of amplification, was 
detected starting 6  hours after recovery in drug-free medium (To: 2 1 % of 
control) (Fig. 37). Twenty-four hours from the end of treatment ( T 2 4 ) ,  the level 
of amplification reached 58.1% of control and no additional removal of DNA 
adducts was observed in the following 24 hours (T^: 57% of control). In these 
cells a negligible inhibition of signal amplification was observed at the end (To: 
99% of control) and after 6  hours from the end of BBR 3464 exposure (Ta: 
96% of control), thus suggesting slow kinetics of DNA lesion induction. The 
highest level of amplification inhibition was detected 24 hours after drug 
withdrawal ( T 2 4 :  5% of control) and it was almost unmodified in the following 
24 hours (T4 8 : 8 % of control), thus indicating that DNA lesion removal did not 
occur.
After exposure of A2780cp8 cells to cisplatin, a kinetics of accumulation and 
removal of DNA lesion similar to those observed, with the same drug, in 
parental A2780 cells was detected, although in A2780cp8 cells the highest 
inhibition of signal amplification (which indicates the presence of the greatest
234
(4) Results
number of lesions) was detected after 6 hours from the end of drug treatment 
(To: 16% of control; Tg: 9.3 % of control) (Fig. 37). Also in these cells, slow 
kinetics of DNA adduct induction by BBR 3464 was recorded. The maximum 
inhibition of signal amplification was reached 24 hours after drug withdrawal 
(T2 4: 8% of control) although in these cells, which showed a moderate degree 
of resistance to BBR 3464, a slight but significantly (p<0.05) higher increase in 
the level of amplification, with respect to what observed in A2780 cells, was 
appreciable 48 hours after the end of treatment (T^: 23% of control), thus 
indicating a certain ability of these cells to partially remove DNA lesions 
generated by the novel trinuclear platinum complex.
4.8 Analysis of cell cycle perturbations induced by cisplatin and BBR 3464 
in OAW42 and OAW42Mer cell lines
The analysis of the effects induced by BBR 3464 and cisplatin on cell cycle 
progression of OAW42 and OAW42Mer cells was carried out by flow 
cytometry with the aim being to determine whether cell cycle perturbations 
could be responsible, at least in part, for the different pattern of drug sensitivity 
observed in the two cell lines. Cells were exposed to the I C 5 0  concentration of 
BBR 3464 (5.2 pM and 0.36 pM for OAW42 and OAW42Mer cells, 
respectively) and cisplatin (8.3 pM and 83 pM for OAW42 and OAW42Mer 
cells, respectively) for 1 hour, and their cell cycle distribution profiles were 
assessed at different intervals, (24, 48 and 72 hours) after drug withdrawal 
(Tab. XII).
235
Table XII. Cell cycle perturbation induced by cisplatin and BBR 3464. Data 
represent mean values ± SD of three independent experiments.
1 Calculated from the end of a 1-hour treatment.
2 Specific I C 5 0  concentration.
3 P < 0.05, Student’s t-test, compared to controls.
&1
C/D
00
O
$
C / D
S
o
!
C/D
O
+ 1
m
+j
CN
I
S
S
CN
g
+1
m
s
+ î
< s
:
m
o
S
+1
I
a
S
sm
ti
U
5
m
S
I
S
S
Sir>
S
3
CN
$
S
9
m
m
4-1
m
CN
44
m
I
m
44
mun
y
44
m
m
Sun
J3
&
9
3
m
I
S
m
§
3Tf
I
S
3
CN
!
3
■*t
m
i
s
44un
m
S
3
m
S
CN
S
CN
3
m
J5
»
U
-T
ab
le 
X
II
-
(4) Results
In OAW42 cells, cisplatin induced a transient accumulation of cells in the S 
phase, appreciable 24 hours after the end of treatment, which was followed by 
a stable increase in the G2M cell fraction, still present after 72 hours. As 
regards BBR 3464, after exposure to the trinuclear platinum complex OAW42 
cells were stably blocked in the G2M compartment until 72 hours. In 
OAW42Mer cells, exposure to cisplatin induced an accumulation of cells in the 
S phase at 24 hours followed by an increase in the G2M cell fraction, which 
was almost completely resolved at 72 hours. In this cell line, BBR 3464 caused 
a persistent accumulation of cells in the G2M phase, although less pronounced 
than that observed in OAW42 cells.
4.9 Evaluation of the effects induced by cisplatin and BBR 3464 on 
proteins involved in G2 to M transition regulation
Since cisplatin and BBR 3464 mainly induced alterations in cell progression 
throughout the G2M phase, the effect of drug treatment on the expression of 
cdkl and cyclin B1 proteins, key regulators of the G2 checkpoint, was 
determined (Fig. 38). To this purpose, OAW42 and OAW42Mer cells were 
exposed to the IC50 concentrations of cisplatin and BBR 3464 for 1 hour. 
Protein expression was then assessed by western blotting at 24, 48 and 72 
hours after drug withdrawal and quantified by densitometric analysis of the 
autoradiographic films. Only differences in band intensities greater than 25% 
with respect to control were considered significant.
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Figure 38. Effect of BBR 3464 and cisplatin on the expression of proteins 
involved in the control of G2 checkpoint in OAW42 and 
OAW42Mer cells. Cells were incubated with solvent (control, lane 
1) or with the IC50 concentration of BBR 3464 (lane 2) or cisplatin 
(lane 3) for 1 hour. At the end of treatment the cells were incubated 
for an additional 24, 48 and 72 hours in drug-free medium. Western 
blots, performed as described in Materials and Methods, were 
probed with antibodies for cdkl and cyclin Bl. The densitometric 
values of band intensities are indicated above the corresponding 
blots and represent the mean values ± SD of 3 independent 
experiments.
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In OAW42 cells, BBR 3464 and cisplatin induced a marked increase in 
cyclin Bl expression that was highest 24 hour after treatment and still present, 
although to a lesser extent, at 72 hour (Fig. 38). No appreciable difference with 
respect to controls was found in cdkl protein expression. Comparable findings 
were observed in OAW42Mer cells (Fig. 38)
The kinase activity of cyclin Bl-associated cdkl on the substrate histone HI 
was also measured after drug treatment in both cell lines (Fig. 39). When the 
results were expressed in terms of kinase activity value divided by the number 
of GiM cells (as detected by flow cytometry), we found that OAW42 cells 
accumulating in GzM phase after cisplatin exposure showed a cdkl catalytic 
activity consistently lower than that of control cells at all time points 
considered. In OAW42 cells exposed to BBR 3464, an unexpected and marked 
increase in cdkl kinase activity was observed 24 hours after treatment, then the 
enzyme catalytic activity dropped to values lower than those observed in 
control cells. As regards the OAW42Mer cell line, cisplatin and BBR 3464- 
treated cells were characterised by levels of cdkl kinase activity comparable to 
those of controls until 48 hours after treatment, whereas a marked increase in 
enzyme catalytic activity was observed at 72 hours in cells exposed to either 
drug (Fig. 39).
4.10 Evaluation of apoptosis induction by BBR 3464 and cisplatin
Activation of the programmed cell death pathway in cisplatin- and BBR 
3464-treated OAW42 and OAW42Mer cells was determined by considering
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Figure 39. Effect of BBR 3464 and cisplatin on cyclin Bl/cdkl kinase activity 
in OAW42 and OAW42Mer cells. Cells were incubated with 
solvent or with the IC50 concentration of BBR 3464 or cisplatin for 
1 hour. At the end of the treatment, cells were incubated for an 
additional 24, 48 and 72 hours in drug-free medium.
Immunoprécipitation and kinase assay were performed as described 
in Materials and Methods. Following autoradiography, reactions 
were quantified by densitometry; for each sample the results 
obtained at 24 (□  ), 48 (B  ) and 72 hours (■ ) were expressed in 
terms of kinase activity [arbitrary densitometric units (a.d.u.)] 
divided by the number of cells in the G2M phase as assessed by 
flow cytometry.
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different end points. Cells were exposed to the IC50 concentrations of cisplatin 
and BBR 3464 for 1 hour, and the ability of the drugs to induce apoptosis was 
assessed 48 and 72 hours from the end of treatment.
The percentage of cells with an apoptotic nuclear morphology in drug- 
treated samples was initially determined by fluorescence microscopy after 
staining of cells with propidium iodide and calculated on the total cell 
population (Fig. 40). Spontaneous apoptosis was observed in a negligible 
fraction (<0.1 %) of OAW42 control cells. Drug treatment induced a time- 
dependent increase in the percentage of OAW42 cells with an apoptotic 
morphology. This effect was slightly more pronounced for cisplatin (14-18%) 
than for BBR 3464 (3-12%). In untreated OAW42Mer cells spontaneous 
apoptosis was seen in about 1% of the overall cell population. This percentage 
increased after exposure of cells to cisplatin (7-9 %) or BBR 3464 (8-14 %).
Successively, the presence of DNA oligonucleosomal fragments in drug- 
treated samples was assessed by conventional DNA gel electrophoresis. 
Results of gel electrophoresis experiments carried out on DNA obtained from 
OAW42Mer cells showed the accumulation of oligonucleosome fragments 48 
hours and 72 hours after treatment with cisplatin or BBR 3464 (Fig. 41). 
Similar results were also obtained in OAW42 cells.
Degradation of nuclear lamin B, a specific substrate for terminal caspases, 
was also investigated by western blotting in drug-treated cells. Degradation of 
lamin B, as demonstrated by the appearance of a 45 KDa cleavage product and 
a concomitant decrease in the full-length protein level, was detected in OAW42
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Figure 40. Induction of apoptosis by BBR 3464 and cisplatin in OAW42 and 
OAW42Mer cells. After a 1-hour treatment with solvent (control) or 
with the IC50 concentration of BBR 3464 or cisplatin, samples were 
incubated in drug-free medium and harvested after 48 (g  ) and 72 
hours ( □  ). The cells were then stained with propidium iodide as 
described in Materials and Methods and the slides were examined 
by fluorescence microscopy. The percentage of apoptotic cells with 
respect to the total cell number was determined by scoring at least 
200 cells in each sample. Data are means ± SD of three independent 
experiments.
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Figure 41. Electrophoretic pattern of DNA extracted from OAW42Mer 
floating cells. After a 1-hour treatment with solvent (control) or 
with the IC50 concentration of BBR 3464 or cisplatin, cells were 
incubated in drug-free medium and harvested after 48 and 72 hours.
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-Figure 41-
(4) Results
cells after exposure to cisplatin or BBR 3464. Conversely, in OAW42Mer cells 
lamin B cleavage was only detectable after BBR 3464 treatment (Fig. 42).
Since the disruption of mitochondrial membrane potential (Av|/mt ) has been 
linked to the induction of apoptosis by different stimuli, we investigated 
whether the Av|/mt was altered by cisplatin or BBR 3464 treatment in the two 
cell lines. For this purpose control and drug-treated cells were stained with the 
Av|/mt -sensitive dye JC-1. At relatively high Av|/mt, the dye forms JC1- 
aggregates, which emit at 590 run in the orange range of visible light. 
Conversely, in the absence of or at low Ax|/mt, JC-1 exists as a monomer, 
remaining in the cell but emitting at 527 nm in the green range. Representative 
flow cytometric data, in which fluorescence at 590 nm is plotted against 
fluorescence at 527 nm, are shown in Figures 43 and 44. In untreated cells JC-1 
exists predominantly in a highly aggregated form indicated by intense 
fluorescence emission at 590 nm. Conversely, in cells exposed to valinomycin, 
a K+ ionophore that uncouples oxidative phosphorylation, JC-1 was largely 
present in its monomeric state, thus indicating a low Av|/mt. As regards drug 
treatment, cisplatin and BBR 3464 induced negligible decreases in Av|/mt of 
OAW42 cells (Fig. 43B). Conversely, in OAW42Mer cells cisplatin had almost 
no effect on Avj/mt whereas after treatment of cells with BBR 3464 the Avj/mt was 
markedly diminished, as demonstrated by the 29% reduction of cells positive 
for JC1-aggregates (Fig. 44B).
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Figure 42. Degradation of lamin B induced by BBR 3464 or cisplatin in 
OAW42 and OAW42Mer cells. After a 1-hour treatment with the 
IC50 concentration of BBR 3464 or cisplatin, cells were incubated in 
drug-free medium and harvested after 48 and 72 hours. Western 
blotting was performed as described in Materials and Methods. The 
numbers on the left correspond to the migration position of protein 
markers. Lamin B-specific cleavage product bands are indicated on 
the right. Lanes: 1= untreated control sample; 2= BBR 3464-treated 
sample; 3= Cisplatin-treated sample. The blot of OAW42Mer cells 
has been overexposed to evidence the cleavage product.
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Figure 43.. Effect of BBR 3464 and cisplatin on the Av|/mt in OAW42 cells.
After a 1-hour treatment with IC50 concentration of BBR 3464 or 
cisplatin, cells were incubated in drug-free medium, stained with 
JC-1 and analysed by flow cytometry as described in Materials and 
Methods. At relatively high A\j/mt, JC-1 forms J-aggregates, which 
emit at 590 nm within the orange range of visible light. In contrast, 
in the absence of or at low A\j/mt) JC-1 exists as a monomer, emitting 
at 527 nm in the green range. Cells treated for 30 min at 37°C prior 
to JC-1 addition with 5 pM valinomycin were used as positive 
control for Av|/mt disruption. (A) Representative examples of the 
fluorescence pattern of cells incubated with the solvent (control) or 
with BBR 3464 or cisplatin. (B) Percentage of cells staining 
positive for J-aggregate formation (emitting at 590 nm) in untreated 
(control) and in BBR 3464 or cisplatin-treated cell populations. 
Data are means ± SD of three independent experiments.
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Figure 44.. Effect of BBR 3464 and cisplatin on the Av|/mtin OAW42Mer cells.
(A) Representative examples of the fluorescence pattern of cells 
incubated with the solvent (control) or with BBR 3464 or cisplatin.
(B) Percentage of cells staining positive for J-aggregate formation 
(emitting at 590 nm) in untreated (control) and BBR 3464 or 
cisplatin-treated cell populations. Data are means ± SD of three 
independent experiments.
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4.11 Evaluation of the effects induced by BBR 3464 and cisplatin on the 
expression of proteins involved in the control of apoptosis
Finally, the expression of proteins involved in the control of programmed 
cell death was assessed by western blotting analysis in OAW42 and 
OAW42Mer cells at different intervals (48 and 72 hours) after a 1-hour 
exposure to the IC50 concentration of cisplatin or BBR 3464 (Fig. 45). In 
OAW42 cells an increase in p53 protein expression and a consequent 
transactivation of p21 WAF1/CIP1 were observed after exposure to cisplatin or 
BBR 3464. In the OAW42Mer cell line p53 expression was also slightly 
increased after drug treatment, whereas the p21WAF1/CIP1 signal remained 
undetectable. Moreover, drug treatment did not significantly modify bax 
expression in the two cell lines. As regards bcl-2, a slight reduction in protein 
levels was appreciable 72 hours after cisplatin exposure in the OAW42 cell 
line.
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Figure 45. Effect of BBR 3464 and cisplatin on the expression of proteins 
involved in the control of apoptosis in OAW42 and OAW42Mer 
cells. Cells were incubated with solvent (control) or with the IC50 
concentration of cisplatin or BBR 3464 for 1 hour. At the end of the 
treatment the cells were incubated for an additional 48 and 72 
hours in drug-free medium. Western blots, performed as described 
in Materials and Methods, were probed with antibodies for p53, bcl- 
2, bax, and p21wafl. Anti-tubulin a  monoclonal antibody was used to 
ensure equal loading of protein on the gel. Lanes: 1= untreated 
control sample; 2= BBR 3464-treated sample; 3= Cisplatin-treated 
sample.
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Cisplatin is one of the most effective drugs for the treatment of a wide 
spectrum of human solid tumours. However, its clinical therapeutic efficacy is 
limited by the emergence of tumour cell subpopulations with intrinsic or 
treatment-induced resistance to the compound. Much effort has been dedicated 
to the development of new platinum-based molecules in order to overcome 
such resistance. Several mononuclear platinum compounds have been 
developed for this purpose (Kelland et al., 1992; Farrell, 1996), most of them 
showing a certain degree of cross-resistance to cisplatin as a consequence of 
the similarity in structure and molecular mechanism of action.
Multinuclear platinum compounds represent a different approach to 
circumvent cellular resistance to cisplatin in that they are endowed with a 
different DNA-binding profile compared to their mononuclear counterparts 
(Perego et al., 1999). BBR 3464 has been identified as the most active member 
of this class of compounds. The drug is more potent than cisplatin (Brabec et 
al., 1999) and is active in cisplatin-resistant experimental human tumour 
models (Pratesi et al., 1997; Manzotti et al.,2000). However, the cellular 
determinants responsible for BBR 3464 activity are largely unknown. 
Moreover, the relevance of factors contributing to cisplatin resistance, such as 
decreased drug accumulation (Loh et al., 1992; Mistry et al., 1992), increased 
detoxification (Fram et al., 1990; Mistry et al., 1991; Kasahara et al., 1991) and 
increased DNA repair and tolerance to DNA damage (Eastman and Schulte, 
1988; Kelland et al., 1992b; Johnson et al., 1997; Hill et al., 1990; Behrens et 
al., 1987), in determining the cellular sensitivity profile to BBR 3464 needs to 
be established.
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The ability of BBR 3464 to induce peculiar platinum-DNA adducts (such as 
Tong-distance’ intra- and inter-strand cross-links (Farrell et al., 1995) which 
are not produced by conventional mononuclear platinum compounds suggests 
that BBR 3464 may escape, at least in part, the classical mechanisms of 
cisplatin resistance related to DNA damage recognition and repair (Yamada et 
al., 1997; Parker et al., 1991). Moreover, due to its ability to modify DNA in a 
way which is different from that of cisplatin, BBR 3464 could differently 
evoke pathways of cellular response to DNA damage such as triggering of the 
apoptotic pathway, as a function of the genetic background of the tumour 
model. In fact, it has recently been demonstrated that, unlike cisplatin which 
generally is less active against tumour models carrying a mutated p53 gene, 
BBR 3464 displays high activity in human tumour cell lines and xenografts 
characterised by mutant p53 (Pratesi et al., 1999), probably as a consequence 
of its ability to induce p53-independent programmed cell death.
In this study we focused on the cellular basis of the cytotoxic activity of 
BBR 3464 in human ovarian cancer cell lines sensitive to cisplatin and in their 
corresponding sublines selected in vitro for resistance to this agent. One of the 
cisplatin-resistant cell lines, OAW42Mer, showed a marked collateral 
sensitivity to BBR 3464 (being 14 times more sensitive to this agent than 
parental OAW42), whereas the second cisplatin-resistant cell line, A2780cp8, 
was characterised by a low degree of cross-resistance to BBR 3464.
It is well known that the status of DNA repair systems can be important in 
determining cellular response to alkylating agents and cisplatin (Aebi et al., 
1996; Anthoney et al., 1996; Colella et al., 1999; Branch et al., 1993; Brown et
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al., 1997; Drummond et al., 1996). Specifically, by removing DNA lesions, 
NER contributes to cellular resistance whereas MMR, by recognising the 
damage and generating apoptotic signals, contributes to the sensitivity of cells 
to the DNA damaging agent (Yamada et al., 1997). It has been reported that 
many cisplatin-resistant cell lines have a defective MMR system and present 
microsatellite instability (Fink et al., 1996; Aebi et al., 1996; Colella et al., 
1999; Codegoni et al., 2000). Although mutations in several MMR genes have 
been found to be associated to the increased resistance observed in cancer cell 
lines to a variety of chemotherapeutic agents including cisplatin and 
carboplatin (Fink et al., 1998), several lines of evidence suggest a predominant 
role for hMLHl in the acquisition of drug resistance in ovarian tumours. 
Specifically, an increased frequency of loss of hMLHl expression has been 
observed in post-chemotherapy tumours compared to pre-chemotherapy 
samples (Brown et al., 1997). In addition, almost all of the cisplatin-resistant 
sublines derived from the A2780 ovarian cancer cell line showed a complete 
loss of hMLHl protein expression. These resistant cells lack hMLHl 
expression because of méthylation of the hMLHl gene promoter (Strathdee et 
al., 1999). To explain such a finding, it is possible to hypothesise that the 
A2780 cell population from which the resistant cell lines were derived contain 
a small subpopulation of cells with méthylation of both alleles of hMLHl gene, 
and that this MMR-deficient subpopulation is selected in vitro during exposure 
to cisplatin. This hypothesis is supported by findings that indicate the hMLHl 
promoter as particularly susceptible to hypermethylation (Strathdee et al., 
1999).
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As for other cell lines (for example, the HCT-116 colon cancer cells), in 
which the lack of the expression of the hMLHl protein was due to a 
hemizygous mutationin hMLHl gene resulting in a truncated protein (Parson et 
al., 1993; Boyer et al., 1995), also in cisplatin-resistant A2780 cell line 
derivatives, re-expression of hMLHl protein can be achieved by chromosome 
3 transfer (Koi et al., 1994). Moreover, since in the cisplatin-resistant A2780 
cell line derivatives the lack of hMLHl expression is due to methylation- 
mediated gene silencing, there is the additional possibility to re-express 
hMLHl by treatment with the demethylating agent 5-Azacytidine, a known 
inhibitor of the human DNA methyltransferase enzyme (Plumb et al., 2000). In 
preclinical studies carried out in human cancer cell lines and xenografts that are 
hMLHl negative because of gene promoter hypermethylation, the treatment 
with non-toxic doses of 5-Azacytidine and DAC (2'-deoxy-5azacytidine) was 
found to be able to induce hMLHl re-expression (Plumb et al., 2000). 
Moreover, it has been shown that DAC treatment sensitises drug-resistant 
human tumour xenografts to a number of clinically important cytotoxic drugs, 
thus raising the possibility that drug resistance mediated by méthylation of 
hMLHl could be overcome clinically.
Analysis of the MMR status in our cellular models evidenced that cisplatin- 
resistant cell lines OAW42Mer and A2780cp8 were characterised by 
deficiency in hMLHl and hPMS2 proteins and showed microsatellite 
instability at a substantial number of loci. However, the lack of cross-resistance 
of OAW42Mer to BBR 3464 suggests that the cytotoxic activity of the 
trinuclear platinum compound is not dependent on the integrity of MMR. This
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hypothesis is corroborated by previous findings of Perego et al. (1999), who 
showed that the absence of the hMLHl protein in the colon cancer cell line 
HCT-116 or the hPMS2 protein in the osteogenic sarcoma cell line U20S/Pt 
did not confer resistance to BBR 3464. The hypothesis is also in trend with 
data we obtained with the A2780d cell clone. In fact, A2780d cells, which were 
selected in culture from parental A2780 cells without drug exposure and are 
characterised by a defective MMR and microsatellite instability due to the lack 
of hMLHl expression, show a moderate degree of resistance to cisplatin but 
maintain the same sensitivity to the trinuclear platinum compound when 
compared to the parental A2780 cell line.
A possible explanation for the selection of this MMR-defective cell clone is 
that the original population of parental A2780 cells was not homogeneous but 
contained a small population of cells in which lack of hMLHl expression 
occurred by spontaneous gene-silencing through hypermethylation of the 
promoter of both alleles of hMLHl. It is possible that with respect to the 
mechanisms of selection proposed by Strathdee et al. (1999), in this specific 
case, the selective pressure for the MMR defective subpopulation selection 
could be represented by a long-time period of cell growth in culture flask. In 
fact, it is well known that cells defective for the MMR pathway are 
characterised not only by a reduced sensitivity to DNA damaging agents but 
also by a mutator phenotype which can confer to the cells some growth 
advantages.
As regards the NER pathway, an inverse correlation between intracellular 
levels of ERCC1 and cisplatin sensitivity has been reported. Specifically, low
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levels of the protein appear to be responsible for cellular hypersensitivity to the 
drug whereas an increased expression can generate a modest degree of 
resistance to cisplatin (Yu et al., 1998; Damia et al., 1996). In our models we 
observed an increase in ERCC1 levels in the OAW42Mer cells whereas in the 
A2780cp8 cells ERCC1 levels were not different from those of the parental cell 
line. However, the high level of ERCC1 in both A2780 and A2780cp8 is 
comparable to that in OAW42Mer and 3-fold higher than the level in OAW42. 
In each cell line the overall NER activity might represent the sum of the 
activities of the different enzymes involved. Among these, ERCC1 seems to 
play an important role in this pathway since it is responsible for the incision 
step and acts upstream of the other enzymes such as DNA polymerases. In fact, 
it has been reported that in Chinese hamster ovarian cells overexpression of 
ERCC1 may enhance the sensitivity to alkylating agents because a greater 
number of DNA lesions are induced than the other enzymes involved in the 
pathway can repair (Bramson and Panasci, 1993). Moreover, Yu et al. (1998) 
reported that the ratio between a full-length active form of ERCC1 mRNA and 
a shorter inactive form derived from alternative splicing is associated with the 
cisplatin sensitivity/resistance profile. Overall, these findings could partially 
explain why among our cell lines those with a high level of ERCC1 
(OAW42Mer, A2780 and A2780cp8) are more sensitive to BBR 3464 than the 
OAW42 cells, which express less protein. In fact, it is possible to speculate that 
in cells overexpressing ERCC1 the particular bulky DNA lesions generated by 
the trinuclear platinum compound are not completely processed by the NER 
pathway probably because they are able to induce ERCC1 to make more
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incisions than the remaining NER enzymes are able to repair. To better 
evaluate the importance of cellular ERCC1 levels in determining cellular 
sensitivity to BBR 3464, additional experiments will be performed. For 
example, possible variations in cellular sensitivity to BBR 3464 will be 
determined after transfection of OAW42 cells with the human ERCC1 cDNA 
as well as with antisense constructs directed against the endogenous ERCC1 
mRNA.
In an attempt to characterise the mechanisms responsible for the peculiar 
cytotoxicity profile of BBR 3464 observed in our cell models with respect to 
that of cisplatin, the cellular uptake of the drugs as well as the extent and type 
of interactions with DNA were determined. Results from atomic absorption 
spectrometry and mass spectroscopy experiments indicated that, while after 
exposure to cisplatin the intracellular accumulation of the drug and DNA 
platination levels are lower in the two cisplatin-resistant cell lines (OAW42Mer 
and A2780cp8) compared to the sensitive parental counterparts, after treatment 
with BBR 3464 consistent differences were not observed in the different cell 
lines independently of their sensitivity profile to this compound. It is important 
to stress that drug uptake experiments are only able to detect possible 
differences in the drug influx/efflux rates between resistant and sensitive cell 
lines. In fact, since the amount of platinum atoms present in the cells or bound 
to genomic DNA was measured immediately after a 1-hour drug exposure, the 
results are not influenced by a different activity of cellular detoxification 
systems or by different ability of cellular DNA repair pathways to remove 
DNA adducts generated by the two platinum-based compounds in the different
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cell lines. Overall, our intracellular drug accumulation and DNA platination 
results did not explain the different sensitivity profile we obtained in the four 
experimental models. However, in accordance with results obtained in a 
previous study (Perego et al., 1999), our data indicated that intracellular 
accumulation and DNA binding are much higher for BBR 3464 than for 
cisplatin This finding is consistent with an increased affinity of BBR 3464 to 
DNA, due to the presence of two reactive platinum centres in the molecule and 
to the high positive charge (+4) that could contribute to drug interaction with 
DNA through electrostatic and hydrogen binding.
The sequence specificity of DNA damage caused by BBR 3464 and cisplatin 
was then mapped by a Taq stop assay in genomic DNA of ovarian cancer cells 
and the repetitive alphoid DNA was used as the target DNA. The sites of BBR 
3464 adducts were almost identical to the sites of cisplatin adducts and were 
consistent with the motifs GG, AG or GA. A BBR 3464 sequence preference 
for d(GG) or d(G) sites previously was observed in the pSP73 plasmid (Brabec 
et al., 1999). Moreover, when a comparison was made between adduct 
formation in naked genomic DNA treated with drugs in vitro and in genomic 
DNA isolated after drug treatment of intact cells, a similar sequence-specific 
position of the damage was observed in both systems. However, a higher 
overall reactivity of BBR 3464 as compared to cisplatin was observed.
Gene-specific repair of lesions induced by BBR 3464 and cisplatin in the N- 
ras gene was then analysed in all cell lines by quantitative PGR. In the cell line 
pair OAW42 and OAW42Mer different lesion accumulation and removal 
kinetics were observed after drug treatment, whereas superimposable results
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were obtained for BBR 3464 and cisplatin within each cell line. Moreover, the 
maximum number of lesions accumulated as well as the extent of DNA 
damage repaired after treatment with the two drugs was similar in the two cell 
lines and did not explain the different cytotoxicity profiles observed. In A2780 
and A2780cp8 cells the extent and the kinetics of induction and repair of 
cisplatin lesions were similar. As regards BBR 3464, the results obtained in 
both cell lines showed an almost negligible accumulation of DNA lesions until 
6 hours after drug withdrawal, thus suggesting a very slow conversion of 
monoadducts to biftmctional adducts after treatment of these cell lines with the 
trinuclear platinum complex. In fact, although theoretically Taq DNA 
polymerase is affected by each kind of adduct, the PCR stop assay is expected 
to reflect mainly biftmctional adducts and in particular intrastrand cross-links 
which represent the majority of drug adducts for cisplatin (Bubley et al., 1994; 
Murray et al., 1992) and probably for BBR 3464 as well (Brabec et al., 1999). 
Moreover, a lack of substantial conversion of BBR 3464 monoadducts to 
biftmctional adducts (in this case interstrand cross-links) up to 5 hours from the 
end of treatment was observed previously (Perego et al., 1999) in a pair of 
human osteosarcoma cell lines sensitive and with experimentally induced 
resistance to cisplatin. In A2780cp8 cells, which showed a moderate degree of 
resistance to BBR 3464, a higher degree of repaired DNA damage was 
observed after BBR 3464 exposure compared to A2780-sensitive cells.
Overall, these results suggest that the peculiar cytotoxicity profile of BBR 
3464 probably is sustained by its ability to modify DNA in a way which is 
different from that of cisplatin. In fact, it has been demonstrated that antibodies
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raised to cisplatin-adducted DNA did not recognise DNA modified by BBR 
3464 (Brabec et al., 1999). However, since the different sensitivity to cisplatin 
and BBR 3464 observed in our cellular models might also be attributable to a 
different ability to activate other pathways of cellular response to DNA damage 
as a function of the genetic background of the tumour model, we decided to 
comparatively evaluate in our ovarian cancer cell lines the effects of cisplatin 
and BBR 3464 in terms of interference with cell cycle progression and 
induction of apoptosis.
As regards drug effects on cell cycle progression, a 1-hour treatment with the 
IC50 cisplatin concentration induced an early increase in the S-phase cell 
fraction that was followed by accumulation of cells in the G2M compartment, 
whereas BBR 3464 (IC50) caused a persistent arrest of cells in the G2M phase. 
Similar, although less pronounced perturbations, were observed in OAW42Mer 
cells after drug exposure.
We investigated whether differences in cell cycle perturbation could be 
ascribed to differences in expression of proteins involved in control of the G2 
checkpoint. Since the major regulator of G2 to M transition is the M phase- 
promoting factor (MPF), a complex constituted of the catalytic subunit cdkl 
and of the regulatory subunit cyclin B1 (Lewin, 1990), we focused our 
attention on the expression level of the two proteins and also evaluated the 
effect of drug treatment on the cyclin B1-associated cdkl kinase activity using 
histone HI as a substrate. When kinase activity was expressed as a function of 
the number of cells in the G2M compartment (i.e., the cells that, together with 
late S-phase cells, mainly account for this specific kinase activity), we found
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that OAW42 cells accumulating in the G2M phase after exposure to cisplatin or 
BBR 3464 generally showed a reduced ability to phosphorylate histone HI 
with respect to untreated control cells. This observation is in agreement with 
previous findings obtained after cisplatin treatment in other experimental 
tumour models (Nishio et al., 1993). The only exception was a marked increase 
in cyclin B 1 -associated kinase activity found in cells accumulated in the G2M 
phase 24 hours after treatment with BBR 3464. This increase could be. 
sustained by the high level of cyclin B 1 induced by treatment at this time point, 
which could allow increased formation of the cyclin Bl-cdkl active complex.
In OAW42Mer cells accumulating in G2M after exposure to cisplatin or 
BBR 3464 the cyclin B1-associated kinase activities were almost 
superimposable to those of control cells until 48 hours after treatment. The 
inability of treated cells to escape the G2 block could be explained by assuming 
that the active cyclin Bl-cdkl complexes are confined to the cytoplasmic 
compartment. In fact, it has previously been demonstrated that exclusion of 
cdkl kinase activity from the nucleus may contribute to the cell cycle delay 
occurring after irradiation in HeLa-Sl cells (Kao et al., 1999). An increased 
kinase activity was observed at later intervals (72 hours) after cisplatin or BBR 
3464 in correspondence with the resolution of G2M blocks.
Since apoptosis is a major mode of cell death induced by several DNA 
damaging agents (Hickman, 1992), we evaluated the induction of apoptosis 
after exposure of OAW42 and OAW42Mer cells to cisplatin or BBR 3464. 
Fluorescence microscopy analysis indicated the presence of cells with an 
apoptotic nuclear morphology in both cell lines after treatment with either
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drug. The occurrence of apoptosis was also confirmed by the presence of DNA 
fragmentation in both cell lines. Although the percentage of apoptotic cells was 
generally modest, there was a trend towards a correlation between cell 
sensitivity to a specific drug and apoptotic response. Specifically, the parental 
OAW42 cells (which are sensitive to cisplatin) showed a slightly higher 
percentage of apoptotic cells after treatment with cisplatin than they did 
following treatment with BBR 3464, whereas in OAW42Mer cells (which are 
sensitive to BBR 3464) an inverse pattern was observed.
At the molecular level we investigated the effects of drug treatment on the 
expression of proteins involved in the control of apoptosis such as p53 
(Liebermann et al., 1995) and some of the major downstream genes controlled 
by p53 including p2 l WAFIZC,P1, bax and bcl-2 (el-Deiiy, 1998). In the OAW42 
cell line exposure to cisplatin or BBR 3464 caused a marked increase in p53 
expression and a consequent transactivation of p2 l WAF1/cn>1. Moreover, no 
variation in the levels of bax and bcl- 2  expression was observed after drug 
treatment. It is important to stress that both OAW42 and OAW42Mer cell lines 
are characterised by wild-type p53 gene as determined by DNA sequencing 
analysis. However, whereas in OAW42 cells, p53 was found to be able to 
transactivate downstream genes such as p2 1  WAF1/Cn>1 as well as to induce a 
block of cells in Gi phase after exposure to y-radiation, these findings were not 
observed in OAW42Mer cell line. As previously reported by other 
investigators (Perego et al., 1997), it is possible that the lack of functional 
activity of the wild-type p53 protein observed in OAW42Mer cells is due to its 
stabilisation and compartmentalisatipn in the cytoplasm as a consequence of
253
(5) Discussion
the interaction with other proteins such as Mdm2. Such an hypothesis shows 
also the possibility to explain the high basal level of p53 detected by western 
blot analysis in OAW42Mer cells.
Overall, our findings indicate that the presence of a wild-type and functional 
p53 protein that allows cells to undergo p53-dependent apoptosis is an 
important determinant of tumour cell sensitivity to cisplatin, as already 
demonstrated in experimental and clinical studies (Righetti et al., 1996; 
Sugimoto et al., 1999; Jones et al., 1998). Conversely, the presence of an 
apparently non-functional p53 protein, as indicated by the lack of p21 WAF1/CIP1 
induction in OAW42Mer cells, is not detrimental for the susceptibility of cells 
to BBR 3464. This observation is in agreement with previous findings of 
Pratesi et al. (1999), who demonstrated superior activity of the trinuclear 
platinum complex against p53-mutant human tumour xenografts as compared 
to those carrying the wild-type gene. These authors also showed that the 
transfer of functional p53 in a p53-null human osteosarcoma cell line resulted 
in a marked reduction of cellular sensitivity to BBR 3464. The efficacy of the 
trinuclear platinum complex in tumour cells with mutant or non-functional p5 3  
protein suggests that the drug is able to induce a p53-independent response 
through the induction of specific DNA lesions. However, since in OAW42Mer 
cells the apoptotic response to BBR 3464 is quite modest, the efficacy of the 
trinuclear platinum complex could also be due to the induction of a persistent 
cytostatic effect resulting from the inability of cells to recognise and repair 
drug-induced DNA lesions.
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There is increasing evidence for a major role of mitochondria in the 
apoptotic process. In fact, it has been demonstrated that apoptosis-inducing 
stimuli can trigger uncoupling of electron transport from ATP production, 
leading to a decrease in the Av|/mt and a corresponding production of reactive 
oxygen species that are responsible for the oxidative degradation of 
mitochondrial components (Zamzami et al., 1995). The occurrence of 
mitochondrial changes during the apoptotic process induced by cisplatin in 
sensitive HeLa cells has recently been reported (Melendez-Zajgla et al., 1999). 
Moreover, a more general role of mitochondrial damage in determining the 
cytotoxic activity of this compound has previously been proposed by Zhang et 
al. (1994), who reported that the toxic activity of cisplatin in renal cortical 
slices was related to a rapid loss of mitochondrial protein-SH followed by a 
substantial decrease in Ca2+ uptake and a decline in mitochondrial membrane 
potential. We found that in OAW42 cells cisplatin and BBR 3464 did not 
appreciably affect the Ax|/mt. Conversely, in 0AW42Mer cells a marked 
decrease in A\|/mt was only evident after exposure to BBR 3464, which indicates 
the impairment of mitochondrial membrane function as a possible determinant 
of the chemosensitivity to the trinuclear platinum complex observed in this cell 
line.
Disruption of mitochondrial membrane function also leads to the release of 
protease activators (Kluck et al., 1997). In particular, the release of cytochrome 
C from the mitochondria into the cytoplasm may play a central role in the 
activation of the executioner phase of apoptosis through its participation in the 
proteolytic activation of caspases (Matsuyama et al., 2000). To investigate
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whether different executioners of apoptosis are involved in the pathways of 
programmed cell death induced by the two drugs in the same cellular models, 
we assessed the expression of lamin B, a well-known caspase substrate, in 
drug-treated cells. In fact, proteolysis of lamin A and B has been reported to 
occur during apoptosis induced by different stimuli (Kaufinann, 1989b; 
Shimizu et al., 1997; Oberhammer et al., 1994) in various cell lines. Cleavage 
of lamin B was clearly detected in OAW42 cells after treatment with BBR 
3464 or cisplatin. Conversely, in OAW42Mer cells it was only observed after 
exposure to the trinuclear platinum complex. Since nuclear lamin disassembly 
and proteolysis involves hyperphosphorylation of lamins by lamin kinases and 
cleavage by caspases (Shimizu et al., 1998; Buendia et al., 1999), it may be 
hypothesised that in the different cellular settings the two drugs may differently 
activate the lamin pathway leading to apoptosis.
In conclusion, the results of our study would suggest BBR 3464 to be a 
promising drag for the treatment of human tumours resistant to cisplatin as a 
consequence of alterations in the DNA repair systems or inactivation of p53 
function. Moreover, the evidence that BBR 3464 is able to induce apoptotic 
pathways which are different from those caused by cisplatin in the same 
tumour models suggests that multinuclear platinum complexes represent an 
entirely new class of DNA binding agents rather than simple cisplatin 
analogues.
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